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 CHAPTER 1
General Introduction
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PROSTATE CAnCER DETECTIOn bY PROSTATE SPECIFIC AnTIGEn (PSA)
Prostate specifi c antigen (PSA) is a protein produced by the prostate luminal epithelial cells, 
and is detected in both seminal fl uid and serum. It is a serine protease and its function is to 
help liquefy semen after ejaculation. [1, 2] PSA is also known as human kallikrein peptidase 
(hK3) and is a member of the human kallikrein family with 15 members to date. Th ese 
proteases are produced from chromosome 19 and they have similar amino sequences. [3]
PSA was discovered in the 1970s but it was until 1980s when it was being applied 
for prostate cancer detection. [4-9] Being present at a level x106 times higher in semen 
(in the range of 0.5-5.0 mg/mL), PSA (ng/mL) is released into the blood stream due to a 
disruption of cellular architecture in the prostate gland. Th is can occur in prostate cancer or 
benign conditions like prostatitis, benign prostatic hyperplasia, or prostatic manipulation 
like digital rectal examination or instrumentation. [8, 10]
It is highly organ specifi c but not cancer specifi c as the values of PSA overlap extensively 
benign prostatic conditions (predominantly benign prostatic hyperplasia or prostatitis) or 
prostate cancer. [9, 11, 12]
Despite the poor sensitivity and specifi city of PSA in predicting prostate cancer, espe-
cially at a mildly elevated range of 4-10 ng/mL, it has been and still is extensively utilized 
in early prostate cancer detection. Th is has led to earlier diagnoses and, in combination 
with adequate treatment lead to a reduction in prostate cancer mortality, but also to harms 
including over-investigation (unnecessary prostate biopsies), over-diagnosis (detection of 
indolent cancers), and related over-treatment. 
PROSTATE CAnCER SCREEnInG – PROS AnD COnS AnD THE WAY 
FORWARD
Since Prostate Specifi c Antigen (PSA) has been put into clinical use for prostate cancer 
screening in the early 1990s, an overall reduction of prostate cancer mortality is seen in the 
United States. [13] Whether a screening intervention can however result in an improvement 
of cancer specifi c survival would need evidence from randomized controlled trials (RCT). 
Th e 2 largest RCTs, namely the European Randomized Study of Screening for Prostate 
Cancer (ERSPC)[14] in Europe and the Prostate, Lung, Colorectal, and Ovarian (PLCO) 
Cancer screening trial in United States [15], were initiated in 1993 and randomized thou-
sands of men to repeated PSA screening or control groups. 
Th e ERSPC showed that PSA screening (with or without digital rectal exam) every 
4 years in 162,243 men in the core age group of 55-69 resulted in a 20% reduction in 
prostate cancer mortality and 41% reduction in metastatic disease at 9 years of follow-up. 
[14] However, 1410 men need to be screened and 48 men need to be treated in order to 
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prevent one death from prostate cancer. The number needed to screen (NNS) and number 
needed to treat (NNT) to reduce one cancer death progressively reduced to 570 and 18 at 16 
years follow-up, respectively. [16] In the Swedish section of ERSPC with 2-yearly screening, 
the prostate cancer mortality reduction was 42% at 18 years, and the NNS and NNT was 
only 139 and 13. [17] In the Rotterdam section of ERSPC, the prostate cancer mortality 
reduction increased from 32% to 51% at 13 years after correction of non-attendance and 
contamination. [18]
The PLCO trial offered yearly PSA screening for 6 years and digital rectal exam (DRE) 
for years in 76,693 men at 55-74 years old. [15] At a median of 17 years of follow-up, there 
was no difference in prostate cancer mortality between screened and control groups. [19]
Pooling together the results of these 2 trials resulted in an insignificant prostate cancer 
mortality reduction(RR 0.96, 95% CI 0.70-1.30). [20] However, the contamination rates 
in the control group of these trials, i.e. PSA or DRE screening in the control group, needs to 
be taken into consideration. The ERSPC study had 20% contamination in control group. 
[14] On the other hand, the contamination rate in PLCO study was up to 52% at the 6th 
year of study. [15] A follow-up survey published in 2016 showed that the contamination 
rate should be up to 85% during and after the initial 6-year screening period. [21] Therefore, 
there was almost no difference in screening rates in the 2 groups in PLCO study, and its 
result should be interpreted with caution. Extended analyses actually showed that, with 
good compliance and no contamination, the PLCO trial actually reduced prostate cancer 
mortality as well. [22, 23]
The benefit of cancer mortality reduction was counter-balanced by the harms of over-
investigation and over-diagnosis of indolent prostate cancers. Prostate cancer investigation 
with transrectal ultrasound (TRUS) biopsy could result in a number of complications includ-
ing life-threatening sepsis (1-3%), bleeding, and pain. [24] Therefor, unnecessary biopsies in 
men without prostate cancer results in harm. In addition it leads to unnecessary costs 
The large RCT’s and reports from daily clinical practice, where PSA testing is widely em-
braced have shown clearly that a significant proportion of prostate cancers is in fact indolent, 
i.e. low-volume, low grade cancers. Actively treating these cancers will only result in over-
treatment and associated treatment complications. [25] Therefore, screening the right men 
with the right tools is crucial to improve the harm-benefit ratio of prostate cancer screening. 
The data above show that PSA testing and early detection is undoubtedly beneficial for 
some individuals. However, a one size fits all approach on the basis of the result of one single 
blood test is not the way to go. Including other relevant information to better assess the 
individual risk of having a potentially life threatening prostate cancer is the way to go. [26] 
This has been the goal of decades of prostate cancer research and has resulted in the discovery 
of many other biomarkers and prediction models where biomarker information is combined 
with clinical data. This all have led to the development of so-called risk-adapted screening 
algorithms. [27, 28] 
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DIFFEREnCES In THE EPIDEMIOlOGY OF PROSTATE CAnCER AnD 
THE PERFORMAnCE OF PSA In ASIAn POPulATIOn
Th e age-standardised cancer incidence of prostate cancer in Asian men was about 10 per 
100,000, far less than the reported 64-75 per 100,000 in Caucasian according to epidemiol-
ogy studies. [29] Nevertheless, the incidence of prostate cancer in Asian has been increasing 
in recent years with the increasing use of PSA for early detection.
Th e percentage of prostate cancer being diagnosed in PSA grey-zone of 4-10 ng/mL is 
also signifi cantly lower in Asian. Th e positive biopsy rates in systematic biopsies for PSA 
4-10 ng/ml varies across diff erent ethnic groups, ranging from 26-47% in Caucasian to only 
15-25% in Asian. [30, 31]
Th erefore, both incidence and performance of PSA vary widely in diff erent ethnic 
groups. Th is implies that research on performance characteristics of biomarkers and other 
risk stratifi cation models and tools, predominantly developed in Caucasian men, need to be 
assessed and adjusted if necessary to an Asian setting.
PROSTATE HEAlTH InDEX (PHI)
Prostate specifi c antigen (PSA) originated from preproPSA, which contains a 17-amino acid 
leader sequence. [32] Cleavage of the preproPSA results in a proenzyme called proPSA or 
[-7] proPSA with 244 amino acids. [33, 34] Subsequent cleavage of the 7-amino acid leader 
sequence of proPSA by human kallikrein peptidase 2 (hK2) produces the active form of PSA 
with 237 amino acids. [35] When incomplete removal of the 7-amino acid leader sequence 
occurs, proPSAs with 2, 4 or 5 leader amino-acids would be created ([-2] proPSA, [-4] 
proPSA, and [-5] proPSA). [35] Th ese proPSAs exist as part of the free PSA in serum. 
Mikolajczyk et al reported signifi cantly elevated forms of proPSA, in particular [-2] 
proPSA, in prostate cancer tissue. [36, 37] Th e [-2] proPSA, or more recently called p2PSA, 
has been shown to be a promising biomarker for prostate cancer. Multiple clinical studies 
have since proved the utility of [-2] proPSA in men with elevated PSA 2-10 ng/mL before 
initial or repeated biopsies. [38-41]
Besides predicting prostate cancer, it also predicts Gleason score 7 or above prostate 
cancers. [-2] proPSA was combined with free PSA and total PSA in a formula that calculates 
the Prostate Health Index (PHI) (Figure 1). [39, 40, 42] Th e PHI blood test was approved 
by the Food and Drug Administration (FDA) in the United States in 2012 for men aged 50 
or above with PSA 4-10 ng/mL and a normal digital rectal examination (DRE) to reduce 
unnecessary biopsies. [43] 
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ObjECTIvES OF THIS THESIS
The first objective of the thesis is to assess the performance of currently available methods to 
reduce the harms of prostate cancer screening and whether and how these tools can be ap-
plied to Asian populations. The second objective of the thesis is to investigate in more detail 
the role of the serum biomarker Prostate Health Index (PHI) in prostate cancer diagnosis in 
Asian populations. 
OuTlInE OF RESEARCH quESTIOnS ADDRESSED In THIS THESIS
The first part of this thesis focuses on risk stratification tools in prostate cancer detection and 
its application in Asian populations, and is described in 4 chapters addressing the following 
research questions: 
1. Can we screen for prostate cancer and reduce the coinciding overdiagnosis? (Chapter 2)
2. Can we use PSA density to risk stratify Asian men? (Chapter 3)
3. Can we use Rotterdam prostate cancer Risk calculator in Asian men and is adjustment 
to an Asian setting indicated? (Chapter 4)
4. Can risk prediction models also be of aid in reducing complications of prostate biopsy? 
(Chapter 5)
The second part of the thesis focuses on the use of Prostate Health Index in prostate cancer 
diagnosis in Asian populations, and is described in 6 chapters addressing the following 
research questions:
1. What are the performance characteristics of PHI in the Asian setting and do we need a 
different PHI reference range for Asian and Caucasian? (Chapters 6-9)
2. Has PHI added value in PSA based risk prediction models? (Chapter 10)
3. To what extent can PHI reduce the number of unnecessary biopsies in a contemporary 
Asian clinical setting? (Chapter 11)
Figure 1. Prostate Health Index (PHI) formula.
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Can we screen and still reduce overdiagnosis?
Peter Ka-Fung Chiu, Monique J. Roobol
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AbSTRACT
Screening for cancer aims to find cancers as early as possible when the chance of cure is 
highest and as such involves healthy people who don’t have any symptoms at that point in 
time. Overdiagnosis is the diagnosis of a latent disease that would not have been diagnosed 
during a person’s lifetime (and would not have affected the person at all) without screening. 
Whether the diagnosis of a cancer in a particular patient can be considered as overdiagnosis 
is an interaction of how latent the disease is and how long the patient will live. A relatively 
rapid growing cancer might not necessarily harm the patient or be the cause of death if the 
patient had a short remaining lifetime. On the other hand, a slow growing cancer might 
harm the patient if he or she lives long enough. Prostate cancer is particularly amenable 
to overdiagnosis as there is a considerable reservoir of so-called latent disease which can be 
detected by a relatively simple procedure, the systematic prostate biopsy. Although obvious 
as it may seem, prostate cancer screening is frequently mixed up with PSA based screen-
ing. While systematic large scale screening for prostate cancer by a PSA-only approach may 
not be appropriate, it does not mean that there should no prostate cancer screening at all. 
The issue is not that black and white. Better tools for detection of (potentially aggressive) 
prostate cancer have emerged since the PSA era, which include multivariate approaches, i.e. 
combining relevant information from multiple sources like e.g. clinical data, blood, urine 
markers, genetic tools, and novel imaging techniques. Such an approach may help to reduce 
unnecessary testing (e.g. biopsy) and over-diagnosis of non-lethal cancers, while, and this is 
crucial, not missing the diagnosis of a potentially lethal prostate cancer. 
In this chapter, we aim to summarize the harms and benefits of prostate cancer screening, 
and assess the possibilities on who, when and how to screen prostate cancer aiming to keep 
the benefit and avoid the harm. 
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Autopsy studies of subclinical prostate cancer
To be able to fully grasp the potential problem of overdiagnosis it is important to understand 
the natural history of prostate cancer. In a very nice overview of van der Kwast et al the 
diff erent types of prostate cancer in relation to their clinical presentation and symptoms is 
given (Figure 1).[1]
Figure 1. Scheme depicting the age-related natural history of fi ve hypothetical forms of prostate cancer 
(presented by the curved lines I–V) in relationship to their clinical signs and symptoms, visualizing 
their sojourn time in the latent reservoir (grey coloured zone). Th e X-axis represents patient age. Signs 
and symptoms of prostate cancer are represented by the horizontal lines. Indolent (curve I) and low 
risk (curve II) cancers are thought to remain in the latent reservoir, although low-risk prostate cancer 
can grow in size and become PSA-detectable and DRE-detectable over time. When grade progression 
occurs in initially low-risk prostate cancers (curve III), these tumours can escape from the latent reser-
voir and become clinically detectable. It is thought that a small fraction of de novo poorly diff erentiated 
late-onset prostate cancers (curve IV) develop rapidly with a short sojourn time in the latent reservoir, 
precluding their timely detection by PSA screening. Th e size of the curved lines indicates their fre-
quency in a population. A very small fraction of early-onset prostate cancers (curve V) with growth 
kinetics comparable to those of late-onset prostate cancers with grade progression (curve III) represents 
a biologically distinct subset of prostate cancers. Abbreviation: DRE, digital rectal examination.[1]
To be able to address the problem of overdiagnosis, fi rst the proportion of indolent 
cancers needs to be identifi ed. Autopsy studies of non-prostate cancer related deaths and 
observational natural history studies might provide some insight into this problem. A Greek 
autopsy study showed that subclinical cancers were found in 13.8% (60-69 years), 30.5% 
(70-79 years), and 40% (80-89 years) men.[2] More recent autopsy studies showed that in 
1,056 white and black men in the United States, the proportion of latent prostate cancer was 
as high as 44-46% (50-59 years), 68-72% (60-69 years), and 69-77% (70-79 years), with 
the vast majority having potentially indolent Gleason score 6 or less cancers (84-93%).[3] 
Th ese men obviously would not benefi t from a diagnosis of prostate cancer in their lifetime. 
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natural history of untreated low-risk prostate cancer
Johanssen et al followed up 223 Swedish men with localized prostate cancer who were 
diagnosed in the pre-PSA era (1977-1984) without initial active treatment.[4] In 2004, 
it was reported that most observed men had an indolent course in the first 15 years, but 
progression and death from prostate cancer increased sharply from 15-20 years in those men 
still alive. In 2013, an updated analysis of the series was reported after 30 years of follow-up.
[5] After the death of 99% of men in the cohort, it was found that only 17% of men died 
of prostate cancer (which means 83% died of competing causes), and prostate cancer deaths 
occurred mostly between 15 and 25 years from diagnosis.[5]
Albertsen et al described another cohort of 767 men (age 55-74) diagnosed with local-
ized prostate cancer around 1971-1984 and observed for more than 20 years.[6] At 20 years, 
the prostate cancer mortality rate was 30 per 1000 person-years in Gleason 6 cancer, 65 per 
1000 person-years in Gleason 7 cancer, and 121 per 1000 person-years in Gleason 8-10 
cancers. More than 70% of men died of other causes for Gleason 6 men at 20 years.[6] It 
should be noted that both cohorts represented an era without PSA testing, and it is expected 
that most of these patients were diagnosed at a later stage as compared with prostate cancer 
detected nowadays. Therefore, the early localized prostate cancers that were diagnosed in 
more recent years might have a more indolent course than those in the natural history 
studies. 
The control arms of the 2 randomized trials of surgery versus observation also provided 
insights in the natural history of localized prostate cancer; the Scandinavian Prostate Cancer 
Group 4 (SPCG4)[7] in pre-PSA era and Prostate cancer Intervention Versus Observation 
Trial (PIVOT)[8] in the early PSA era. SPCG4 randomized 699 men with prostate cancer 
(cT1-T2) in 1989-1999 to radical prostatectomy or watchful waiting.[7] Only 5% patients 
were cT1c, and 75% had palpable disease (cT2) at time of diagnosis. The prostate cancer 
Figure 2. Number of cancers detected per 100 000 men in 25 years for three screening scenarios (1-
year interval ages 55–70: int1, 2-year interval ages 55–70: int2, 4-year interval ages 55–75: to75) for 
clinically detected cancers (interval cancers), relevant cancers (screen-detected cancers that would have 
given rise to clinical symptoms later in life) and overdetected cancers (screen-detected cancers that 
would never give rise to clinical symptoms and would not lead to death caused by prostate cancer).
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mortality in the observation group was about 20% at 15 years, and in the low risk subgroup, 
the cancer mortality was only 10% at 15 years. 
PIVOT randomized 731 men with prostate cancer (cT1-T2) in 1994-2002 to radical 
prostatectomy or observation.[8] About half of the patients were cT1c and 90% was Gleason 
score 6-7. Prostate cancer mortalities of both arms were less than 20% at 15 years, and in the 
low risk subgroup the cancer mortality was less than 5% at 15 years. 
In summary, localized prostate cancer shows an excellent 15-year cancer-specifi c survival 
without initial curative-intent treatment, and only younger (<65 years old) patients might 
benefi t from detection and radical treatment. 
Estimation of the extent of overdiagnosis
Overdiagnosis on a population level can be estimated by either epidemiological or clinical 
criteria. Epidemiological studies can estimate overdiagnosis using 2 approaches, the so-called 
lead-time approach or calculating excess incidence created by active screening.[9] In clinical 
studies, overdiagnosis is often expressed as the number or percentage of low-risk prostate 
cancers that are being detected. Th e diff erent approaches have a widely variable estimation 
of overdiagnosis and are in addition, diffi  cult to translate to an individual.[9-11]
Th e ERSPC study fi rst reported 20% reduction of prostate cancer mortality by PSA-based 
screening in 2009 at a median follow-up time of 9 years.[12] A 30% reduction in metastatic 
prostate cancer was also shown.[13] However, the excess incidence of predominantly low 
risk prostate cancer cases was signifi cant. Th is was expressed in the so-called numbers needed 
to screen and numbers needed to diagnose (in excess to a clinical situation) in order to pre-
vent one death from prostate cancer being 1410 and 48 men respectively. With additional 
follow-up these numbers reduced to 781 men and 27 men.[14] Mathematical simulation 
models on the basis of the Rotterdam section of ERSPC data showed that compared to a 
situation without screening, applying a 4- year interval PSA based screening algorithm from 
55 until age 70 would lead to 40% of prostate cancers detected to be over diagnosed.[15] 
Th ree alternative screening strategies (1) screening from age 55 to 70 with 1-year intervals 
(2) screening from age 55 to 70 with 2-year intervals and (3) screening from age 55 to 75 
with 4-year interval showed percentages of potentially over diagnosed prostate cancers of 
49%,48% and 57% respectively.[15]
Th e higher rate of overdiagnosis when screening men at higher age is confi rmed by 
other modeling studies. Gulati et al using a contemporary cohort of US men modelled the 
eff ects of 35 screening strategies that vary by start and stop ages, screening intervals, and 
thresholds for biopsy referral concluded that less intensive screening in older men (higher 
PSA threshold for biopsy referral) reduces the risk for overdiagnosis.[16]
Th is is confi rmed by a recent cost-eff ectiveness analysis of the MIcrostimulation SCreen-
ing ANalysis (MISCAN) model, based on ERSPC data. Th ere it was shown that a screening 
algorithm with two year intervals between the ages 55-59 (3 screenings) had the best incre-
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mental cost-effectiveness ratio.[17] However, if a better quality-of-life for the post treatment 
period could be achieved (i.e applying active surveillance for low-risk prostate cancer), men 
at older age up to 72 could also be included in a screening program.[17]
Next to detecting prostate cancers that are very likely to have an indolent course based 
on their clinical characteristics at time of diagnosis there is obviously another factor that is 
closely related to over diagnosis; i.e life expectancy. As is shown above a low risk prostate can-
cer at time of diagnosis can become potentially life threatening if its host lives long enough. 
Finding the balance between two difficult to predict individual-level outcomes is needed. 
This balance is graphically displayed in Figure 3 where it is obvious that we need to be able 
to predict both course of disease and life expectancy to be able to screen for prostate cancer 
with keeping the proven benefits and avoiding the harms.
The next sections of this chapter hence focus on who and how to screen for prostate 
cancer. 
Figure 3. Prostate cancer screening in association with life expectancy and disease course.
Who to screen? 
There are certain patient groups that have been associated with higher risks of potentially 
aggressive prostate cancer in population studies, and they included those with positive family 
history, ethnically black men, and those with genetic predisposition to prostate cancer. 
Family history of prostate cancer
Meta-analyses on family history and prostate cancer risk demonstrated a relative risk (RR) 
of 2.5 in having a life-time risk of prostate cancer in men with positive family history of 
prostate, and up to RR of 3.5-4.4 with two affected first-degree relatives.[18] Those with 
brother having prostate cancer had an even higher risk of prostate cancer than those with 
father having prostate cancer (RR 3.1 Vs 2.4).[19] The effect of family history was also 
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associated with earlier disease onset (before 65 years old) (RR 2.9 Vs 1.9).[20] In the Swiss 
arm of the ERSPC, men with positive family history of prostate cancer had a 60% higher 
chance of diagnosing prostate cancer, but most of them were low grade cancers.[21]
Racial diff erences on prostate cancer
Th e lifetime risk of a prostate cancer diagnosis varies in diff erent ethnic groups. In a study in 
United Kingdom (UK), the risk ranged from 13.3% in Caucasian, 29.3% in Black, to 7.9% 
in Asian men. Th e risk of dying from prostate cancer also varied from 4.2% in Caucasian, 
8.7% in Black, to 2.3% in Asian men.[22] Th erefore, diff erent races had a similar diagnosis-
to-death ratio of around 3:1, and Black men did not have a higher risk of dying from 
prostate cancer once diagnosed.[22] An earlier meta-analysis, however, showed that Black 
men diagnosed with prostate cancer had a 13% higher risk of prostate cancer death, which 
was not fully explained by comorbidity, PSA screening, or access to health care.[23]
Genetic mutations associating with higher risk of prostate cancer
Twin studies suggested that the inherited component of prostate cancer risk is more than 
40%.[24] Genomewide association studies (GWAS) evaluated the entire genome for com-
monly inherited variants (>1-5% population frequency), and more than 40 prostate cancer 
susceptibility loci explaining approximately 25% risk were found.[25] A more recent meta-
analysis of 43,303 prostate cancer and 43,737 controls from European, African, Japanese, 
and Latino men have identifi ed 23 new susceptibility loci for prostate cancer, explaining 
33% of familial risks.[26] In terms of screening or early detection, it is not cost-eff ective to 
screen for all susceptible loci, and whether this would provide a better harm-to-benefi t ratio. 
Is the presence of a risk factor a license to screen?
A study using estimates from the literature reported that screening men with a PSA level at 
the highest 10th percentile at 45 years old provided a better harm-to-benefi t ratio comparing 
with those with positive family history and black race. A higher PSA at 45 years accounted 
for 44% of prostate cancer deaths, while family history and black race only accounted for 
14% and 28% cancer deaths, respectively.[27] Hence, it is important to weigh both harm 
and benefi t as equally important, in a high risk population there might be a larger benefi t, 
but with applying a screening approach that is not selective for potentially lethal disease the 
harm may be equally increased.[28]
When to screen?
When to screen for prostate cancer is another controversial topic. It includes the starting 
and ending age for screening, including the so-called baseline PSA measurement at relatively 
young age and the screening interval
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Starting screening, baseline PSA at younger age
A large case-control study in the Swedish population showed that a higher baseline PSA at 
younger age groups of 45-49 and 51-55 years was associated with higher risk of metastasis 
and prostate cancer deaths after a follow-up of 25 year. More than 40% of metastasis and 
deaths from prostate cancer occurred in men with PSA with the highest 10th percentile ( > 
1.6 ng/ml at age 45-49 and > 2.4 ng/ml at age 51-55).[27]
In a study investigating the PSA level of again Swedish men at the age of 60, a PSA level 
of <1 ng/mL was associated with only 0.5% risk of metastasis and 0.2% risk of prostate 
cancer death at the age of 85.[29] In a Danish study, men with a PSA concentration of 4-10 
ug/L had a 7-fold risk of prostate cancer death compared with men with PSA < 1 ug/L.[30] 
These data were confirmed in analyses based on the ERSPC where it is repeatedly shown that 
men aged 55-69 with baseline PSA levels below 1.0 ng/ml have a very low risk of prostate 
cancer detection, let alone dying from the disease.[31, 32]
In a comparison of prostate cancer incidence and mortality between the Dutch, Swedish 
and Finnish parts of ERSPC and a cohort without PSA screening ( Northern Ireland) results 
showed that that the yield of prostate cancer screening increased with the increasing baseline 
serum PSA level at study entry. The benefits of early detection may be small for men with a 
baseline serum PSA of 0-3.9 ng/mL at study entry. The number needed to investigate (NNI) 
to save one prostate cancer death was 24,642 in men with initial PSA <2 ng/mL, compared 
to NNI of 133 in men with PSA 10-20 ng/mL.[33]
However, starting PSA testing at mid age might also result in yet more testing, biopsies 
and subsequent over diagnosis. The retrospective analyses presented above, recommending 
e.g. retesting intervals up to 10 year if the baseline PSA is considered low, cannot assess the 
effect in contemporary daily clinical practice. In an editorial by Carter et al. this lack of 
knowledge is clearly described. The authors question whether it is realistic to assume that 
a clinician will advise not to return for a PSA test within the next 10 years when the data 
actually show that more than half of the prostate cancer deaths in men aged 45-49 occur in 
men with a PSA of less than 1.6 ng/ml (90% of the population).[34] So while the concept 
of a baseline PSA test at midlife definitely sounds appealing in retrospective analyses, the 
question remains whether this advice will be followed in contemporary practice.
Screening interval
As mentioned above, in the Rotterdam section of ERSPC, men of age 55 to 65 years with a 
baseline PSA of less than 1 ng/mL was associated with very low cancer detection after 8 years. 
Only 3.3% men had PSA >3ng/mL and 0.49% cancer detection rate. As a result, an 8-yearly 
interval for screening in men with baseline PSA less than 1 ng/mL was recommended.[32]
A similar conclusion was drawn on the basis of a multiethnic study in United States. 
Gelfond et al reported a 10-year prostate cancer risk of 3.4% for men (median age 58) with 
PSA <1 ng/mL, and among the diagnosed cancers 90% were of low risk cancers. In contrast, 
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those with PSA 3.1-10 ng/mL had a 39.0% 10-year risk of prostate cancer diagnosis. A 
recommendation of screening interval of 10 years or more was suggested for men with 
baseline PSA <1 ng/mL.[35]
In comparing 2-yearly (Goteborg section) and 4-yearly (Rotterdam section) PSA-based 
screening in the ERSPC trial in men with age 55-64, a 2-year screening interval reduced the 
incidence of advanced prostate cancer by 43% but increased the detection of low-risk pros-
tate cancer by 46%.[36] Th is direct relationship between benefi t and the intensity of a PSA 
based screening algorithm was recently confi rmed by another ERSPC analyses by Auvinen 
et al., where it was shown that the extent of overdiagnosis and the mortality reduction was 
closely associated.[37] Eff orts to maximize the mortality eff ect applying a PSA based screen-
ing algorithm in all men are bound to increase overdiagnosis. Th e authors correctly note that 
this harm-to-benefi t ratio might be improved by focusing on men considered to be at high 
risk but how we actually can achieve that remains unclear.[37]
Ending age of screening
In a simulation study by Ross et al, the number needed to treat (NNT) in order to prevent 
one cancer death increased with age. Comparing with screening until age 65 (NNT 7.7), 
NNT of screening to 75 (NNT 12.5) and 80 (NNT 17.5) years was 2-3 times higher.[38] 
Zhang et al described the optimal stopping age of PSA testing from both patients’ and 
societal perspectives from a decision process model. Patients’ perspective was to maximize 
expected QALYs, while societal perspective was to maximize cost eff ectiveness for QALYs. 
From the patients’ perspective, the optimal policy was stopping PSA testing and biopsy at 
76, while the estimated age was 71 from societal perspective.[39]
With increasing age, the benefi ts of early detection reduces when deaths from other 
causes increases. Th e optimal age to stop screening is diffi  cult to be determined. As men-
tioned before in the natural history studies and in the RCTs comparing surgery and watchful 
waiting (SPCG4[7] and PIVOT[8]), men with life expectancy less than 10-15 years are 
not recommended to have any prostate cancer screening in the American and European 
Urological association guidelines.[40, 41]
However, due to the continuous increase in life expectancy of men, the diffi  culty in 
estimating the remaining lifetime of older men, and the availability of better treatment with 
fewer complications, we are now facing a changing scenario. Th erefore, it would be diffi  cult 
to set a rigid age to stop screening. An individual assessment with proper counselling and 
shared decision making should be off ered instead.
How to screen?
Nowadays, there are better tools than PSA in screening for prostate cancer which might 
improve the harm-to-benefi t ratio in screening. As the newer tools have better sensitivity 
or specifi city in detecting prostate cancer, a proportion of unnecessary biopsies based solely 
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on elevated PSA might be avoided. This could reduce both unnecessary biopsies and over 
diagnosis. The most obvious way to move forward, while the 100% sensitivity and specificity 
lethal prostate cancer test is lacking, is to combine relevant information into prediction 
tools. In addition, novel imaging techniques can certainly be of aid in identifying those men 
that can benefit from early detection and treatment. 
PSA-based prostate cancer risk calculators
There are many risk calculators available, all having their advantages (widely externally 
validated, easy to use) and disadvantages (only suitable in particular settings, requiring 
complicated data and calculations). A meta-analysis of 6 risk calculators (out of 127 unique 
prediction models) included Prostataclass, Finne, Karakiewcz, Prostate Cancer Prevention 
Trial (PCPT), Chun, and the European Randomized Study of Screening for Prostate Cancer 
Risk Calculator 3 (ERSPC RC3).[42]
It showed that PCPT risk calculator did not differ from PSA testing in terms of AUC 
(0.66), while Prostataclass and ERSPC RC3 had the highest AUC of 0.79. The latter models 
doubled the sensitivity of PSA testing (44% Vs 21%) while maintaining the same specificity.
[42]
Calibration of the models, which is important in assessing the actual predicted risk, was 
however poorly reported. In assessing the performance of prediction models, it was reported 
that both discrimination (AUC) and calibration are important.[42] Decision-analytic mea-
sures (decision curve analysis) should be reported if a model relates to clinical decisions.[43] 
novel biomarkers for prostate cancer prediction
Urine PCA3
The Prostate Cancer Antigen 3 (PCA3) is a non-coding messenger RNA found to be elevated 
in urine of most men with prostate cancer. A post-prostatic massage urine sample is needed 
for analysis. A higher PCA3 score was associated with a greater risk of prostate cancer. The 
discriminative ability of PCA3 was significantly better than PSA (AUC 0.76 Vs 0.58).[44, 
45] However, when combined to an existing risk calculator (ERSPC RC3) there was hardly 
any additional predictive capability.[46] PCA3 is currently approved by United States Food 
and Drug Administration (FDA) in 2012 as a prostate cancer diagnostic test in men with 
previous negative prostate biopsy. 
Urine TMPRSS2-ERG
The gene fusion TMPRSS2-ERG between transmembrane protease serine 2 (TMPRSS2) 
gene and the v-ets erythroblastosis virus E26 oncogene homolog (ERG) gene exist in up to 
80% of prostate cancers. Urine levels of TMPRSS2-ERG correlate with clinically signifi-
cant prostate cancer.[47] Adding post-DRE urine PCA3 to urine TMPRSS2-ERG further 
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improved the prediction of prostate cancer and clinically signifi cant prostate cancer on 
repeated prostate biopsies. Th e AUC for prostate cancer detection was 0.72, 0.65, 0.77, and 
0.88 for PSA, PCA3, TMPRSS2-ERG, and combination of PCA3 and TMPRSS2-ERG, 
respectively.[48] Th is is confi rmed by a larger prospective multicentre study (n=443), in 
which TMPRSS2-ERG had independent additional predictive values to PCA3 and ERSPC 
risk calculator in predicting prostate cancer.[49]
Prostate health index (PHI)
PSA isoform [-2]proPSA (p2PSA) was shown to be more accurate than PSA or %free PSA 
in predicting prostate cancer.[50] Prostate Health Index (PHI) was created by combining 
PSA, free PSA, and p2PSA in the formula (p2PSA/free PSA) × √total PSA. PHI and p2PSA 
had specifi city 3 times of that of PSA, with best performance in the range of PSA 2-10. Th is 
could reduce unnecessary biopsies while maintain a high cancer detection rate.[51] In 2012, 
the FDA has approved the use of PHI and p2PSA in men older than 50 years old with a 
total PSA 4-10 ng/mL and normal DRE to reduce unnecessary prostate biopsies. PHI was 
also associated with more aggressive or clinically signifi cant prostate cancers.[52, 53] Using 
a simulation model, PHI was shown to be more cost eff ective than PSA-only screening.[54] 
Four-kallikrein panel (4K)
Th e 4-kallikrein panel consisting of PSA, free PSA, intact PSA, and human kallikrein 2 (hK2) 
was shown to diff erentiate pathologically indolent and aggressive disease. It was shown that 
more than 50% of biopsies could be reduced by applying the 4K panel, while missing 12% 
high grade cancer and avoiding overdiagnosis of one-third of low grade cancers.[55-57]
Th ese fi ndings were confi rmed in a large cohort of 6129 men in the Prostate Testing 
for Cancer and Treatment (ProtecaT) study, with better AUC compared with PSA (0.82 
Vs 0.74). Using 6% risk of high grade cancer as cutoff , more than 40% biopsies could be 
reduced while delaying diagnosis of only 10% of high grade cancers.[58]
A 4Kscore was created by combining the 4-kallikrein panel with age, DRE fi ndings, and 
history of prior prostate biopsy, and was validated to accurately identify men with high-
grade prostate cancer.[59] Using the 4Kscore can reduce 30-58% biopsies while delaying 
diagnosis in less than 5% high grade cancers. However, when combined in a multivariate 
prediction model the added value is limited.[46]
STHLM3
Th e population based Stockholm 3 (STHLM3) study reported that the so-called STHLM3 
model, which included plasma protein biomarkers (PSA, free PSA, intact PSA, hK2, 
MSMB, MIC1), genetic polymorphisms (232 single nucleotide polymorphisms), and clini-
cal variables (age, family history, previous prostate biopsy, DRE), predicted Gleason 7 or 
above prostate cancer in a large development (n=11130) and validation (n=47688) cohort in 
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Sweden. The STHLM3 model performed significantly better than PSA (AUC 0.74 Vs 0.56) 
for Gleason 7 or above prostate cancers, and could reduce 32% biopsies.[60] The issue of 
overdiagnosis was however not fully addressed as most prostate cancers diagnosed were still 
low grade cancers, and the cost effectiveness of such an extensive model is questionable.[61]
Which novel biomarker for prostate cancer diagnosis should we choose?
All of the aforementioned novel biomarkers and imaging techniques like MRI have proved 
to be more specific and more discriminative (in terms of AUC) than PSA, and could poten-
tially reduce a significant proportion (up to 50%) biopsies while delaying diagnosis in only 
a handful of clinically aggressive prostate cancers. However, there are very few head-to-head 
comparisons of different novel tools in terms of performance and cost-effectiveness, and the 
ever increasing cost of novel tests would make screening for prostate cancer unaffordable. 
This creates a difficult scenario for both physicians and patients in choosing the optimal 
test before biopsy decisions.[62] One conclusion can be drawn from these data: combining 
relevant pre-biopsy information as compared to decision making on the basis of a single PSA 
measurement will always help to reduce unnecessary testing and overdiagnosis.
Prostate imaging - Multiparametric MRI of the Prostate
Conventional TRUS prostate has a poor sensitivity and specificity in identification of 
prostate cancers, and therefore the main use of it is to guide prostate biopsy but not for 
diagnosis.[63] Recently the multi parametric MRI entered the urological diagnostic practice 
and is considered a promising imaging modality for the detection of prostate cancer.[64] A 
systematic review showed that targeted biopsy (with MRI information) had a higher detec-
tion rate of significant prostate cancer (sensitivity 0.91 Vs 0.76) and a lower detection rate 
of insignificant cancer (sensitivity 0.44 Vs 0.83).[65]
COnCluSIOnS
On the basis of natural history and screening studies we can conclude that the risk of over-
diagnosis of prostate cancer is present and considerable when applying systematic PSA based 
screening in combination with random TRUS based prostate biopsy. This should however 
not prevent us from screening for prostate cancer at all, as none of us want to return to the 
era when many prostate cancers presented at an advanced or metastatic stage. We should aim 
to screen the right men (at particular high risk of aggressive prostate cancer and/or with a 
long life expectancy), at the right time, with the right tools. With all available knowledge we 
are able to reduce the current rate of unnecessary biopsies and overdiagnosis of low grade/
risk prostate cancer. However, adapting our way of working by adopting recommendations 
and guidelines is still difficult but should be the way forward. 
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AbSTRACT
Purpose
To compare the performance of PSA density in the diagnosis of prostate cancer in obese and 
non-obese Chinese men.
Methods
The results of transrectal ultrasound-guided(TRUS) prostate biopsies of Chinese men with 
PSA<20ng/mL were reviewed. Parameters including age, body mass index(BMI), TRUS 
prostate volume, and TRUS biopsy results were recorded. The diagnostic yields of PSA 
density(>0.15ng/mL/mL as positive) in obese and non-obese men with PSA<20ng/mL were 
compared. Obesity was defined as BMI≥27kg/m2 according to WHO recommendation for 
Hong Kong Chinese.
Results
TRUS biopsy, BMI, and PSA density data were available for 854 men(mean age 65.9+/-7.3). 
The mean PSA values for the obese and non-obese patients were 7.9+/-3.7ng/mL and 8.2+/-
4.1ng/mL, respectively(p=0.416). TRUS volumes in obese and non-obese men were 63.2ml 
and 51.6ml, respectively(t-test, p<0.001), and PSA density was significantly lower in obese 
men(0.145 vs. 0.188, p<0.001). For obese men, positive PSA density was associated with 
four times(41.1% vs. 9.5%, p<0.001) the risk of prostate cancer, compared to only twice 
the risk(18.8% vs. 9.7%, p=0.001) in non-obese men. The specificity and area under the 
curve of PSA density were 74.2% and 0.731, respectively, for obese men, and 51.4% and 
0.653, respectively, for non-obese men. Among patients with a diagnosis of prostate cancer, 
the obese patient group had a significantly higher proportion of patients with Gleason 
7-10 prostate cancer than the non-obese patient group(48.9% vs. 32.7%, chi-square test, 
p=0.035), and a trend towards a higher proportion of bilateral lobe involvement.
Conclusion
PSA density had better performance in obese men. Positive PSA density in obese men was 
associated with four times the risk of prostate cancer.
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InTRODuCTIOn
Obesity is becoming increasingly common in both Caucasian and Asian populations [1-2]. 
Although many diseases are known to be closely related to obesity, there is increasing evidence 
of a complex relationship between obesity and prostate cancer [3]. Studies have suggested 
that obese patients tend to have larger prostates [4-5]. Obese patients or patients with higher 
body mass indices (BMI) have been shown to have lower prostate-specifi c antigen (PSA) 
levels in both Caucasian and Asian populations [6-8]. Furthermore, some evidence suggests 
that obesity is associated with higher Gleason scores in prostatectomy specimens and an 
increased risk of biochemical failure after treatment [9-10]. Th e poorer treatment outcomes 
might be related to the delay in diagnosis of prostate cancer due to the relatively lower PSA 
levels in obese patients, the increased diffi  culty of physical examinations, and the increased 
chance of missing the diagnosis in a biopsy due to larger prostate size [3].
Currently, there are many PSA derivatives that improve the performance of serum PSA 
in the diagnosis of prostate cancer. Among them, PSA density is a relatively simple approach 
for clinical use [11-13]. A PSA density cutoff  of 0.15 is associated with better diagnostic 
accuracy for prostate cancer than total PSA alone [14].
As obese patients tend to have lower PSA levels and larger prostates, the performance of 
PSA density might be aff ected. Th erefore, we assessed the performance of PSA density in 
obese and non-obese patients in a Chinese population.
METHODOlOGY
Th e cases of Chinese men with PSAs of less than 20 ng/mL who had undergone transrectal 
ultrasound-guided (TRUS) prostate biopsies during the 2009-2012 period were reviewed. 
Th e TRUS biopsies were performed in two regional hospitals in our area, using 10 or 12 
core needle biopsies. 
Parameters including age, body mass index, TRUS prostate volume, and TRUS biopsy 
results were recorded. Th e prostate volume was measured with transrectal ultrasound using 
the ellipse formula. PSA density was calculated by dividing total PSA by prostate volume, 
and a PSA density >0.15 ng/mL/mL was considered positive. Following the recommenda-
tion of the WHO, obesity for Hong Kong Chinese was defi ned as a body mass index (BMI) 
≥27kg/m2 [2]. Cancer grades were classifi ed using the Gleason score (GS): low grade (GS≤6) 
or high grade (GS≥7). 
Statistical analyses were performed using IBM SPSS v.19.0 software (IBM Corp., Ar-
monk, NY, USA). A two-sided p value <0.05 was considered signifi cant. Continuous and 
categorical variables were compared using t-tests and Chi-square tests respectively, and a 
2-sided p-value of <0.05 was considered signifi cant. Th e diagnostic yields of PSA density in 
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obese and non-obese men were compared using sensitivity, specificity, and receiver operating 
characteristic (ROC) curves. The relationship between PSA density and the proportion of 
high Gleason grades was analyzed with a Chi-square test. The association between obesity 
and Gleason score and between obesity and prostate cancer’s bilateral lobe involvement were 
also analyzed.
RESulTS
During the study period, BMI and PSA density data were available for 854 men (mean age 
65.9 +/- 7.3 years) with PSA <20 ng/mL. TRUS biopsies were performed in the two centers, 
and 133 (15.6%) men were diagnosed with prostate cancer. The prevalence of prostate can-
cer for different PSA ranges is listed in Table 1. There was no significant difference between 
the proportion of prostate cancers in the 10-core and 12-core biopsies. The Gleason scores of 
the diagnosed prostate cancers were ≤6 in 68.5% of the cases and ≥7 in 31.5% of the cases. 
Table 1. Comparing prevalence of prostate cancer of different PSA ranges between 10 and 12 core 
biopsies. 
PSA (ng/ml) All
Hospital 1
(10 cores)
Hospital 2
(12 cores) p-valuea
<4 8.3% (7/84 ) 11.5% (3/26) 6.9% (4/58) 0.477
4-9.9 14.2% (77/544 ) 16.6% (30/181) 12.9% (47/363) 0.253
10-19.9 21.7% (49/226) 18.5% (17/92) 23.9% (32/134) 0.333
a Chi-square or Fisher’s exact test
One hundred and sixty-one patients (18.9%) were obese (BMI ≥27). The mean PSAs for 
obese (BMI ≥27) and non-obese (BMI <27) patients were 7.9 +/- 3.7 ng/mL and 8.2 +/- 4.1 
ng/mL, respectively (t-test, p=0.416). The TRUS prostate volumes for obese and non-obese 
patients were 63.2 ml and 51.6 ml, respectively (t-test, p<0.001), and PSA density was 
significantly lower in obese men (0.145 vs. 0.188, p<0.001). The overall sensitivity and 
specificity for PSA density (i.e., > 0.15) was 67.7% and 55.5%, respectively, and the area 
under the ROC curve (AUC) was 0.662.
Comparing the use of PSA density for the diagnosis of prostate cancer in obese and non-
obese patients with PSA<20 ng/mL, the proportion of prostate cancers diagnosed in PSA 
density-positive patients in obese and non-obese patients were 41.1% (23/56) and 18.8% 
(67/356), respectively (Chi-square test, p<0.001). In patients with PSA<20 ng/mL, obese 
PSA density-positive patients had four times the risk of prostate cancer (41.1% vs. 9.5%, Chi-
square test, p<0.001), whereas non-obese patients had two times the risk of prostate cancer 
(18.8% vs. 9.7%, Chi-square test, p=0.001) (Table 2). For patients with PSA <10 ng/mL, the 
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proportion of prostate cancers diagnosed in PSA density-positive patients was 43.8% (14/32) 
of obese patients and 18.8% (39/208) of non-obese patients (Chi-square test, p=0.002). 
Th e sensitivities, specifi cities, and ROC AUC of the total PSA and PSA densities are 
listed in Table 3. For PSAs less than 20 or 10 ng/mL, PSA density had signifi cantly better 
specifi city and AUC than total PSA in obese patients only.
Table 2: Performance of PSA density for obese and non-obese men
no Prostate cancer Prostate cancer Chi-square p-value
Obese and PSA <20
PSA density negative 95 10 (9.5%)
PSA density positive 33 23 (41.1%) p<0.001
Non-obese and PSA <20
PSA density negative 306 33 (9.7%)
PSA density positive 289 67 (18.8%) p=0.001
Obese and PSA <10
PSA density negative 81 10 (11.0%)
PSA density positive 18 14 (43.8%) p<0.001
Non-obese and PSA <10
PSA density negative 283 25 (8.1%)
PSA density positive 169 39 (18.8%) p<0.001
Table 3. Comparing sensitivity, specifi city and ROC AUC of total PSA and PSA density in obese and 
non-obese men
PSA 4 PSA density 0.15 p-value
Obese and PSA <20
Sensitivity 93.8% 70.0%
Specifi city 8.1% 74.2%
ROC AUC 0.507 0.731 p=0.004
Non-obese and PSA <20
Sensitivity 96.0% 67.0%
Specifi city 8.9% 51.4%
ROC AUC 0.623 0.653 p=0.5
Obese and PSA <10
Sensitivity 91.4% 58.3%
Specifi city 10.4% 81.8%
ROC AUC 0.452 0.692 p=0.008
Non-obese and PSA < 10
Sensitivity 94.0% 60.9%
Specifi city 11.8% 62.6%
ROC AUC 0.637 0.668 p=0.58
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The proportion of patients with a Gleason score ≥7 in PSA density-positive patients 
and in PSA density-negative patients were 36.0% and 22.8%, respectively (Chi-square test, 
p=0.076). Obese patients with positive PSA densities were associated with higher Gleason 
grades. The proportions of patients with a Gleason score ≥7 in the obese and non-obese 
groups were 48.9% and 32.7%, respectively (Chi-square test, p=0.035). 
Moreover, there was a trend suggesting that obese patients had a higher chance of bilateral 
disease. For PSA <10 ng/mL, the proportions of patients with bilateral disease in the obese 
and non-obese groups were 48.4% and 29.8%, respectively (Chi-square test, p=0.046). For 
PSA <20 ng/mL, the proportions of patients with bilateral disease in obese and non-obese 
groups were 46.8% and 34.1%, respectively (Chi-square test, p=0.099). 
DISCuSSIOn
Our results suggest that PSA density has significantly better performance for the diagnosis 
of prostate cancer in obese patients. Using PSA density 0.15 as a cutoff, obese patients with 
PSA <20 ng/mL had a four times (41.1% vs. 9.5%) greater risk of being diagnosing with 
prostate cancer if their PSA density was positive, whereas the increase in risk was only two 
fold (18.8% vs. 9.7%) in non-obese patients. This relationship was consistent in patients 
with PSA <10 ng/mL. This is the first time the performance of PSA density in prostate 
cancer diagnosis has been found to be related to body size. Therefore PSA density should be 
included in counseling of obese patients with elevated PSA. 
Obese men with prostate cancer suffer from higher rates of biochemical recurrences and 
mortality [9-10,16]. It has been postulated that the combination of lower PSA and larger 
prostate sizes (and more difficulties in digital rectal examinations) might lead to delay of 
diagnosis in obese men, subsequently leading to more advanced disease upon diagnosis and 
poorer treatment outcomes. To date, there has been no good solution to this situation.
We postulate that as obese men have significantly higher prostate volumes (TRUS vol-
umes in obese and non-obese men were 63.2 ml and 51.6 ml respectively, t-test, p<0.001), 
but only slightly lower total PSA [8], the PSA density in obese men is likely to be lower than 
in non-obese men with the same risk of prostate cancer. Therefore, a high PSA density is 
more useful in predicting the risk of prostate cancer in obese men. The overall ROC curve 
AUC of PSA density in our study (0.662) was similar to published results by Djavan (0.628) 
and Catalona (0.680) [13,15].
Consistent with previous studies [9], our results showed that obesity is associated with 
higher Gleason grades in men diagnosed with prostate cancer. A higher rate of bilateral 
core involvement was also observed in this study. Therefore, obesity is associated with more 
advanced disease at diagnosis.
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Th e drawbacks of this study are its retrospective nature and the lack of comparison 
with other markers such as free-to-total PSA, p2PSA, and PCA3 [17-18]. However, as PSA 
density does not require additional laboratory testing and the prostate size measurement 
can be performed during consultations, it would be a simple method for improving PSA 
performance as a predictor of cancer, particularly in obese patients. 
COnCluSIOn
PSA density has better specifi city and AUC in obese men, and those with positive PSA 
density (>0.15) have four times the risk of prostate cancer. TRUS prostate volumes and PSA 
density should be obtained for better counseling of this group of patients.
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AbSTRACT
background
To adapt the well performing ERSPC risk calculator to the Chinese setting and perform an 
external validation.
Methods
The original ERSPC risk calculator 3(RC3) for Prostate cancer(PCa) and high grade 
PCa(HGPCa) was applied to a development cohort of 3006 previously unscreened Hong 
Kong Chinese men with initial transrectal biopsies performed from 1997-2015, Age 50-
80, PSA 0.4-50ng/mL, and Prostate volume 10-150ml. A simple adaptation to RC3 was 
performed and externally validated in a cohort of 2214 Chinese men from another Hong 
Kong hospital. The performance of the models were presented in calibration plots, area-
under-curve(AUC) of Receiver operating characteristics(ROC), and decision curve analyses. 
Results
PCa and HGPCa was diagnosed in 16.7%(503/3006) and 7.8%(234/3006) men in the 
development cohort, and 20.2%(447/2204) and 9.7%(214/2204) men in the validation 
cohort, respectively. The AUCs using the original RC3 model in the development cohort 
were 0.75 and 0.84 for PCa and HGPCa respectively, but the calibration plots showed 
considerable over-estimation. In the external validation of the recalibrated RC3 model, 
excellent calibration was observed, and discrimination was good with AUCs of 0.76 and 
0.85 for PCa and HGPCa, respectively. Decision curve analyses in the validation cohort 
showed net clinical benefit of the recalibrated RC3 model over PSA.
Conclusions
A recalibrated ERSPC risk calculator for the Chinese population was developed, and it 
showed excellent discrimination, calibration, and net clinical benefit in an external valida-
tion cohort. 
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InTRODuCTIOn
Prostate-specifi c antigen (PSA) has been widely used as a screening tool for prostate cancer 
diagnosis. Th e European Randomized Study of Screening for Prostate Cancer (ERSPC) has 
shown a 21% reduction in prostate cancer mortality at 13 year follow-up, but it was also as-
sociated with unnecessary biopsies, overdiagnosis and overtreatment of potentially indolent 
cancers. 1 Th erefore, using PSA as the only tool to stratify risk of patients is not appropriate.
Risk calculators have been created in diff erent populations to better predict prostate can-
cer with the aim of reducing unnecessary biopsies. Commonly used risk calculators included 
the ERSPC risk calculator 2-3, the Prostate Cancer Prevention Trial (PCPT) risk calculator 4, 
and the Sunnybrook risk calculator 5. Most risk calculators incorporated prostate volume as 
it greatly improved the predictive performances. 6
Validation studies for the diff erent risk calculators have mainly been done in Caucasians, 
and within this particular setting already showed variable performance of the diff erent risk 
calculators, mainly related to calibration. 7-13
A well validated risk calculator for prostate cancer in Chinese is lacking. In this study, 
we aim to apply the original ERSPC risk calculator 3 (RC3) 2 for initial biopsies which 
overall shows excellent discrimination in diff erent settings, in a cohort of Chinese men. After 
recalibration to the Chinese setting, an external validation of the newly adapted ERSPC RC 
was performed. 
MATERIAlS AnD METHODS
From August 1997 to December 2015, 5165 Chinese patients in a prospectively maintained 
database with transrectal ultrasound (TRUS) guided prostate biopsy performed in a tertiary 
referral centre (Hospital 1) in Hong Kong were included (Development cohort). Out of 
5165 patients, 3006 consecutive patients having initial biopsies with Age 50-80 years, 
PSA 0.4-50ng/mL(WHO calibration), and TRUS prostate volume (TRUS-PV) 10-150ml 
were included for validation of the original ERSPC risk calculator 3(RC3) (www.prostate-
riskcalculator.com). 2 Th e variables in the original RC3 included TRUS-PV, TRUS fi nding 
(normal or abnormal), DRE (normal or abnormal), and PSA. PSA was taken in a clinical 
setting in both hospitals, in men with diff erent degrees of urinary tract symptoms.
TRUS-PV was calculated by the ellipsoid formula. All biopsies were evaluated by 
genitourinary pathologists blinded to blood results. Th e primary outcomes were prostate 
cancer (PCa) and high grade prostate cancer (PCa), the latter being defi ned as Gleason 7 or 
above PCa. Th is study conformed to the provisions of the Declaration of Helsinki, and was 
approved by the ethics committee of both hospitals.
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We applied the ERSPC RC3 to the development cohort (Hospital 1) and recalibrated 
the model for the Chinese population. This recalibrated formula was externally validated in 
a validation cohort of 2214 Hong Kong Chinese men from another tertiary referral centre 
(Hospital 2). The TRUS biopsies in this clinical cohort were performed from September 
1999 to December 2013, and 2214 consecutive men with the same inclusion criteria as the 
development cohort were included. 
The baseline characteristics of the cancer and non-cancer patients were compared us-
ing Mann-Whitney U test for continuous data and the chi-square test for categorical data. 
The discriminative ability of the RC3 was analyzed using receiver operating characteristics 
(ROC) and area under the curves (AUC). Calibration plots were created with observed 
and predicted risk of prostate cancer. Decision curve analyses (DCA) 14 were performed to 
show any net benefit of the recalibrated model over PSA in the validation cohort. Statisti-
cal analyses were performed in IBM SPSS Statistics for Windows version 22(IBM Corp., 
Armonk, NY, USA). Calibration plots and DCA curves were created with R version 3.1.1 
(The R Foundation for statistical computing, Vienna, Austria). A 2-sided p-value of <0.05 
was considered significant.
RESulTS
Baseline characteristics of the development and validation cohorts were listed in Table 1. 
All 5220 men from the development and validation cohorts had TRUS biopsy performed. 
In the development cohort (Hospital 1), 16.7%(503/3006) and 7.8%(234/3006) men 
were diagnosed with PCa and HGPCa, respectively. In the validation cohort (Hospital 
2), 20.2%(447/2214) and 9.7%(214/2214) men were diagnosed with PCa and HGPCa, 
respectively. Table 2 listed the baseline characteristics of cancer and non-cancer patients. 
Patients with prostate cancer had significantly higher age and PSA values, higher proportion 
of abnormal DRE, and smaller prostates. 
The ERSPC RC3 for PCa and HGPCa was applied to the development cohort (n=3006), 
and the calibration plots are shown in Figure 1A and 1B. The AUCs were 0.75 (95% CI: 
0.73-0.78) and 0.84 (95% CI: 0.81-0.87) for PCa and HGPCa respectively, but the calibra-
tion was poor with over-estimation of 10-40% for PCa and 10-30% for HGPCa across the 
whole range of predicted probabilities. 
Adaptations of the formulas (by setting-specific adjustments to the intercept constant) 
were performed separately for PCa and HGPCa, and the recalibrated models were applied 
to the validation cohort (n=2214). The external validation showed excellent calibration 
(Figure 1C-1D) across the whole range of predicted probability with calibration slopes of 
0.91 and 0.92, and intercepts of 0.17 and 0.03, for PCa and HGPCa respectively. The AUCs 
of the recalibrated model for PCa and HGPCa were 0.76 (95% CI 0.73-0.79) and 0.85 
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Table 1. Baseline characteristics of the development and validation cohorts
Median
IqR1
All
n=5220
Development cohort
Hospital 1 
n=3006
validation cohort
Hospital 2
n=2214
Age (years) 68
62 - 73
67
62 - 72
68
62 - 73
PSA (ng/mL) 7.3
5.2 – 11.2
7.3
5.3 – 11.5
7.2
5.2 – 11.0
TRUS-PV2 (ml) 43.0
31.0 – 59.7
46.4
33.0 – 63.2
39.5
29.5 – 54.9
Abnormal TRUS fi ndings 254 (8.4%) N/A3
Abnormal DRE 825 (15.8%) 437 (14.5%) 388 (17.5%)
TRUS biopsy cores
6-8 cores 1193 (22.9%) 1071 (35.6%) 122 (5.5%) 
9-10 cores 3513 (67.3%) 1908 (63.5%) 1605 (72.5%) 
>10 cores 495 (9.5%) 14 (0.5%) 481 (21.7%) 
Missing 19 (0.4%) 13 (0.4%) 6 (0.3%) 
Any grade prostate cancer 950 (18.2%) 503 (16.7%) 447 (20.2%)
High grade prostate cancer 448 (8.6%) 234 (7.8%) 214 (9.7%)
1IQR = Inter-quartile range, 2TRUS-PV = Transrectal ultrasound prostate volume, 3N/A = not avail-
able
Table 2. Baseline characteristics of the cancer and non-cancer patients from pooled data of both hos-
pitals.
Median
IqR1
All
n=5220
Cancer patients
n=950
non-cancer patients
n=4270 p-values3
Age (years) 68
62 - 73
71
66 - 75
67
62 - 72
<0.001
PSA (ng/mL) 7.3
5.2 – 11.2
10.0
6.2 – 18.9
7.0
5.1 – 10.1
<0.001
TRUS-PV2 (ml) 43.0
31.0 – 59.7
34.3
25.1 – 46.6
45.5
32.9 – 61.7
<0.001
Abnormal TRUS4 83/503 (16.5%) 171/2503 (6.8%) <0.001
Abnormal DRE 825 (15.8%) 319 (33.6%) 506 (11.9%) <0.001
Gleason sum
<6  24 (2.5%)   
6  468 (49.3%)   
7  181 (19.1%)   
8-10  267 (28.1%)   
Missing  10 (1.1%)   
1IQR = Inter-quartile range, 2TRUS-PV = Transrectal ultrasound prostate volume. 3analyses between 
cancer and non-cancer patients. 4TRUS abnormality data available in development cohort only 
(n=3006)
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 4 (95% CI 0.82-0.87) respectively. The AUCs of PSA only for PCa and HGPCa in the same 
cohort were 0.68 (95% CI 0.68-0.71) and 0.76 (95%CI 0.72-0.80) respectively. 
The performance of the adapted formula was found to be similar in different time peri-
ods (1999-2004, 2005-2009, and 2010-2013) and in different number of biopsy cores (≤8, 
9-11, and ≥12 biopsy cores) in the validation cohort. 
Decision curves were plotted in both development and validation cohorts for assessment 
of clinical utility. (Figure 2) The black line and grey line represent the strategies of perform-
ing biopsies in all and none of the patients, respectively. For the portion of the coloured 
curves with net benefit above both black and grey lines, the area between them represents 
its clinical applicability. Figure 2A compares the original and the recalibrated ERSPC RC3 
Figure 1. Calibration plots for A. Any prostate cancer in the development cohort using the original 
ERSPC RC3 formula, B. High grade prostate cancer in the development cohort using the original 
ERSPC RC3 formula, C. Any prostate cancer in the validation cohort using the Recalibrated ERSPC 
RC3 formula, D. High grade prostate cancer in the validation cohort using the Recalibrated ERSPC 
RC3 formula
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in PCa prediction in the development cohort, and the recalibrated RC3 curve demonstrates 
higher net clinical benefi t than the original RC3 curve. Th e same phenomenon is observed 
in HGPCa (Figure 2B). In the validation cohort, the recalibrated RC3 demonstrates net 
clinical benefi t over PSA only for both PCa (Figure 2C) and HGPCa (Figure 2D) across the 
whole range of risk thresholds. 
Th e number of biopsies that can be avoided and the number of cancers missed at diff er-
ent predicted probability from the new model in the validation cohort are listed in Table 3. 
At 5% and 10% risk threshold for PCa, 12.0% and 41.8% of all biopsies could have been 
saved respectively. At 5% and 10% risk threshold for HGPCa, 57.9% and 76.9% of all 
biopsies could have been saved respectively. 
Th e nomograms for any grade PCa and HGPCa were shown in Figure 3A and Figure 3B, 
respectively. 
Figure 2. Decision curve analyses for A. Any prostate cancer in the development cohort comparing 
original and recalibrated ERSPC RC3 formula, B. High grade prostate cancer in the development 
cohort comparing original and recalibrated ERSPC RC3 formula, C. Any prostate cancer in the valida-
tion cohort comparing PSA and recalibrated ERSPC RC3 formula, D. High grade prostate cancer in 
the validation cohort comparing PSA and recalibrated ERSPC RC3 formula.
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DISCuSSIOn
In this study, it has been shown that the original ERSPC risk calculator 3 (RC3) for initial 
biopsies showed good discrimination but overestimated the positive biopsy rates of PCa and 
HGPCa in a total of 3006 Hong Kong Chinese men. After a simple recalibration of the 
ERSPC RC3 for Chinese patients, the external validation in another Hong Kong Chinese 
cohort of 2214 men demonstrated excellent discrimination and calibration. The decision 
curves show net clinical benefit over the whole range of thresholds in both PCa and HGPCa. 
Significant proportions of prostate biopsies could have been saved at different risk thresholds 
using the risk calculator. 
The ERSPC RC was shown to perform well in another Dutch clinical cohort, despite 
that it was, contrary to the development cohort, a contemporary clinical setting, showing 
excellent calibration in addition to an AUC of 0.77. 7 When the ERSPC RC was applied 
to Finnish and Swedish men, again good AUCs of 0.76 and 0.78 respectively were shown, 
however calibration showed a 10-15% overestimation of the probability of being diagnosed 
with prostate cancer. 8 In a clinical cohort of Swiss men, comparing the performance of the 
ERSPC RCs and the PCPT RC 2.0, the ERSPC RC showed poor calibration and both 
had fair AUCs of 0.65 and 0.66 for any PCa and AUCs of 0.73 and 0.70 for significant 
Table 3. Number of biopsies that can be reduced compared to all-biopsy strategy using the recalibrated 
ERSPC RC3 in the validation cohort (n=2214).
Risk 
threshold
no. men 
biopsied*
no. biopsies saved 
(% of total*)
no. PCa 
detected#
no. PCa missed
(% of total #)
no. HG PCa 
missed (% of 
total #)
PCa 2214 0 447 0 0
5% 1948 266 (12.0%) 432 15 (3.4%) 3 (0.7%)
10% 1288 926 (41.8%) 375 72 (16.1%) 12 (2.7%)
15% 905 1309 (59.1%) 320 127 (28.4%) 35 (7.8%)
20% 656 1558 (70.4%) 269 178 (39.8%) 52 (11.6%)
Risk 
threshold
No. men 
biopsied**
No. biopsies saved 
(% of total**)
No. HGPCa 
detected##
No. of HGPCa 
missed (% of 
total##)
HGPCa 2214 0 214 0
2.5% 1412 802 (36.2%) 198 16 (7.5%)
5% 933 1281 (57.9%) 173 41 (19.2%)
10% 511 1703 (76.9%) 144 70 (32.7%)
15% 354 1860 (84.0%) 127 87 (40.7%)
20% 269 1945 (87.9%) 116 98 (45.8%)
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Figure 3. Nomograms for A. Prediction of Any grade prostate cancer, and B. Prediction of High grade 
prostate cancer.
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PCa respectively. Decision curve analyses revealed a comparable net benefit for any prostate 
cancer and a slightly greater net benefit for significant prostate cancer using the ERSPC-RC. 
11 In an Irish population with a wide range of PSA and 58% positive biopsy rate, the ERSPC 
RCs was shown to perform better than PCPT RC 2.0 (AUC 0.71 Vs 0.64), but both RCs 
under-estimated the rates of PCa and HGPCa. 12 A study in Canadian men also showed the 
superior performance of ERSPC RCs over PCPT RCs (AUC 0.71 Vs 0.63).10 The PCPT-RC 
was better calibrated in the higher prediction range (40-100%), whereas the ERSPC-RC had 
better calibration and avoided more biopsies in the lower risk range (0-30%). 10 A study of 
PCPT RC on 10 different European and North American cohorts showed that the AUC of 
predicting HGPCa varied from 0.64 to 0.88. 13
In summary, the performance of both RC’s is variable in different Caucasian population 
due to differences in setting and prevalence. Over-estimation or under-estimation of PCa 
risks and poor calibrations were observed. This implies that external validation is crucial even 
within a comparable setting. 
As a result of PCa epidemiological differences in different regions of the world, a specific 
risk calculator is needed to allow accurate PCa risk prediction. This can be done with creat-
ing yet another model or by recalibration of an existing RC with proven good discriminatory 
capability, based on high quality data of sufficient sample size, followed by a proper external 
validation. Regular adjustments to existing models might also be required in the face of 
changing epidemiology. 15
To our knowledge a validated well performing risk calculator or nomogram suitable for 
the Chinese population is currently not available. In the current study, the ERSPC RC3 was 
recalibrated in a clinical Chinese cohort and that was externally validated in another Chinese 
population. Excellent calibration was observed in the external validation cohort. This new 
model, although originally based on European data can be of value in the Chinese setting 
and will be incorporated in a mobile phone app (Rotterdam prostate cancer risk calcula-
tor) and website (www.prostatecancer-riskcalculator.com) in English and Chinese language 
specifically for prediction of PCa and HGPCa risks in Chinese men.
In recent years, prostate health index (PHI) has been shown to perform better than PSA 
in predicting PCa and HGPCa in both Caucasians and Asians. 16-17 Nomograms incorporat-
ing PHI have been shown to further improve the performance of PHI in external validation 
studies, 18 but the additional value of PHI to existing ERSPC RCs was small. 19 Addition of 
PCA3 and a 4-K panel to the original ERSPC risk calculator in prescreened men improved 
the AUC of the model by 3% and 1% respectively. 20 Widespread use of the novel blood and 
urine markers in Asia or China has been hampered by cost and availability. Multi-parametric 
MRI has been shown to be promising in selecting significant cancers and enabling targeted 
biopsies, but there are still considerable false positives and false negatives, especially in 
Prostate multi-parametric magnetic resonance imaging (PI-RADS) 3 lesions. 21-22 It is more 
and more common for Chinese patients to have an MRI prostate done with elevated PSA, 
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but most are performed without a standardized multi-parametric MRI scanning protocol 
and reporting system. Th e lack of qualifi ed interpreters of the MRI images and the lack 
of targeted biopsy facilities currently limit the role of MRI in this region. Th erefore, most 
biopsy decisions in Asia or China are still based on PSA alone.
Having a lower prostate cancer incidence in China and lower positive biopsy rates, a 
simple, easily accessible, inexpensive, and validated RC should be used to avoid signifi cant 
number of unnecessary biopsies based on PSA only. Th e validated risk calculator in this 
study provides Chinese men with such a tool, with simple and commonly available clinical 
parameters, and without the extra costs and expertise required in novel biomarkers and/or 
imaging.
Th e main strength of this study is that this is the fi rst large scale adaptation and external 
validation of a PCa risk calculator tailored for the clinical Chinese population. Th e discrimi-
nation and calibration was excellent in the validation cohort and supports using this RC in 
Chinese patients. 
Th ere are certain limitations to this study. Firstly, all patients in the development and 
external validation cohort were Chinese men, and whether this risk calculator could be 
applicable to other Asian men needs further validation. Secondly, this new ERSPC risk 
calculator is currently only applicable to patients with initial biopsies. 
COnCluSIOnS
A recalibrated ERSPC risk calculator for the Hong Kong Chinese population was developed 
and demonstrated excellent predictive abilities in an external validation cohort of Chinese 
men. In future, the risk calculator tailored for Chinese men should be used for risk stratifi ca-
tion before prostate biopsy and should replace purely PSA based decision 
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AbSTRACT
Objective
To investigate biopsy complications and hospital admissions that could be reduced by the 
use of ERSPC risk calculators(RC). 
Materials and Methods
All biopsies in the Rotterdam section of the ERSPC from 1993 to 2015 were included. 
Biopsy complications and hospital admission data were prospectively recorded in question-
naires that were completed 2 weeks after biopsy. The ERSPC RC3 and RC4 were applied 
to men attending the first and subsequent rounds of screening, respectively. Applying the 
predefined RC3/4 probability cut-offs for prostate cancer(PCa) risk of ≥12.5% and high 
grade PCa(HGPCa) risk ≥3%, we assessed the the number of complications, admissions and 
costs that could be reduced by avoiding biopsies in men below these cut-offs.
Results
10747 biopsies with complete questionnaires were included. A total of 7294(67.9%) 
complications, 3.9%(416/10747) post-biopsy fever, and 0.9%(92/10747) hospital admis-
sions were recorded. Fever rate has been static over the years, but hospital admissions had 
tripled from 0.6%(1993-1996) to 2.1%(2009-2015). Among 7704 biopsies which fit 
the criteria of RC3 or 4, 35.8%(2757/7704) biopsies, 37.4%(1972/5268) complications, 
38.4%(123/320) fever, and 42.3%(30/71) admissions could have been avoided by using 
one of the RCs. More complications could have been avoided in the case of RC4 or more 
recent biopsies(2009-2015). 35.9% of the total cost of biopsies and complication treatment 
could be saved. 
Conclusion
A significant proportion of biopsy complications, hospital admissions, and costs could be 
reduced if biopsy decisions were based on ERSPC risk calculators instead of PSA only, and 
this effect was most prominent in more recent biopsies and in men with repeated biopsies 
or screening.
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1. InTRODuCTIOn
Th e European Randomized study of Screening for Prostate Cancer (ERSPC) showed a reduc-
tion of prostate cancer mortality with PSA screening, but it was associated with substantial 
unnecessary biopsies, over-diagnosis and over-treatment. [1] Sepsis and other complications 
are common after prostate biopsies and they have been on the rise in recent years [2-3]. 
Th ese complications are associated with increased morbidities, hospital admissions, and 
costs. [4] Hence, complications and especially those in unnecessary biopsies increase the 
morbidities and costs of screening. 
Risk factors for post-biopsy infections are variable in diff erent studies. Th e biopsy sepsis 
rates in the Rotterdam section of the ERSPC have been reported, and diabetes mellitus and 
prostate enlargement were signifi cant risk factors for fever after biopsy [5]. A large Swedish 
cohort, on the other hand, showed that prior urinary tract infection, a higher Charlson 
comorbidity index, and diabetes mellitus were risk factors for post-biopsy infections. [6] 
Risk factors form the basis for targeted infection prophylaxis in certain patient groups, 
but augmented or more potent antibiotics might eventually result in future antimicrobial 
resistance. [3] In addition, post-biopsy bleeding and/or pain are not being avoided with this 
approach. 
Th e best way of reducing biopsy complications is to reduce the number of unnecessary 
biopsies. Externally validated risk calculators (RC) like the ERSPC RC and the Prostate 
Cancer Prevention Trial (PCPT) RC [7-9] have been developed to more accurately assess 
the risk of prostate cancer and as such reduce the number of unnecessary biopsies. Th e use 
of RC3/4 at initial or second screening was shown to reduce unnecessary biopsies by 33 to 
37% while detecting all life threatening PCa cases [7].
In the current study we do not focus on prostate cancers detected in relation to biopsies 
saved but we assess the potential of pre-biopsy risk stratifi cation using the ERSPC RCs in 
avoiding various biopsy complications and hospital admissions. In addition, we estimate the 
eff ect on associated costs. 
2. MATERIAl AnD METHODS
2.1 Study population and antibiotic prophylaxis
All prostate biopsies from 1993 to 2015 in the Rotterdam section of the ERSPC were 
included in this study. [10]. Th e standard antibiotic prophylaxis was given 2 hours before 
and 4 hours after a prostate biopsy. Oral Trimethoprim-sulfamethoxazole was used until 
2008, and oral Ciprofl oxacin thereafter. For patients considered at higher risk of infection, 
i.e. patients with diabetes on insulin, steroid, or prosthesis, a 5-day course of ciprofl oxacin 
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was given. For patients with history of endocarditis or artificial cardiac valves, intravenous 
Amoxicillin was given 1 hour prior to prostate biopsy on top of the standard regime. 
2.2 Prospective assessment of complications
A questionnaire on complications was completed by the attending doctor when each man 
returned for the standard 2-week post-biopsy follow-up for pathology results. Complica-
tions after prostate biopsy in the questionnaire included fever, hematuria, hematospermia, 
pain (persistent after biopsy), and any hospital admission within the first 2 weeks. These 
complication data, together with baseline clinical information, were prospectively recorded 
into the study database. In the first part of this study we analyzed the complication and 
admission rates, and in addition assessed potential predictors of complications in 10747 
biopsies with complication information available. 
2.3 Applying the ERSPC risk calculators
In the second part of this study, the proportion of biopsies, complications, and admissions 
that could be avoided by applying the ERSPC risk calculators (RC) for men with a PSA 
value ≥3.0 ng/ml at initial and repeat biopsy was assessed. [7] RC3 was applied to men in 
the first round of screening. RC4 was applied to men in all subsequent rounds of screening 
(Rounds 2 to 5) independent of previous biopsy status. (www.prostatecancer-riskcalculator.
com). [7-8] For both RC3 and RC4, a cutoff of 12.5% for prostate cancer (PCa) and 3% 
for high grade PCa (HGPCa) was used according to previously published data. [7] HGPCa 
was defined as PCa with clinical T-stage >T2b and/or Gleason score ≥7. [8] Complications, 
admissions, and costs that could have been reduced by avoiding biopsies in men with RC3/4 
PCa risks less than 12.5% and HGPCa less than 3% were assessed. Data on healthcare costs 
that could have been saved by avoiding biopsies and hospital admissions were obtained from 
reimbursement data from the hospital finance department. 
2.4 Statistical analyses
The baseline characteristics of men with or without post-biopsy fever and hospital admis-
sions were compared, using chi-square tests for categorical variables, and T-tests (for nor-
mally distributed data) and Mann Whitney U tests (for non-normally distributed data) for 
continuous variables. Multivariate analyses for prediction of fever and hospital admissions 
were performed with variables including age (continuous), diabetes mellitus, heart disease, 
prior negative biopsy (PNB), fever in previous biopsy, and prostate volume (continuous). 
Statistical analyses were performed in IBM SPSS Statistics for Windows version 21(IBM 
Corp., Armonk, NY, USA). A 2-sided p-value of <0.05 was considered significant. This 
study conformed to the provisions of the Declaration of Helsinki, and was approved by the 
ethics committee of the institution (Clinical trial number ISRCTN49127736).
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3. RESulTS
3.1 Patient characteristics and biopsy complications
A total of 10970 biopsies from 7422 men were performed in the Rotterdam section of the 
ERSPC from 1993 to 2015. Evaluation of 10747 questionnaires with complete complication 
and hospital admission data showed that a least one complication (any complication) oc-
curred in 67.9% (7294/10747) of biopsies. Post-biopsy fever occurred in 3.9% (416/10747) 
of biopsies, and hospital admission was required in 0.9% (92/10747) of biopsies. A com-
parison of baseline characteristics between men with and without fever, and men with and 
without admission, is listed in Table 1.
3.2 Trends of post-biopsy fever and admissions over time
In fi gure 1, it is shown that from 1993 to 2015, the incidence of fever after biopsy has been 
quite stable in the range of 3.7-4.4%, but the hospital admission rates gradually increased 
from 0.6% (1993-1996) to 2.1% (2009-2015) (linear-by-linear association test, p<0.001), 
and admissions due to fever gradually increased from 0.5% (1993-1996) to 1.6% (2009-
2015) (linear-by-linear association test, p<0.001) over the past 20 years. 
Table 1. Baseline characteristics of the ERSPC Rotterdam section who received a prostate biopsy. 
Total (n=10747) Fever vs no fever
Admission vs no 
Admission
Age, yr, median (IQR)a 68.0 (64.0-71.5) 67.2 Vs 67.4, p=0.559b 68.1 Vs 67.4, p=0.136b
Prostate volume, ml, median 
(IQR)
45.0 (34.0-59.4) 52.6 Vs 49.5, p=0.005b 58.2 Vs 49.5, p<0.001b
Fever in previous biopsy, n(%) 100 (0.9%) 8.0% Vs 3.8%, p=0.032c 5.0% Vs 0.8%, p<0.001c
Diabetes, n(%) 692 (6.4%) 5.3% Vs 3.8%, p=0.036c 1.6% Vs 0.8%, p=0.032c
Heart disease, n(%) 1883 (17.5%) 3.9% Vs 3.9%, p=0.969c 1.0% Vs 0.8%, p=0.441c
Any complications, n(%) 7294 (67.9%)
Fever, n(%) 416 (3.9%)
Hematuria, n(%) 2733 (25.4%)
Haematospermia, n(%) 5369 (50.0%)
Pain, n(%) 490 (4.6%)
Hospital admission, n(%) 92 (0.9%)
aIQR = Inter-quartile range, bindepedent sample T-test, cChi-square test.
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3.3 Risk factors for post-biopsy fever and admissions
Multivariate analyses of potential predictors showed that diabetes mellitus and larger 
prostates (volume) were the only 2 significant predictors for post-biopsy fever, while larger 
prostates (volume), fever in previous biopsy, and more recent biopsies (biopsy year) were the 
3 predictors for hospital admissions. (Table 2)
3.4 Applying the ERSPC risk calculators
Among the 10747 biopsies with completed questionnaire, we excluded 2218 biopsies in 
men with PSA <3ng/mL (biopsy done in side studies for various indications), 346 early 
repeat biopsies within 6-8 weeks for high grade prostatic intraepithelial neoplasia or atypical 
small acinar proliferation, 41 biopsies which lacked RC data, and 438 biopsies which were 
Figure 1. The change in post-biopsy fever and hospital admissions over time
Table 2. Multivariate analyses of post-biopsy fever and hospital admissions. (n=10747)
Fever* Admission (all cause)*
Age at biopsy (continuous) 0.98 (0.96-1.01); p=0.163 0.97 (0.92-1.02); p=0.221
Biopsy year (continuous) 1.01 (0.99-1.03); p=0.390 1.11 (1.06-1.16); p<0.001
Prostate volume (continuous) 1.01 (1.00-1.01); p=0.006 1.01 (1.00-1.02); p=0.003
Diabetes 1.42 (1.00-2.02); p=0.048 1.61 (0.85-3.06); p=0.147
Heart disease 1.02 (0.79-1.33); p=0.865 1.20 (0.72-2.02); p=0.481
Fever in previous biopsy 2.01 (0.97-4.19); p=0.061 4.52 (1.77-11.58); p=0.002
*Data presented in Odds ratios (95% confidence interval); p-values
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not performed at the year of screening. Th is resulted in 7704 evaluable biopsies for the RC 
analysis.
RC3 (fi rst round of screening) and RC4 (all subsequent rounds) cutoff s of 12.5% for 
PCa and 3% for HGPCa were applied. When biopsies were not performed in men with 
risks lower than the cutoff , a reduction of 35.8% (2757/7704) biopsies, 37.4% (1972/5268) 
complications, 38.4% (123/320) fever, and 42.3% (30/71) hospital admissions could be 
established. (Table 3) Th e reduction in biopsies, complications and admissions were more 
prominent when RC4 was applied to men in the 2nd- 5th rounds of screening and/or previous 
negative biopsy. 
3.5 Costs 
Th e median number of days of admission was 5 (Interquartile range 4-6) days, and among 
the admitted patients, 1 patient stayed in the ICU for 2 days. Th e cost of each systematic 
prostate biopsy was €1276, the average daily cost of hospital admission for post-biopsy 
complication was €535, and each general practitioner visit was €175. When all 7704 men 
were subjected to biopsy, the total cost of biopsies, admissions and general practitioner visits 
was estimated to be €437.557 per year [(€1276 x 7704 + €535 x 5 x 71 + €175 x 249) 
divided by 23 years]. If biopsy decisions would have been made according to the ERSPC 
RC recommendations of 12.5% for PCa and 3% for HGPCa, the total costs of biopsy, 
admissions and general practitioner visits that could have been avoided was estimated to be 
€157.150 per year [(€1276 x 2757 + €535 x 5 x 30 + €175 x 93) divided by 23 years], a 
35.9% cost reduction.
Table 3. Biopsies, Complications, and Admissions that could be reduced by avoiding biopsies in ap-
plying ERSPC risk calculator 3 (RC3) and risk calculator 4 (RC4). (n=7704)
Events reduced by avoiding 
biopsy if RC3 or RC4: PCaa 
risk <12.5% AnD HGPCab 
risk <3%
Whole cohort (RC3 
or RC4)
n=7704
RC3 for fi rst round of 
screening and without 
previous biopsies 
n=3083
RC4 for 2nd – 5th rounds of 
screening and/or previous 
negative biopsy (RC4)
n=4621
Biopsy 35.8% (2757/7704) 27.1% (837/3083) 41.5% (1920/4621)
Any complications 37.4% (1972/5268) 28.2% (564/2000) 43.1% (1408/3268)
Fever 38.4% (123/320) 30.9% (38/123) 43.1% (85/197)
Hematuria 43.3% (893/2063) 32.1% (224/698) 49.0% (669/1365)
Haematospermia 35.8% (1363/3810) 27.4% (407/1483) 41.1% (956/2327)
Pain 39.0% (141/362) 33.3% (48/144) 42.7% (93/218)
Hospital admissions 42.3% (30/71) 15.4% (2/13) 48.3% (28/58)
aPCa = Prostate cancer, bHGPCa = High grade prostate cancer
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4. DISCuSSIOn
The current study showed that by using previously defined and validated ERSPC RC cutoffs 
in a screening cohort consisting up to 5 screening visits with a 4-year interval that, 35.8% 
of biopsies, 37.4% of biopsy complications and 42.3% of hospital admissions could be 
avoided in a screening cohort. An even higher proportion of these complications could be 
avoided in biopsies of more recent years (2009-2015), in men with multiple screening epi-
sodes and repeated biopsies. Therefore, besides avoiding unnecessary biopsies and potential 
overdiagnosis, using the ERSPC RC has the additional benefit of reducing morbidities due 
to (severe) biopsy complications. Up to date, this is the first study to describe this additional 
benefit of applying a risk based strategy in the decision to perform a prostate biopsy. 
The original versions of ERSPC RC3 and RC4 including TRUS prostate volume, TRUS 
lesion and DRE abnormality were used in this study. (www.prostatecancer-riskcalculator.
com) [7] When TRUS is not readily available in the Urology clinic, the DRE versions of 
RC3 and RC4 using DRE-estimated prostate volume (DRE-PV) were shown to be similarly 
effective in achieving a good prediction for PCa and HGPCa [8,11].
Most fever cases did not require hospital admission and were managed by general prac-
titioners or emergency department doctors. Less than 1% of biopsied men required hospital 
admission within 2 weeks, and most hospitalizations were due to biopsy-related infections. 
Although only 0.9% of the whole cohort required hospital admission, these men usually 
required a period of intravenous antibiotics, resulting in a median hospital stay of 5 days. 
The post-biopsy fever rates were stable over the years (3.7-4.4%), but admissions increased 
more than 3 times from 0.6% (1993-1996) to 2.1% (2009-2015) (Figure 1). This might 
be explained by a significantly increasing proportion of diabetes mellitus (an independent 
predictor of biopsy fever in multivariate analysis) in men having biopsy over the years: 4.6% 
in 1993-1996, 5.1% in 1997-2000, 6.3% in 2001-2004, 9.9% in 2005-2008, and 10.3% 
in 2009-2015. Even though a proportion of diabetic patient already received a longer course 
of oral antibiotics after biopsy, the infection rate was still increasing. Larger prostate being 
more pronounced in the more recent rounds of screening (mean of 51.2ml in 1993-1996 
and 56.4ml in 2009-2015) was also associated with more biopsy infections. Increasing age 
(mean of 66.5 years in 1993-1996 and 71.8 years in 2009-2015) was not associated with 
more infection in multivariate analysis. The increasing admissions in more recent years could 
be due to more severe infection at presentation and/or lower threshold in admitting older 
patients with more comorbidities. 
Other complications described in this study included hematuria (25%), haematospermia 
(50%), and persistent pain after biopsy(5%). These were mostly self-limiting and did not 
require hospital admission. However, hematuria and haematospermia were very common 
and they added to the suffering of a significant proportion of men with biopsies done, in 
which more than 1/3 of them might be unnecessary. It has been described in a cohort of 
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active surveillance patients that men were less likely to receive scheduled repeated biopsies 
when there were previous biopsy complications. [12] Although the current study was not 
on active surveillance patients, it could be postulated that the complications experienced 
in prior biopsies might deter men from receiving another biopsy even when the indication 
was stronger by that time. Th ere was no biopsy-related mortality from 1993 to 2015, which 
confi rmed the rare mortality rate in a previous systematic review. [3]
Th e multivariate analyses predicting infection and admission were updates from a previ-
ously published report in the same cohort from 1993-2011 (n=9241). [13] Th e multivariate 
analyses were repeated in 10747 biopsies 1993-2015 in the current study. For post-biopsy 
infections, diabetes and larger prostates were the only 2 signifi cant risk factors as previously 
reported. [13] However, for hospital admission prediction, in addition to the previously 
reported risk factor of later year of biopsy, infection in previous biopsy episodes and larger 
prostates were also signifi cant risk factors. Th e diff erences observed in the risk factors for 
hospital admissions would likely be related to a signifi cant increase in admission rates 
(mostly related to severe infection) from 0.8% before 2011 to 2.9% after 2011.
Blood markers like Prostate health index (PHI), urine markers like Prostate Cancer 
Antigen 3 (PCA3), and multiparametric MRI (mpMRI) of the prostate with or without 
combination with risk calculators are possible alternatives to reduce unnecessary biopsies and 
potentially their related complications. [14-17] However, they all incur additional facilities 
or costs, and in the case of diagnostic mpMRI prostate, there are still signifi cant variations 
in reporting quality despite the availability of standardized Prostate Imaging - Reporting and 
Data System (PI-RADS) reporting. [18]
Th e main strength of this study was the prospective collection and continual recording of 
complications and admission data within a large randomized screening cohort over 23 years. 
Th ere were certain limitations in this study. Some complications like retention of urine 
or per rectal bleeding were not included in the questionnaire and therefore data was not 
available. Although complication data and admission episodes were prospectively recorded, 
the admission details (length of stay and any further morbidity) and hospital costs were 
retrospectively traced. Furthermore, the average cost instead of specifi c cost of each patient 
was quoted. 
COnCluSIOn
A signifi cant proportion of biopsy complications, hospital admissions, and associated costs 
could be reduced if biopsy decisions were done on the basis of an individual multivariate risk 
assessment using the ERSPC risk calculators. Th is eff ect was most prominent in men having 
had multiple biopsy sessions. 
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AbSTRACT
Purpose
To investigate the role of the Prostate Health Index (phi) in prostate cancer (PCa) detection 
in patients with a prostate-specific antigen (PSA) level of 4–10ng/mL receiving their first 
prostatic biopsy in an Asian population. 
Methods
This was a retrospective study of archived serum samples from patients enlisted in our tissue 
bank. Patients over 50 years old, with PSA level of 4–10ng/mL, a negative digital rectal 
examination, and received their first prostatic biopsy between April 2008 and April 2013, 
were recruited. The serum sample collected before biopsy was retrieved for the measurement 
of various PSA derivatives and the phi value was calculated for each patient. The performance 
of these parameters in predicting the prostatic biopsy results was assessed.
Results
230 consecutive patients, with 21(9.13%) diagnosed with PCa, were recruited for this study. 
Statistically significant differences between PCa patients and non-PCa patients were found 
for total PSA, PSA density, [-2]proPSA(p2PSA), free-to-total PSA ratio (%fPSA), p2PSA-
to-free PSA ratio (%p2PSA), and phi. The areas under the curve of the receiver operating 
characteristic curve for total PSA, PSA density, %fPSA, %p2PSA, and phi were 0.547, 
0.634, 0.654, 0.768, and 0.781, respectively. The phi was the best predictor of the prostatic 
biopsies results. At a sensitivity of 90%, the use of the phi could have avoided unnecessary 
biopsies in 104 (45.2%) patients.
Conclusions
Use of the phi could improve the accuracy of PCa detection in patients with an elevated PSA 
level and thus avoid unnecessary prostatic biopsies.
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InTRODuCTIOn
Prostate cancer (PCa) is the second most common cancer in the world, and its incidence 
in the Asia-Pacifi c region is increasing. [1] Fortunately, the use of serum levels of prostate-
specifi c antigen (PSA) as a diagnostic tool has increased the detection rate of PCa at an 
earlier stage, when management with various therapies can adequately control the disease. 
[2] Unfortunately, the level of PSA in serum is not an ideal cancer biomarker, because it can 
be elevated due to many other conditions (such as benign prostatic hyperplasia and pros-
tatitis), and is therefore not cancer-specifi c. Th us, due to the false-positive results obtained 
by the PSA test during screening, many patients are subjected to an unnecessary transrectal 
ultrasound-guided prostatic biopsy (TRUSPB), which is an invasive procedure that can lead 
to signifi cant morbidity, and even mortality. [3,4] 
Many approaches have been explored to improve the performance of PSA in the detec-
tion of PCa, such as correlating the PSA level with the prostate volume (PSA density), the 
rate of change in PSA over time (PSA velocity), and the ratio of diff erent non-complexed 
forms of PSA in the serum. [5] One of the most recent approaches has been to measure the 
PSA isoform, [-2]proPSA (p2PSA) and its derivatives, and calculate the Beckman Coulter 
Prostate Health Index (phi). [6-8] In 2012, the US Food and Drug Administration approved 
the use of the phi for the detection of PCa in men over 50 years of age with a serum PSA 
level of 2–10 ng/mL and negative digital rectal examination (DRE) fi ndings. Th e initial 
clinical validation of this new marker to improve the detection of PCa compared with PSA 
was performed mainly on Caucasian populations. [9] To confi rm the clinical effi  ciency of 
the phi in an Asian population, we compared the performance of the phi with that of other 
PSA derivatives in the detection of PCa in patients with a serum level of PSA between 4 and 
10 ng/mL, who had been selected for an initial TRUSPB.
METHODS
Study design
Th is was a retrospective study on archived serum samples from patients enlisted in our 
prostate tissue bank. Patients with a total serum PSA level of 4–10 ng/mL (measured using 
a Roche Cobas e601 system with standardization against the WHO 96/670 reference stan-
dard) and negative DRE fi ndings who received their fi rst TRUSPB between April 2008 and 
April 2013 were recruited. As in most of the centres in our area, patients who are suspected 
of having PCa, because of either an elevated level of serum PSA > 4 ng/mL or an abnormal 
DRE, are recommended to have a TRUSPB for further assessment. In our centre, imme-
diately before each patient undergoes a TRUSPB, additional informed consent is obtained 
for blood collection to establish a prostate disease tissue bank, which has been approved by 
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our local institutional ethics committee. All of the studies were conducted according to the 
Declaration of Helsinki. If the patient agreed to participate in the study, then the blood was 
collected immediately before the biopsy. These archived sera are the basis of our study. 
Men aged 50 years or older with a serum PSA level in the range of 4–10 ng/mL and 
negative DRE findings were included in the study. A previous history of TRUSPB was an 
exclusion criterion and all men who were included had been scheduled for an initial biopsy. 
At least 10 systematic prostatic biopsy cores were taken during the TRUSPB, and all of 
the clinical data were available for review. The 10 cores of prostatic biopsy were based on 
the classical sextant biopsy with two additional lateral biopsies on each side. We used this 
10-core extended biopsy template for all our patients receiving their first TRUSPB. This 
template would be adequate for detecting PCa in men for their first biopsy, without excessive 
increases in complication rate. [10,11] Patients with a known history of PCa or a history of 
past prostatic surgery for any prostatic condition would be excluded. And patients with his-
tory of urinary tract infection, acute urinary retention, bladder stone and prostatic massage 
within three months before blood taking would be excluded. Patients had a history of use 
of a 5-α reductase inhibitor or any other drugs that have anti-androgenic properties (such 
as androgen receptor blockers, ketoconazole etc) at any time before blood collection were 
also excluded. Finally, patients whose serum samples had been archived for more than three 
years were not included.
After identifying the eligible subjects, their clinical data, serum samples collected before 
biopsy, and biopsy results were retrieved for the study. 
Specimens and laboratory analysis
Blood samples collected from consenting patients were immediately stored at 0oC and then 
processed (centrifuged and refrigerated) within 3 h of blood collection. The sera were then 
frozen at –70°C or below for future research. 
The measurement of serum PSA and its derivatives was performed with an Access2 
automated immunoassay analyzer system (Beckman Coulter, Brea, CA, USA). The research 
staffs who operated the system were blinded to the clinical information of the patients. The 
assay used was a paramagnetic particle, chemiluminescent immunoassay for the quantitative 
determination of p2PSA. The levels of total PSA (tPSA), free PSA (fPSA), and p2PSA were 
determined by calibration to the Hybritech standard. All assays were performed using the 
same batch of calibrators, and all results were obtained by a single determination.
The free-to-total PSA ratio (%fPSA) and p2PSA-to-free PSA ratio (%p2PSA) were calcu-
lated. The Beckman Coulter Prostate Health Index (phi) was determined by the formula phi 
= (p2PSA/fPSA) × (square root of tPSA). The levels of these parameters were then compared 
between patients diagnosed with PCa (PCa patients) and those with no evidence of PCa 
(non-PCa patients). The receiver operating characteristic (ROC) curves of these parameters 
were also constructed and compared.
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STATISTICAl METHODS
Th e PSA density was calculated by dividing the serum level of tPSA (measured by the 
Hybritech-calibrated Assess2 system) by the prostate volume (determined by transrectal 
ultrasound during the biopsy). Th e diff erences in mean age, prostate volume, and levels 
of various PSA derivatives between the PCa and non-PCa patients were assessed using the 
Student t-test for normal data and the Mann-Whitney U test for skewed data. All of the de-
scriptive statistics and comparisons were performed using the SPSS v.20.0 software package 
(SPSS, Chicago, IL, USA). Th e areas under the ROC curves (AUC) and the sensitivity and 
specifi city were calculated to assess the diagnostic performance of the various assays in terms 
of PCa detection. Th e AUCs of the ROC curves and the multivariable analysis were derived 
using MedCalc (Version 12.6.1.0-64 bit). A two-sided p value of <0.05 was considered to be 
signifi cant in all of the analyses.
RESulTS
Between April 2008 and March 2013, 1,766 patients received an initial TRUSPB in our 
center, and 930 consented to give blood samples. Of these, 230 consecutive patients fulfi lled 
the inclusion criteria and their clinical data and sera were retrieved for the study. Twenty-one 
patients (9.13%) were diagnosed as having PCa from the results of the initial biopsy. Th e 
baseline information of these patients is given in Table 1.
Th e values of the various PSA parameters are also summarized in Table 1. Patients with 
PCa had a smaller prostate than the non-PCa patients. Statistically signifi cant diff erences be-
tween the PCa patients and non-PCa patients were noted for PSA density, p2PSA, %p2PSA, 
and phi. However, the tPSA, fPSA, and %fPSA levels of the two groups were not statistically 
signifi cantly diff erent (Table 1).
Th e AUCs of the ROC of tPSA, PSA density, %fPSA, %p2PSA, and phi were 0.547, 
0.634, 0.654, 0.768, and 0.781, respectively (Figure 1). Of the various parameters, the phi 
showed the best performance in predicting the results of the initial prostatic biopsy in our 
population.
To assess the performance of the various parameters further, we set the sensitivity level 
at 90%, which eliminated two of the 21 cancer cases. Th e phi had the best specifi city of 
49.76% (95% confi dence interval: 42.8–56.7) (Table 2). If we had applied the phi to the 
cohort during the initial assessment, 104 (45.2%) patients with no evidence of PCa after 
their initial TRUSPB would have avoided undergoing a biopsy. Th e two PCa cases that 
were eliminated from the analysis were both clinically T1c disease, with only one positive 
core (out of 10 biopsy cores) that was assessed as Gleason 3+3. Both of these were therefore 
considered to be low-risk cases. [12]
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Table 1. Patient characteristics of the study population
Mean (Range) Overall 
n=230
non-cancer patients
n=209
Cancer patients
n=21 p-value
Age (Years) 65.9 (50-79) 65.7 (50-84) 69.2 (57-76) 0.172
Total PSA (ng/
ml) *
6.285 (4 – 9.5) 6.260 (4 – 9.5) 7.424 (4.6 – 9.4) 0.378
Prostate volume 
(ml)
46.2 (11 – 163) 46.8 (11 – 163) 39.6 (16.3 – 97.4) 0.061
Total PSA ** 6.745 (3.18 – 9.98) 6.721 (3.18 – 9.98) 6.985 (4.75 – 9.11) 0.451
PSA density (ng 
/ ml2)
0.175 (0.044 – 0.513) 0.171 (0.044 – 0.513) 0.213 (0.073 – 0.414) 0.043
Free PSA (ng/ml) 1.31 (0.39 – 4.09) 1.32 (0.39 – 4.09) 1.24 (0.50 – 2.36) 0.566
Free to total PSA 
ratio (%fPSA, %)
19.688 (6.227 – 47.379) 19.839 (6.297 – 47.379) 18.188 (6.227 – 31.307) 0.275
p2PSA level (pg/
ml)
14.42 (4.29 – 67.33) 14.02 (4.29 – 67.33) 18.42 (6.27 – 35.82) 0.020
p2PSA to free PSA 
ratio (%p2PSA, 
%)
1.141 (0.393 – 2.572) 1.105 (0.393 – 2.528) 1.493 (0.629 – 2.572) <0.001
phi 29.30 (9.58 – 78.08) 28.20 (9.58 – 78.08) 39.45 (13.89 – 77.63) <0.001
* Measured by a Roche Cobas e601 system calibrated with the WHO 96/670 reference standard.
** Measured by a Hybritech-calibrated Beckman Coulter Assess2 System.
Figure 1. Receiver operating characteristic (ROC) curves of the various prostate-specific antigen (PSA) 
derivatives
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Multivariate analysis was used to assess the value of %p2PSA and phi in the diagnosis of 
PCa at TRUSPB, as suggested by Guazzoni et al. [7] Age, tPSA, prostate volume and %fPSA 
were put into the multivariate analysis as base prediction model. Th e p2PSA level free PSA 
and PSA density were omitted from the base model to avoid problems of multicollinearity. 
Both %p2PSA and the phi improved the AUC of the base multivariate model from 0.668 
to 0.786 and 0.792, respectively. Because not every patient would have had a transrectal 
ultrasound for prostate volume before TRUSPB, we tested an additional base model using 
only clinical parameters: patient age, tPSA, and %fPSA. We then tested the eff ect of adding 
%p2PSA and the phi on the accuracy of diagnosis (Table 4). Both %p2PSA and the phi 
improved the AUC of this second base multivariate model from 0.623 to 0.783 and 0.787, 
respectively. Comparing the fi rst and second base models after the inclusion of the phi, no 
signifi cant diff erence in the AUC with or without prostate volume was observed (0.792 
versus 0.787). Th erefore, the measurement of prostate volume (for the determination of 
PSA density) may not improve the performance of %p2PSA and the phi in the diagnosis of 
PCa further.
We also compared the phi value between PCa patients with a Gleason score of 3+3 and 
those with Grade 4 or 5 components (i.e., Gleason sum = 7 or above). Th e mean phi levels 
for Gleason 6 and Gleason 7 or above were 35.28 (standard deviation = 10.12) and 52.77 
(standard deviation = 14.81) (p = 0.007).
Table 2. Performance characteristics at a pre-set sensitivity of 90% or not missing any Gleason 7-10 
cancer.
Cutoﬀ  for needing biopsy
Specifi city at 90% 
sensitivity
(%, 95% CI)
number of patients with 
no evidence of cancer 
that could have avoided 
a biopsy
(Total 209)
Total PSA
(ng/ml)
>5.251 17.22
(12.4 – 23.0)
36
PSA density
(ng/ml2)
>0.102 18.18
(13.2 – 24.1)
38
Free to total PSA ratio (%) <27.978 11.0
(7.1 – 16.1)
23
p2PSA (pg/ml) >9.269 22.97
(17.4 – 29.3)
48
p2PSA to free PSA ratio 
(%)
>0.995 42.11
(35.3 – 49.1)
88
phi >26.54 49.76
(42.8 – 56.7)
104
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DISCuSSIOn
Despite its benefi cial role in the detection of early stage PCa, several issues related to the 
use of PSA in the diagnosis of PCa remain unsettled. One is its lack of cancer specifi city, 
which leads to a large number of patients with elevated PSA levels undergoing unnecessary 
TRUSPBs. Th e phi has been shown to give better results than tPSA and %fPSA in the 
diagnosis of PCa in patients with serum PSA levels ranging from 2 to 10 ng/mL. In a recent 
meta-analysis, at a sensitivity of 90%, the specifi city of the phi was 32% (range, 26–43%) 
and the AUCs obtained by ROC analysis were between 0.703 and 0.77. [9] Most of the 
current data on the phi were based on studies in Caucasian populations, which have a higher 
incidence of PCa. According to Filella and Giménez, [9] the positive biopsy rate for patients 
with a PSA level of 2–10 ng/mL ranged from 39.9% to 57.2%. However, data on the ap-
plication of the phi in Asian populations, which have a lower incidence of PCa, were sparse. 
Ito et al. reported the application of p2PSA and the phi in a Japanese population with levels 
of tPSA that ranged from 2 to 10 ng/mL, with or without abnormal DRE fi ndings. [13] Th e 
results showed that the performance of the phi in diagnosing PCa was superior to that of 
tPSA and %fPSA at all levels of sensitivity. 
Table 4. Multivariate analyses of the predictive value of each of the parameters in the diagnosis of 
prostate cancer, with patient age, tPSA, %fPSA, %p2PSA and phi only
AuC
95% CI of AuC
univariable 
analysis
OR (95%CI); 
p-value
Multivariable analysis
base model
OR (95%CI);
p-value
With %p2PSA
OR (95%CI);
p-value
With phi
OR (95%CI);
p-value
Age 0.594 (0.487 - 
0.702)
1.057 (0.986 – 
1.132);
0.119
1.068 (0.987 – 
1.156);
0.100
1.062 (0.785 – 
1.436);
0.091
1.076 (0.988 – 
1.172);
0.092
tPSA 0.582 (0.459 - 
0.704)
1.195 (0.934 – 
1.529);
0.156
1.044 (0.780 – 
1.398);
0.774
1.062 (0.785 – 
1.436);
0.697
0.844 (0.603 – 
1.179);
0.319
%fPSA 0.572 (0.437 – 
0.708)
0.965 (0.901 – 
1.034);
0.311
0.951 (0.884 – 
1.022);
0.169
0.974 (0.908 – 
1.044);
0.455
0.975 (0.909 – 
1.045);
0.473
%p2PSA 0.784 
(0.686 - 0.881)
9.705 (3.519 – 
26.762);
<0.001
-- 8.856 (2.874 – 
27.289);
<0.001
--
phi 0.803 
(0.706 - 0.899)
1.086 (1.047-
1.126); 
<0.001
-- 1.085 (1.039-
1.133);
<0.001
AUC of the Multivariable models
 (95% CI)
0.623 (0.493 – 
0.752)
0.783 (0.676 – 
0.890)
0.787 (0.683 – 
0.891)
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Our results showed that the phi also performed better than the other parameters, even 
with a positive biopsy rate of around 10%. The AUC of the ROC analysis of phi was 0.781, 
which was comparable with that reported in the literature. [9] Compared with the report 
from Ito et al., our population had a lower positive biopsy rate (9.13% versus 18.3% in 
patients with normal DRE findings). [13] Nevertheless, both studies support the use of phi 
in Asian populations to improve the accuracy of PCa diagnosis.
In addition to its role in the diagnosis of PCa, the use of phi might also help to predict 
the pathology and tumor aggressiveness of PCa. [6,14] In our study, a significant differ-
ence was observed between the phi level in patients with a Gleason score of 3+3 and those 
with Gleason 4 or 5 components. However, because of the small sample size (only 21 cases 
of PCa, five of which had Gleason 4 or 5 components), more meaningful analysis of the 
correlation with pathology was difficult. Therefore, further studies of the role of the phi in 
predicting pathology results in Asian populations are needed.
First introduced by Benson et al. in 1992, PSA density is another simple approach that 
improves the diagnostic and prognostic value of PSA. [5] While ultrasound prostate size 
assessment was routinely used in some part of the world, unfortunately, it was not a routine 
procedure during either PCa screening or the assessment of lower urinary tract symptoms in 
our local hospitals. Thus, the determination of PSA density implies an additional procedure 
in our centers. Moreover, from our results, phi alone had a better performance than PSA den-
sity in diagnosis prostate cancer in our study population. Furthermore, when we compared 
the use of two different base models for multivariate analysis using the phi, the inclusion of 
PSA density or a measurement of prostate volume produced minimal further improvements 
in the AUC in the multivariate model. Therefore, use of the phi would provide a more 
accurate prediction of prostate cancer and also might help to save the need of prostate size 
measurement during the initial assessment of patients in some centres.
During assessment of the effect of the phi on the diagnosis of PCa, it might be prudent to 
assess its financial impact on the healthcare system in addition to its diagnostic performance. 
From our results, the use of the phi could have avoided a large proportion of unnecessary 
TRUSPBs (45%), even when the sensitivity level was set at 90%. The financial savings 
on unnecessary TRUSPBs would need to be set against the additional cost of testing each 
patient. Nichol et al. used a mathematical model to calculate the cost-effectiveness of an 
additional phi measurement over a 25-year cycle of annual screening in the US healthcare 
system, [15] and concluded that the addition of a phi measurement to routine PSA screening 
was more cost-effective than PSA testing alone. However, this conclusion might not be ap-
plicable to other healthcare systems or non-annual screening situations. Moreover, as many 
different tests are available to improve the diagnostic yield of TRUSPB, a comparison of 
the various approaches, such as the phi, PSAD, and even prostate cancer antigen 3, [16,17] 
would be helpful to determine the most cost-effective approach in clinical management.
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One of the drawbacks of our study is its retrospective nature and the use of stored blood 
samples. In this study, as all patients’ data and blood were collected prospectively for prostate 
tissue bank and we hoped this would minimize potential bias. Moreover, our standard prac-
tice ensured that all of the blood samples were handled immediately after collection (within 
3 h) and stored at –70ºC until further use. [18] We also limited the study to samples that 
had been in storage for less than 3 years, and thus the use of stored samples hopefully did 
not aff ect the assessment of the PSA derivatives. However, further prospective studies may 
be needed to verify our results. 
Another problem is the diff erence in the assays used to measure serum levels of tPSA. 
Th e initial PSA measurement (which was an inclusion criteria) was made with our own 
hospital laboratory system, which is calibrated according to the WHO 96/670 reference 
standard. However, in the subsequent study, the measurement of PSA and its derivatives 
was performed with a Beckman Coulter Access2 system that was calibrated to a Hybritech 
Tandem-R calibrator. Th is may have led to some discrepancy in the two tPSA levels. [19] 
Th us, although the inclusion criterion was set as patients with a tPSA level of 4–10 ng/mL, 
the tPSA range measured by the Access2 system was 3.18–9.98 ng/mL. We understood that 
there were many diff erent commercial assays used for PSA measurement available, and they 
may diff er slightly in their calibration and also measured PSA values. In real life clinical 
practice, diff erent centres may use diff erent PSA measuring systems. Th erefore, our main 
study objective was to assess the role of phi as a separate tool in PCa diagnosis among 
patients with PSA level between 4 to 10 ng/mL in our current practise. However, in order 
to ensure that measurements were comparable in all of the analyses (including PSA density), 
those parameters obtained from the Access2 system were used for comparison alone. Th e 
PSA level measured by the Roche Cobas e601 system was only used in the inclusion criteria. 
Nevertheless, our data showed a promising role for phi in improving the accuracy of the need 
for TRUSPB in our population.
COnCluSIOn
As demonstrated in other studies, the use of p2PSA and its derivatives improves the accuracy 
of the detection of PCa in patients with an elevated level of PSA among an Asian population 
that has a lower incidence of this tumor. Among the various parameters, the phi showed the 
best performance, and its use could signifi cantly decrease the number of patients who are 
selected to undergo a prostatic biopsy.
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Extended Use of Prostate Health Index (PHI) 
and %p2PSA in Chinese Men with PSA 10-20 
ng/mL and Normal Digital Rectal Examination
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AbSTRACT
Purpose:
The rate of prostate cancer detection in Chinese men with PSA 10-20ng/mL was comparable 
to that of the Western population with PSA 4-10ng/mL. We investigated the extended use 
of Prostate Health index (PHI) and %p2PSA in Chinese men with PSA 10-20ng/mL and 
normal digital rectal examination (DRE). 
Materials and Methods:
All consecutive Chinese men with PSA 10-20ng/mL and normal DRE who agreed for 
transrectal ultrasound (TRUS)-guided 10-core prostate biopsy were recruited. Blood 
samples were taken immediately before TRUS-guided prostate biopsy. The performances 
of total PSA(tPSA), %free PSA(%fPSA), %p2PSA and Prostate Health Index(PHI) were 
compared using logistic regression, receiver operating characteristics(ROC), and decision 
curve analyses(DCA). 
Results:
From 2008 to 2015, 312 consecutive Chinese men were included. Among them, 53 out 
of 312(17.0%) men were diagnosed to have prostate cancer on biopsy. The proportions 
of men with positive biopsies were 6.7% in PHI<35, 22.8% in PHI 35-55, and 54.5% in 
PHI>55(chi-square test, p<0.001). The AUC of the base model including age, tPSA and 
status of initial/repeated biopsy was 0.64. Adding %p2PSA and PHI to the base model im-
proved the AUC to 0.79(p<0.001) and 0.78(p<0.001) respectively, and provided net clinical 
benefit in DCA. The positive biopsy rates of Gleason 7 or above prostate cancers were 2.2% 
for PHI<35, 7.9% for PHI 35-55, and 36.4% for PHI>55(chi-square test, p<0.001). By 
utilizing the PHI cutoff of 35 to men with PSA 10-20ng/mL and normal DRE, 57.1% 
(178/312) biopsies could be avoided.
Conclusions:
Both PHI and %p2PSA performed well in predicting prostate cancer and high grade pros-
tate cancer. The use of PHI and %p2PSA should be extended to Chinese men with PSA 
10-20ng/mL and normal DRE.
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InTRODuCTIOn
Prostate specifi c antigen (PSA) has been widely used for a screening tool for early pros-
tate cancer detection. Th e European Randomized Study of Screening for Prostate Cancer 
(ERSPC) showed that PSA screening could reduce prostate cancer-specifi c mortality. [1] 
However, PSA has a poor specifi city at the common cutoff  of 4ng/mL,[2] and this may lead 
to many unnecessary negative prostate biopsies and biopsy-related morbidities. Th ere is a 
need for a better tool for early prostate cancer detection, and prostate health index (PHI) is 
one of the more promising biomarkers being investigated.
Previous studies showed that PHI and the percentage of prostate-specifi c antigen isoform 
[-2]proPSA (p2PSA) were more accurate than total PSA (tPSA) or %free PSA (%fPSA) in 
predicting prostate cancer.[3] In 2012, the United States Food and Drug Administration 
(FDA) has approved the use of PHI and p2PSA in men older than 50 years old with a total 
PSA 4-10 ng/mL and normal DRE to reduce unnecessary prostate biopsies. However, the 
incidence of prostate cancer varies widely between diff erent countries and ethnicities.[4] In 
the Western population, the cancer detection rate was 20.7% for patients with normal DRE 
and PSA of 4.1-9.9ng/mL.[5] Whereas in our locality, the rates of prostate cancer detection 
in Chinese men with normal DRE were 13.4% for PSA 4-10 ng/mL and 21.8% for PSA 
10.1-20 ng/mL.[6] At the PSA level of 10-20ng/mL, the rate of prostate cancer detection 
in Chinese men is more comparable to that of the Western population at the PSA level of 
4-10ng/mL. We postulated that the use of PHI and p2PSA could be extended to PSA level 
of 10-20ng/mL in Chinese men, and this may be more clinically applicable and benefi cial.
Na et al. previously reported the performances of PHI and p2PSA in Chinese men with 
PSA 10.1-20ng/mL.[7] However, the cohort was relatively heterogeneous as patients with 
abnormal DRE were also included in this study. Th e true performances of PHI and p2PSA 
in patients with PSA 10-20ng/mL and normal DRE remained undetermined. In this current 
study, we investigated the diagnostic performances of PHI and %p2PSA in a homogeneous 
cohort of Chinese men with PSA 10-20 ng/mL and normal DRE. 
MATERIAlS AnD METHODS
Study Design
All consecutive patients with PSA 10-20ng/mL and normal DRE who agreed to undergo 
transrectal ultrasound-guided (TRUS) prostate biopsy were recruited for prospective blood 
sample collection and informed consents were signed. Th ere were 391 men with PSA 10-
20ng/ml, and 79 men with PSA 10-20 ng/ml and abnormal DRE were excluded. Blood 
samples from the resulting 312 consecutive patients with PSA 10-20 ng/ml and normal 
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DRE were collected prospectively immediately before TRUS biopsy from November 2008 
to July 2015.
Blood samples were centrifuged within 3 hours after blood taking, and the serum was 
stored at -80°C. The bloods were subsequently analyzed for tPSA, fPSA, and p2PSA using 
the Beckman Coulter Access 2 Immunoassay System (Beckman Coulter Inc., Brea, CA, 
USA) and according to the criteria described by Semjonow et al.[8] Men with known history 
of prostate cancer, abnormal digital rectal examination (DRE), usage of androgen depriva-
tion therapy or 5 alpha-reductase inhibitor before blood taking would be excluded from this 
study. 
Patients had TRUS prostate biopsy with 10 biopsy cores taken at peripheral portions 
of the prostate gland. The biopsy specimens were evaluated by experienced genitourinary 
pathologists. Prostate cancer was graded according to International Society of Urological 
Pathology 2005 consensus.[9] This study was conducted in a university hospital and the 
study protocol was approved by the Joint Chinese University of Hong Kong-New Territories 
East Cluster Clinical Research Ethics committee. This study conforms to the provisions of 
the Declaration of Helsinki (as revised in Tokyo 2008).
Study outcomes
The primary outcome of the study was to compare the diagnostic accuracies of %p2PSA 
and PHI with tPSA and %fPSA in predicting prostate cancer, as determined by the area 
under curves (AUC) of the receiver operating characteristic (ROC) curves. All PSA values 
were derived from Hybritech calibration. The ability of %p2PSA and PHI in predicting 
high grade prostate cancers (Gleason score 7 or above) [1] were also analyzed. %p2PSA was 
calculated by p2PSA (pg/mL) / free PSA (ng/mL) / 1000. PHI was calculated using the 
following formula: (p2PSA/free PSA) × √total PSA. 
Sample Size Calculation
In the Chinese study by Na et al.,[7] regardless of the DRE findings, a difference in AUC of 
0.23 between PHI and tPSA was demonstrated in patients with PSA 10-20ng/mL. In our 
previous study[10] on patients with PSA 4-10ng/mL and normal DRE, a difference in AUC 
of 0.234 between PHI and tPSA was demonstrated. In this current study, in order to detect 
a difference in AUC of 0.20 with alpha error 0.05 and 80% power, an estimated sample size 
of 250 is required. 
Statistical Analyses
T-test and Mann-Whitney U test were used to compare normally and non-normally 
distributed continuous variables, respectively. Chi-square test was used to compare cat-
egorical variables. Univariate and multivariate logistic regression was used to predict status 
of prostate cancer and high grade prostate cancer. The defined base model in multivariate 
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analysis included age, tPSA, and status of initial/repeated biopsy. Using the non-parameteric 
method of DeLong, the AUC of the ROC curves were compared between the defi ned base 
model, base model + %fPSA, base model + %p2PSA, and base model + PHI. Decision curve 
analysis (DCA)[11] was used to evaluate whether adding PHI or %p2PSA to the base model 
would yield net clinical benefi t. Th e decision curves were plotted with y-axis being the net 
clinical benefi t and the x-axis being the threshold probability. Th e threshold probability is 
the probability of the outcome (diagnosis of prostate cancer) that the patient would opt for 
prostate biopsy. 
All statistical analyses were performed using IBM SPSS Statistics for Windows version 
22 (IBM Corp., Armonk, NY, USA). Th e R package “pROC” [12] was used to compare 
ROC curves and decision analysis curves were plotted with R version 3.1.1 (Th e R Founda-
tion for statistical computing, Vienna, Austria). A 2-sided p-value of <0.05 was considered 
signifi cant.
RESulTS
Out of the 312 men who fi t the inclusion criteria, 260 samples were initial biopsies and 52 
were repeated biopsies. 53 patients (17.0%) were diagnosed to have prostate cancer after 
TRUS biopsy. Th e baseline characteristics of the cohort were listed in Table 1. Th e mean age 
was 68.1 ± 6.2 years old, and patients with prostate cancer had signifi cantly older age. Th e 
tPSA values between prostate cancer patients and non-cancer patients had no signifi cant 
diff erence. %p2PSA and PHI were signifi cantly higher in prostate cancer patients. (Table 1)
Table 1. Baseline characteristics
Mean ± SD
Range
Overall
n=312
non Cancer
n=259
Cancer patients
n=53 p-value
Age 68.1 ± 6.2
51-82
67.6 ± 6.1
51-82
70.3 ± 5.9
58-81
0.005
Total PSA(tPSA) 13.27 ± 2.71
9.95 – 20.01
13.36 ± 2.67
9.95 – 20.01
12.82 ± 2.89
10.07 – 19.58
0.182
Prostate volume 64.0 ± 28.5
12 – 179
67.3 ± 28.0
20 – 179
48.0 ± 25.7
12 – 117
<0.001
Repeated Biopsy (%) 52 (16.7%) 45 (17.4%) 7 (13.2%) 0.458
%fPSA 0.21 ± 0.11
0.05 – 1.08
0.22 ± 0.11
0.06 – 1.08
0.17 ± 0.73
0.05 – 0.42
<0.001
%p2PSA 1.05 ± 0.53
0.12 – 4.66
0.94 ± 0.37
0.12 – 3.01
1.55 ± 0.83
0.29 – 4.66
<0.001
PHI 37.53 ± 19.64
4.16 – 179.28
33.96 ± 13.78
4.16 – 108.33
54.95 ± 31.51
13.04 – 179.28
<0.001
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The rates of prostate cancer detection for different PHI ranges were 6.7% for PHI <35, 
22.8% for PHI 35-55, and 54.5% for PHI >55 (p<0.001) (Table 2). The rates of prostate 
cancer detection for different %p2PSA ranges were 7.1% for %p2PSA <1%, 22.6% for 
%p2PSA 1-1.5%, and 52.8% for %p2PSA >1.5% (p<0.001) (Table 2). Similar trends for 
initial and repeated biopsies were observed for both PHI and %p2PSA, except that for PHI 
< 35 and %p2PSA < 1%, the positive biopsy rates were particularly low at 3.1% and 0% 
respectively (Table 2).
Concerning the prediction of prostate cancer, the AUC for tPSA, %fPSA, %p2PSA and 
PHI were 0.58, 0.69, 0.76, and 0.73 respectively upon univariate analyses (Table 3). Upon 
multivariate analyses, using the base model including age, tPSA and status of initial/repeated 
biopsy, the AUC was 0.64 (95% CI 0.56-0.72) (Table 3). Adding %fPSA to the base model 
increased the AUC to 0.75 (95% CI 0.67-0.82, p=0.007). Adding %p2PSA to the base 
model increased the AUC to 0.79 (95% CI 0.71-0.86, p<0.001), and adding PHI to the 
base model increased the AUC to 0.78 (95% CI 0.70-0.86, p<0.001).
With the concern of any interaction between PSA and other PSA derivatives in the 
multivariate models, interaction tests have been performed. There was no significant interac-
tion between PSA and %fPSA (p=0.275), PSA and %p2PSA (p=0.510), and PSA and PHI 
(p=0.538). In addition, all 3 models (base model + %fPSA, base model + %p2PSA, and base 
model + PHI) had lower AUC values when PSA was removed from each model. Therefore, 
PSA should remain in the 3 models. 
Upon decision curve analyses (DCA) in predicting prostate cancer diagnosis (Figure 1), 
%p2PSA and PHI demonstrated net clinical benefit over tPSA or %fPSA over whole range 
of threshold probabilities. Comparing the different models upon DCA (Figure 2), adding 
Table 2. Positive biopsy rates (any grade prostate cancer) for different Prostate health index (PHI) and 
%p2PSA ranges
PHI <35 35-55 >55 Total p-value
Whole cohort 12/178 (6.7%) 23/101 
(22.8%)
18/33 
(54.5%)
312 <0.001
Initial biopsies 11/146 (7.5%) 30/85
 (23.5%)
15/29 
(51.7%)
260 <0.001
Repeated biopsies 1/32 
(3.1%)
3/16 
(18.8%)
3/4 
(75.0%)
52 0.001
%p2PSA <1% 1-1.5% >1.5% Total p-value
Whole cohort 13/183 (7.1%) 21/93 
(22.6%)
19/36 (52.8%) 312 <0.001
Initial biopsies 13/150 (8.7%) 17/78 
(21.8%)
16/32 (50.0%) 260 <0.001
Repeated biopsies 0/33 
(0%)
4/15 
(26.7%)
3/4 
(75.0%)
52 <0.001
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%p2PSA or PHI to the base model demonstrated net clinical benefit over whole range of 
threshold probabilities.
PHI and %p2PSA predicted high grade (Gleason 7 or above) prostate cancers in the 
PSA range of 10-20ng/mL. The positive biopsy rate of high grade prostate cancers was 7.7% 
(24/312) for the whole cohort. Dividing into different PHI ranges, the proportion of high 
Figure 1. Decision curve analysis for prediction of prostate cancer diagnosis, comparing total PSA, 
%free-to-total PSA (%fPSA), %p2PSA, and PHI. X-axis (threshold probability) is the probability of 
prostate cancer diagnosis that the patient would opt for prostate biopsy. Y-axis is the net clinical benefit 
for different models.
Figure 2. Decision curve analysis for prediction of prostate cancer diagnosis, comparing base model, 
base model + %free-to-total PSA (%fPSA), base model + %p2PSA, and base model + PHI. Base model 
included age, total PSA, and status of initial / repeated biopsy. X-axis (threshold probability) is the 
probability of prostate cancer diagnosis that the patient would opt for prostate biopsy. Y-axis is the net 
clinical benefit for different models.
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grade prostate cancers were 2.2% (4/178) for PHI <35, 7.9% (8/101) for PHI 35-55, and 
36.4% (12/33) for PHI > 55 (chi-square test, p<0.001). Th e AUCs for high grade prostate 
cancers were 0.62 for tPSA, 0.68 for base model, 0.77 for base model +%fPSA, 0.83 for base 
model + %p2PSA, and 0.84 for base model + PHI. 
By utilizing the PHI cutoff  of 35 to men with PSA 10-20ng/mL and normal DRE, 
57.1% (178/312) biopsies could be avoided with the cost of missing 6.7% (12/178) any 
grade prostate cancer and 2.2% (4/178) high grade prostate cancer in men with PHI<35.
All Gleason scores in the current study were derived from biopsy pathology. Th ere were 
15 out of 53 (28.3%) cancer cases who had radical prostatectomy performed, and others 
treatments included radiotherapy with or without androgen deprivation therapy (34.0%), 
active surveillance (3.8%), watchful waiting / refusal of treatment (18.9%), and androgen 
deprivation therapy only (13.2%). Among the 15 cases with radical prostatectomies done, 8 
were biopsy Gleason 6 cancers and none of them had any upgrading of Gleason score in fi nal 
pathology. For the 2 prostatectomy cases with PHI < 35, there was one Gleason 6 and one 
Gleason 8 on biopsy, but both were organ confi ned disease (pT2) in fi nal pathology. On the 
other hand, 3 out of 13 prostatectomy cases with PHI >35 had pT3 disease.
DISCuSSIOn
Th e rates of prostate cancer detection in Caucasians in the classical grey-zone of PSA 4-10 
ng/mL ranged from 26-47%.[4] Diff erent markers for predicting prostate cancer including 
free PSA [2], PSA density [13,14], PCA3 [15,16], p2PSA and PHI [3] mainly targeted 
patients with PSA <10ng/mL as the rate of prostate cancer detection in this range is lower 
and the use of these markers could help reduce unnecessary prostate biopsies. Compared to 
Caucasians, Chinese men have much lower rates of positive biopsies across diff erent PSA 
ranges.[6] In our current study on Chinese men with PSA 10-20ng/mL and normal DRE, 
the overall prostate cancer detection rate was 17.2%, which is comparable to that of the 
Western population at PSA level of 4-10ng/mL.[5] Another recent Chinese cohort showed 
a higher positive biopsy rate of 36.5% for men with 10-20 ng/mL (about 30% abnormal 
DRE) [7], but that was still similar to that in Caucasian with PSA 4-10ng/mL. Although 
PHI was classically indicated in men with PSA 4-10 ng/mL and normal DRE, we believe 
PHI may play an important role at PSA 10-20ng/mL in the Chinese population, and the 
current study is the fi rst to address this specifi c group of men. 
A previous study on Chinese men reported better performance of p2PSA and PHI than 
total or free PSA across a wide range of PSA. However, about 30% of the cohort had abnor-
mal DRE and the results should be interpreted with caution.[7] As the risk of prostate cancer 
in those with abnormal DRE is much higher (52% in the range of PSA 10-20ng/mL),[6] 
prostate biopsy should be off ered directly instead of PHI. Th e performances of p2PSA and 
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PHI may also be different in men with abnormal DRE. The true performances of PHI and 
p2PSA in patients with PSA 10-20ng/mL and normal DRE remained undetermined. In the 
current study, our analyses were based on a homogeneous cohort of Chinese men with PSA 
10-20ng/mL and normal DRE, and we believe the results would be of significant value. 
The current study demonstrated the role of %p2PSA and PHI in predicting prostate 
cancer diagnosis in a Chinese cohort with PSA 10-20 with normal DRE. For the group of 
patients with %p2PSA <1% (n=183) and PHI < 35 (n=178), the rates of prostate cancer 
detection were only 7.1% and 6.7% respectively. Upon univariate analyses, the AUCs of 
%p2PSA and PHI were better than tPSA and %fPSA. In the multivariate logistic regression 
model, adding %p2PSA or PHI to the pre-defined base model (Age, tPSA, and status of 
initial/repeat biopsy) significantly increased the predictive accuracy from 0.64 to 0.78-0.79. 
Our results showed that p2PSA and PHI could help stratify the risk of prostate cancer in 
Chinese men with PSA 10-20 ng/mL with normal DRE. In Chinese men with PSA 10-20 
ng/mL, biopsy decisions should not be based on PSA alone, but should be based on the 
additional PHI & p2PSA information after personalized counselling by a Urologist.
PHI and p2PSA were associated with more aggressive pathologies in the tPSA range of 
4-10 ng/mL in previously published studies. [17,18] In the current study, %p2PSA and PHI 
were also associated with more aggressive prostate cancers in the range of PSA 10-20. The 
positive biopsy rates of Gleason 7 or above prostate cancers for PHI ranges of <35, 35-55, 
and >55 were 2.2%, 7.9%, and 36.4%, respectively. PHI could serve as a guide for men who 
wish to be treated only if there is aggressive prostate cancer.
Analyses of PCa and HGPCa in the current study were derived from biopsy pathology 
but not from prostatectomy pathology, as only 28.3% (15/53) PCa men opt for radical 
prostatectomy in this cohort. Among the 15 cases with prostatectomy pathology, 2 had 
PHI <35 and 13 had PHI >35. None of the 2 cases with PHI <35 had pT3 disease, while 
3 out of 13 cases with PHI > 35 had pT3 disease. These findings were in line with previ-
ous evidence showing PHI was associated with more aggressive prostatectomy pathology. 
[19] Furthermore, none of the 15 prostatectomy pathology showed upgrading of Gleason 
score from biopsy pathology, and this might support the fact that biopsy pathology was 
representative in the current study. A lack of final pathology in all cancer cases, however, was 
definitely a limitation of the study.
In contrast to Caucasian men, Asian men have very different prostate cancer epidemiol-
ogy. The incidence of prostate cancer in Caucasian men was 5-10 times more than that in 
many regions of Asia and 10 times of that in Chinese men. [20] Most prostate cancers in 
Caucasians were diagnosed at an early stage, whereas in China, 65% PCa were diagnosed 
with PSA >10 ng/mL, and 45% PCa were either locally advanced or metastatic. Neverthe-
less, there were variations in Asia, and only about 35-40% prostate cancers were diagnosed 
with PSA >10ng/mL in Hong Kong, Singapore, and Korea. [20] The above differences in 
cancer epidemiology in Caucasian and Asian might be explained by lifestyle and genetic 
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diff erences. In general, Asians consume more vegetables and less meat in their diet compared 
with Western population. [20] In terms of genetic diff erences, there were signifi cant varia-
tions in single nucleotide polymorphisms. [20] Th e rates of TMPRSS2-ERG gene fusion 
[21] and PTEN inactivation [22] were also lower in Asian or Chinese population compared 
with Caucasians. 
Th e strengths of this study included the prospective collection of blood samples of all 
consecutive patients, the emphasis on a homogeneous patient group with PSA 10-20 and 
normal DRE, the analyses of blood samples according to guidelines recommended by Sem-
jonow et al,[8] the use of standardized systemic 10-core prostate biopsy, and the interpreta-
tion of all biopsy specimens by experienced genitourinary pathologists in our institution. 
Th e limitations of this study included single institution data, the lack of prostatectomy 
pathology in most cases, and the lack of comparison with other predictive models or inves-
tigation modalities.
COnCluSIOnS
Both PHI and %p2PSA performed well in predicting prostate cancer and high grade pros-
tate cancer. Th e use of PHI and %p2PSA should be extended to Chinese men with PSA 
10-20ng/mL and normal DRE.
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 CHAPTER 8
Prostate Health Index (PHI) and 
%p2PSA predict aggressive prostate 
cancer pathology in Chinese patients 
undergoing radical prostatectomy
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AbSTRACT
Purpose
To investigate the performance of prostate health index(PHI) and %p2PSA in predicting 
pathological outcomes at radical prostatectomy(RP) in a Chinese population. 
Methods
This is a prospective study on 135 prostate cancer patients with radical prostatectomy per-
formed. The accuracy of pre-operative %p2PSA (=p2PSA / free PSA) and PHI [=(p2PSA/free 
PSA)x√PSA] in predicting pathological outcomes of RP including pathological T3(pT3), 
pathologic Gleason score(pGS)≥7 , GS upgrade at RP, Tumor volume>0.5ml, and Epstein 
significant tumor were calculated using multivariate analyses and area under curve(AUC). 
The base model in multivariate analysis included age, PSA, abnormal digital rectal examina-
tion (DRE), and biopsy Gleason score(GS).
Results
PHI was significantly higher in patients with pT3 or pGS≥7(p<0.001), pT3 disease(p=0.001), 
pGS≥7(p<0.001), GS upgrade(p<0.001), tumor volume >0.5ml(p<0.001), and Epstein sig-
nificant tumor(p=0.001). %p2PSA was also significantly higher in all the above outcomes. 
The risk of pT3 or pGS≥7 was 16.1% for PHI<35 and 60.8% for PHI>35 (sensitivity 
84.2%, specificity of 60.3%), and the risk of tumor volume >0.5ml was 25.5% for PHI<35 
and 72.6% for PHI>35 (sensitivity 79.1%, specificity 67.2%). In multivariate analysis, 
adding %p2PSA or PHI to the base model significantly improved the accuracy(AUC) in 
predicting pT3 or pGS≥7(by 7.2-7.9%), tumor volume>0.5ml(by 10.3-12.8%), and Ep-
stein significant tumor(by 13.9-15.9%). Net clinical benefit was observed in decision curve 
analyses for prediction of both tumor volume >0.5ml, and pT3 or pGS≥7.
Conclusions
Both PHI and %p2PSA predict aggressive and significant pathologies in radical prosta-
tectomy in Chinese men. This enabled identification of non-aggressive cancers for better 
counselling on active surveillance or treatment.
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InTRODuCTIOn
Th e Prostate health index (PHI) or percentage of prostate-specifi c antigen isoform [-2]
proPSA was shown to be more accurate than PSA, %free PSA (%fPSA), or PSA density in 
predicting diagnosis of prostate cancer in prostate biopsies for patients with PSA less than 
10ng/mL.1-8 PHI or %p2PSA was also associated with higher gleason scores in prostate 
biopsies.1, 2, 4, 7 Th e associations of PHI or %p2PSA with radical prostatectomy (RP) pathol-
ogy have only been reported in European population.1, 9-11 It was reported that higher PHI 
or %p2PSA values predicted pT3 disease, higher pathologic Gleason score (pGS), upgrading 
of Gleason score, and higher tumor volume.9, 11
Th e incidence of prostate cancer is increasing in Asian countries12 with aging population 
and widespread use of PSA testing, and this is associated with more and more over-diagnosis 
and over-treatment of indolent prostate cancers. We need better markers to diff erentiate 
aggressive prostate cancers from less aggressive ones in order to better counsel our patient 
for appropriate treatment options including radical treatment and active surveillance. In 
this study, we aim to investigate the performance of PHI or %p2PSA in predicting RP 
pathological outcomes in a Chinese population. 
METHODS
Th is is a prospective cohort of a single hospital including all patients with biopsy proven 
prostate cancer planning for robotic assisted laparoscopic radical prostatectomy (RP) per-
formed between August 2011 and July 2015. All cancers were diagnosed with transrectal 
ultrasound guided systematic 10-core biopsies. Study bloods were taken 1 day before RP to 
allow more accurate correlation with fi nal pathology, as the waiting time between pre-biopsy 
PSA and RP was at a mean of 31.3 weeks. Th ey were subsequently analyzed for PSA, fPSA, 
and p2PSA. Patients with digital rectal examination (DRE), androgen deprivation therapy, 
or 5 alpha-reductase inhibitor before blood taking would be excluded from this study. 
Th e primary objective of this study was to investigate the accuracy of PHI and %p2PSA 
in predicting fi nal RP pathology. Th ey included status of pT3 or pathological Gleason score 
(pGS) ≥7, pT3, pGS≥7, upgrading of GS (pGS higher than biopsy GS), tumor volume 
>0.5ml, and Epstein signifi cant tumor (≥pT3, pGS≥7, or tumor volume >0.2ml). 13, 14 Clini-
cal data included age at surgery, digital rectal examination (DRE), biopsy Gleason score, 
PSA, fPSA, %fPSA (fPSA/PSA x 100), p2PSA, %p2PSA [(p2PSA)/(fPSAx100)x1000] and 
PHI [(p2PSA/fPSA)x√PSA]. Blood samples were taken at least 6 weeks from prostate biopsy 
as recommended in the Beckman Coulter Access Hybritech p2PSA Instructions for use. 
Bloods were processed by the Beckman Coulter Access 2 Immunoassay System (Beckman 
Coulter Inc., Brea, CA, USA) and according to the criteria described by Semjonow et al.15 
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RP pathological outcomes included pathologic Gleason score (pGS), pathologic T-stage, 
and tumor volume. All pathologic outcomes (biopsy and surgery) were reported by geni-
tourinary pathologists blinded to all blood results. Prostate cancer was graded according to 
International Society of Urological Pathology 2005 consensus.16 The study was approved 
by the hospital ethics committee and conformed to the provisions of the Declaration of 
Helsinki. Informed consents were signed by all patients.
T-test and Mann-Whitney U test were used to compare normally and non-normally 
distributed continuous variables, respectively. Chi-square or Fisher’s exact test were used to 
compare categorical variables. Univariate and multivariate logistic regression was used to 
predict status of pT3 or pGS≥7, tumor volume >0.5ml, and Epstein significant tumor. Odd 
ratios (ORs) with 95% confidence intervals (CIs) were calculated. Area under curve (AUC) 
of receiver operating characteristics (ROC) was used to calculate predictive accuracy in each 
univariate and multivariate analysis. The defined base model in multivariate analysis included 
age, PSA, biopsy GS, and abnormal digital rectal examination (DRE). The performance 
(in terms of AUC) of the base model alone was compared with the addition of %fPSA, 
%p2PSA or PHI to the base model. Decision curve analysis (DCA)17 was used to evaluate 
whether adding PHI or %p2PSA to the base model would lead to net clinical benefit. The 
decision curves were plotted with y-axis being the net clinical benefit and the x-axis being 
the threshold probability. The threshold probability is the probability of the outcome (pT3 
or pGS≥7, or Tumor volume>0.5mL) that the patient or doctor would opt for RP, and this 
threshold can vary widely between different patients or doctors. 
All statistical analyses were performed using IBM SPSS Statistics for Windows version 
21 (IBM Corp., Armonk, NY, USA). Decision curves were plotted with R version 3.0.3 
(The R Foundation for statistical computing, Vienna, Austria). A 2-sided p-value of <0.05 
was considered significant.
RESulTS
Baseline characteristics of the 135 included patients were listed in Table 1. In our cohort, the 
indication of PSA was either lower urinary tract symptoms (LUTS) in 76.3% (103/135), 
opportunistic screening (PSA taken for non-urinary tract symptoms) in 23.0% (31/135), or 
abnormal digital rectal examination (DRE) without LUTS in 0.7% (1/135). The indication 
of all prostate biopsies were related to elevated PSA >4 ng/mL with or without abnormal 
DRE. All study bloods were taken 1 day before operation and at a mean of 24.9 weeks (range 
6-115 weeks) after prostate biopsy. The time from pre-biopsy PSA to RP was at a mean of 
31.3 weeks (range 8-144 weeks, SD 19.8 weeks). PSA 1 day before RP (mean 12.2 ng/mL, 
median 9.0 ng/mL) was significantly higher than the pre-biopsy PSA (mean 10.6 ng/mL, 
median 8.5 ng/mL) (p<0.001, paired t-test).
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Th ere were 42.2% (57/135) with pT3 or pGS≥7, 17.8% (24/135) with upgrade of 
GS at fi nal pathology, 52.3% (67/128) with tumor volume >0.5ml, and 75.9% (101/133) 
patients with Epstein signifi cant tumor. Mean PHI values were signifi cantly higher for ≥pT3 
or pGS≥7 (70.4 Vs 35.9, T-test, p<0.001), ≥pT3 (71.0 Vs 41.8, T-test, p=0.001), pGS≥7 
(84.6 Vs 38.1, T-test, p<0.001), GS upgrade (85.5 Vs 42.9, T-test, p<0.001), Tumor volume 
≥0.5ml (62.2 Vs 31.1, T-test, p<0.001), and Epstein signifi cant tumor (58.5 Vs 27.1, T-
test, p=0.001) (Supplementary Figure 1). Mean %p2PSA values were signifi cantly higher 
for ≥pT3 or pGS≥7(1.77% Vs 1.25%, T-test, p=0.001), ≥pT3 (1.80% Vs 13.3%, T-test, 
p=0.007), pGS≥7 (1.96% Vs 1.30%, T-test, p<0.001), GS upgrade (2.02% Vs 1.36%, 
T-test, p=0.001), Tumor volume ≥0.5ml (1.67% Vs 1.15%, T-test, p<0.001), and Epstein 
signifi cant tumor (1.63% Vs 1.00%, T-test, p=0.001). 
Th e risk of pT3 or pGS≥7 increased from 16.1% with PHI<35 to 60.8% with PHI>35 
(chi-square, p<0.001, sensitivity 84.2%, specifi city of 60.3%). Th e risk of Epstein signifi cant 
tumor increased from 55.6% with PHI<35 to 89.9% with PHI>35 (chi-square, p<0.001, 
sensitivity 70.3%, specifi city 75.0%), and the risk of tumor volume >0.5ml increased from 
25.5% with PHI<35 to 72.6% with PHI>35 (chi-square, p<0.001, sensitivity 79.1%, 
specifi city 67.2%).
Univariate and Multivariate logistic regression analyses were performed for predictions 
of pT3 or pGS≥7 (table 2), tumor volume > 0.5ml (Table 3), and Epstein signifi cant tumor 
Table 1. Clinical and pathological characteristics of patients
Parameters (Median & Interquartile range) Whole cohort (n=135)
Age (years) 65.5 ± 5.4 (mean ± SD)
Total PSA (ng/mL) 9.0 (6.3-15.3)
Free to total PSA (%) 15.32 (11.22 – 19.97)
TRUS biopsy Gleason Score
≤6 99 (76.2%) 
7 20 (15.4%) 
8 8 (6.2%) 
9 3 (2.3%) 
Abnormal DRE 27 (20.8%)
%p2PSA (%) 1.28 (1.08 – 1.76)
Prostate health index (PHI) 38.05 (30.22 – 57.38)
pT3 40/135 (29.6%)
Pathological Gleason score (pGS) ≥7 36/135 (26.7%)
pT3 or pGS≥7 57/135 (42.2%)
Upgrade of Gleason score (GS) 24/135 (17.8%)
Tumor volume >0.5 67/128 (52.3%)
Epstein signifi cant tumor 101/133 (75.9%)
110
C
ha
pt
er
 8
111
PH
I p
re
di
ct
s p
ro
sta
te
ct
om
y 
pa
th
ol
og
y
Ta
bl
e 
2.
 U
ni
va
ria
bl
e 
an
d 
m
ul
tiv
ar
ia
bl
e 
an
al
ys
is 
fo
r p
T
3 
(p
at
ho
lo
gi
ca
l T
3 
sta
ge
) o
r p
G
S 
(p
at
ho
lo
gi
ca
l g
le
as
on
 sc
or
e)
 ≥
7
Au
C
95
%
 C
I 
of
 A
u
C
u
ni
va
ri
at
e 
an
al
ys
is
O
R
 (9
5%
C
I)
;
p-
va
lu
e
M
ul
ti
va
ri
ab
le
 a
na
ly
si
s
b
as
e 
m
od
el
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
fP
SA
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
p2
P
SA
A
dj
us
t O
R
 (9
5%
C
I)
; 
p-
va
lu
e
b
as
e 
m
od
el
 +
 P
H
I
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
Ag
e
0.
50
4 
(0
.4
02
 –
 0
.6
05
)
0.
99
7 
(0
.9
33
 –
 1
.0
66
);
p=
0.
93
5
0.
97
0 
(0
.9
02
 –
 1
.0
43
);
p=
0.
40
7
0.
98
6 
(0
.9
14
 –
 1
.0
63
);
p=
0.
71
1
0.
97
5 
(0
.9
03
 –
 1
.0
52
);
p=
0.
51
3
0.
97
5 
(0
.9
04
 –
 1
.0
51
);
p=
0.
50
6
PS
Aa
0.
68
0 
(0
.5
84
 –
 0
.7
76
)
1.
11
4 
(1
.0
50
 –
 1
.1
83
);
P<
0.
00
1
1.
11
7 
(1
.0
50
 –
 1
.1
88
);
P<
0.
00
1
1.
10
6 
(1
.0
39
 –
 1
.1
77
);
p=
0.
00
1
1.
12
1 
(1
.0
48
 –
 1
.1
99
);
p=
0.
00
1
1.
04
6 
(0
.9
72
 –
 1
.1
25
);
p=
0.
22
8
Ab
no
rm
al
 D
R
Eb
0.
56
5 
(0
.4
65
 –
 0
.6
65
)
2.
20
0 
(0
.9
28
 –
 5
.2
14
);
p=
0.
07
3
1.
51
8 
(0
.5
87
 –
 3
.9
23
); 
p=
0.
38
9
1.
49
8 
(0
.5
65
 –
 3
.9
70
); 
p=
0.
41
6
1.
28
3 
(0
.4
61
 –
 3
.5
74
); 
p=
0.
40
6
1.
37
6 
(0
.5
00
 –
 3
.7
88
); 
p=
0.
53
7
Bi
op
sy
 G
Sc
0.
58
1 
(0
.4
81
 –
 0
.6
81
)
1.
89
1 
(1
.1
01
 –
 3
.2
48
);
p=
0.
02
1
1.
91
6 
(1
.0
79
 –
 3
.4
01
);
p=
0.
02
6
1.
81
3 
(1
.0
04
 –
 3
.2
71
);
p=
0.
04
8
1.
83
5 
(0
.9
97
 –
 3
.3
78
);
p=
0.
05
1
1.
75
0 
(0
.9
62
 –
 3
.1
81
);
p=
0.
06
7
%
fP
SA
d
0.
71
7 
(0
.6
28
 –
 0
.8
05
)
0.
89
5 
(0
.8
39
 –
 0
.9
55
);
p=
0.
00
1
--
0.
92
4 
(0
.8
72
 –
 0
.9
80
);
p=
0.
00
8
--
--
%
p2
PS
A
0.
68
8 
(0
.5
97
 –
 0
.7
79
)
3.
20
8 
(1
.5
67
 –
 6
.5
67
);
p=
0.
00
1
--
--
3.
28
7 
(1
.5
00
 –
 7
.2
02
);
p=
0.
00
3
--
PH
Ie
0.
80
0 
(0
.7
25
 –
 0
.8
75
)
1.
04
2 
(1
.0
22
 –
 1
.0
62
); 
p<
0.
00
1
--
--
--
1.
03
3 
(1
.0
08
 –
 1
.0
57
); 
p=
0.
00
8
AU
C
 o
f t
he
 m
ul
tiv
ar
ia
bl
e 
m
od
el
s (
95
%
C
I)
0.
71
7 
(0
.6
26
 –
 0
.8
09
)
0.
75
7 
(0
.6
71
 –
 0
.8
42
)
0.
79
6 
(0
.7
21
 –
 0
.8
71
)
0.
78
9 
(0
.7
12
 –
 0
.8
65
)
a P
SA
 =
 P
ro
sta
te
-s
pe
ci
fic
 a
nt
ig
en
, b
D
R
E 
= 
D
ig
ita
l r
ec
ta
l e
xa
m
in
at
io
n,
 c G
S 
= 
G
le
as
on
 sc
or
e,
 d %
fP
SA
 =
 P
er
ce
nt
 fr
ee
 to
 to
ta
l P
SA
, e
PH
I =
 p
ro
sta
te
 h
ea
lth
 in
de
x
110
C
ha
pt
er
 8
111
PH
I p
re
di
ct
s p
ro
sta
te
ct
om
y 
pa
th
ol
og
y
Ta
bl
e 
3.
 U
ni
va
ria
bl
e 
an
d 
m
ul
tiv
ar
ia
bl
e 
an
al
ys
is 
fo
r t
um
or
 v
ol
um
e 
>0
.5
m
l
Au
C
95
%
 C
I 
of
 A
u
C
u
ni
va
ri
at
e 
an
al
ys
is
O
R
 (9
5%
C
I)
;
p-
va
lu
e
M
ul
ti
va
ri
ab
le
 a
na
ly
si
s
b
as
e 
m
od
el
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
fP
SA
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
p2
ps
a
A
dj
us
t O
R
 (9
5%
C
I)
; 
p-
va
lu
e
b
as
e 
m
od
el
 +
 P
H
I
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
Ag
e
0.
63
4 
(0
.5
35
 –
 0
.7
32
)
1.
08
3 
(1
.0
09
 –
 1
.1
62
);
p=
0.
02
7
1.
06
9 
(0
.9
94
 –
 1
.1
50
);
p=
0.
07
2
1.
08
4 
(1
.0
04
 –
 1
.1
69
);
p=
0.
03
8
1.
09
0 
(1
.0
06
 –
 1
.1
82
);
p=
0.
03
6
1.
09
5 
(1
.0
07
 –
 1
.1
91
);
p=
0.
03
4
PS
Aa
0.
68
3 
(0
.5
90
 –
 0
.7
76
)
1.
13
0 
(1
.0
53
 –
 1
.2
13
);
P=
0.
00
1
1.
12
1 
(1
.0
43
 –
 1
.2
04
);
p=
0.
00
2
1.
11
1 
(1
.0
35
 –
 1
.1
93
);
p=
0.
00
3
1.
15
9 
(1
.0
58
 –
 1
.2
69
);
p=
0.
00
1
0.
98
7 
(0
.9
01
 –
 1
.0
81
);
p=
0.
77
5
Ab
no
rm
al
 D
R
Eb
0.
56
7 
(0
.4
67
 –
 0
.6
68
)
2.
34
4 
(0
.9
32
 –
 5
.8
94
);
p=
0.
07
0
1.
81
8 
(0
.6
78
 –
 4
.8
74
); 
p=
0.
23
5
1.
74
8 
(0
.6
39
 –
 4
.7
78
); 
p=
0.
27
7
1.
44
0 
(0
.4
67
 –
 4
.4
43
); 
p=
0.
52
6
1.
63
8 
(0
.5
24
 –
 5
.1
18
); 
p=
0.
39
6
Bi
op
sy
 G
Sc
0.
55
5 
(0
.4
54
 –
 0
.6
57
)
1.
31
5 
(0
.7
85
 –
 2
.2
01
);
p=
0.
29
8
1.
21
6 
(0
.6
99
 –
 2
.1
13
);
p=
0.
48
9
1.
14
5 
(0
.6
51
 –
 2
.0
14
);
p=
0.
63
8
1.
05
0 
(0
.5
65
 –
 1
.9
51
);
p=
0.
87
8
0.
92
0 
(0
.4
75
 –
 1
.7
84
);
p=
0.
80
6
%
fP
SA
d
0.
65
1 
(0
.5
55
 –
 0
.7
47
)
0.
93
9 
(0
.8
88
 –
 0
.9
92
);
p=
0.
02
6
--
0.
94
4 
(0
.8
89
 –
 1
.0
02
);
p=
0.
05
9
--
--
%
p2
PS
A
0.
72
4 
(0
.6
34
 –
 0
.8
13
)
4.
88
2 
(2
.1
09
 –
 1
1.
30
1)
;
p=
0.
00
1
--
--
7.
66
1 
(2
.7
02
 –
 2
1.
72
4)
;
p<
0.
00
1
--
PH
Ie
0.
81
8 
(0
.7
46
 –
 0
.8
90
)
1.
07
9 
(1
.0
43
 –
 1
.1
16
); 
p<
0.
00
1
--
--
--
1.
08
6 
(1
.0
42
 –
 1
.1
32
); 
p<
0.
00
1
AU
C
 o
f t
he
 m
ul
tiv
ar
ia
bl
e 
m
od
el
s (
95
%
C
I)
0.
71
7 
(0
.6
28
 –
 0
.8
06
)
0.
73
9 
(0
.6
54
 –
 0
.8
25
)
0.
82
0 
(0
.7
49
 –
 0
.8
91
)
0.
84
5 
(0
.7
80
 –
 0
.9
10
)
a P
SA
 =
 P
ro
sta
te
-s
pe
ci
fi c
 a
nt
ig
en
, b
D
R
E 
= 
D
ig
ita
l r
ec
ta
l e
xa
m
in
at
io
n,
 c G
S 
= 
G
le
as
on
 sc
or
e,
 d %
fP
SA
 =
 P
er
ce
nt
 fr
ee
 to
 to
ta
l P
SA
, e
PH
I =
 p
ro
sta
te
 h
ea
lth
 in
de
x
112
C
ha
pt
er
 8
Ta
bl
e 
4.
 U
ni
va
ria
bl
e 
an
d 
m
ul
tiv
ar
ia
bl
e 
an
al
ys
is 
fo
r E
ps
te
in
 si
gn
ifi
ca
nt
 tu
m
or
Au
C
95
%
 C
I 
of
 A
u
C
u
ni
va
ri
at
e 
an
al
ys
is
O
R
 (9
5%
C
I)
;
p-
va
lu
e
M
ul
ti
va
ri
ab
le
 a
na
ly
si
s
b
as
e 
m
od
el
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
fP
SA
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
b
as
e 
m
od
el
 +
 %
p2
P
SA
A
dj
us
t O
R
 (9
5%
C
I)
; 
p-
va
lu
e
b
as
e 
m
od
el
 +
 P
H
I
A
dj
us
t O
R
 (9
5%
C
I)
;
p-
va
lu
e
Ag
e
0.
59
7 
(0
.4
80
 –
 0
.7
14
)
1.
05
5 
(0
.9
74
 –
 1
.1
44
);
p=
0.
19
0
1.
05
5 
(0
.9
73
 –
 1
.1
44
);
p=
0.
19
1
1.
07
9 
(0
.9
89
 –
 1
.1
76
);
p=
0.
19
4
1.
06
9 
(0
.9
73
 –
 1
.1
75
);
p=
0.
16
5
1.
07
4 
(0
.9
74
 –
 1
.1
84
);
p=
0.
15
4
PS
Aa
0.
61
0 
(0
.4
98
 –
 0
.7
23
)
1.
07
5 
(0
.9
99
 –
 1
.1
57
);
P=
0.
05
3
1.
06
4 
(0
.9
92
 –
 1
.1
42
);
P=
0.
08
4
1.
05
2 
(0
.9
77
 –
 1
.1
32
);
p=
0.
17
9
1.
11
9 
(1
.0
06
 –
 1
.2
46
);
p=
0.
03
9
0.
90
4 
(0
.8
11
 –
 1
.0
07
);
p=
0.
06
7
Ab
no
rm
al
 D
R
Eb
0.
51
9 
(0
.4
01
 –
 0
.6
37
)
1.
27
6 
(0
.4
35
 –
 3
.7
46
);
p=
0.
65
7
0.
79
0 
(0
.2
64
 –
 2
.3
68
);
p=
0.
67
4
0.
71
6 
(0
.2
23
 –
 2
.2
96
); 
p=
0.
57
4
0.
48
9 
(0
.1
33
 –
 1
.8
04
); 
p=
0.
28
3
0.
59
6 
(0
.1
61
 –
 2
.2
07
); 
p=
0.
43
9
Bi
op
sy
 G
Sc
0.
58
9 
(0
.4
82
 –
 0
.6
97
)
2.
55
7 
(0
.9
77
 –
 6
.6
89
);
p=
0.
05
6
2.
50
7 
(0
.9
68
 –
 6
.4
91
)
p=
0.
05
8
2.
70
1 
(0
.9
48
 –
 7
.6
95
);
p=
0.
06
3
2.
57
2 
(0
.9
20
 –
 7
.1
90
);
p=
0.
07
2
%
fP
SA
d
0.
72
7 
(0
.6
36
 –
 0
.8
19
)
0.
90
8 
(0
.8
54
 –
 0
.9
67
);
p=
0.
00
2
--
0.
90
7 
(0
.8
51
 –
 0
.9
66
);
p=
0.
00
2
--
--
%
p2
PS
A
0.
76
9 
(0
.6
71
 –
 0
.8
66
)
9.
53
3 
(2
.9
42
 –
 3
0.
88
9)
;
P<
0.
00
1
--
--
19
.8
52
 (4
.6
71
 –
 
84
.3
66
);
p<
0.
00
1
--
PH
Ie
0.
81
7 
(0
.7
39
 –
 0
.8
95
)
1.
11
0 
(1
.0
54
 –
 1
.1
69
); 
p<
0.
00
1
--
--
--
1.
13
9 
(1
.0
72
 –
 1
.2
10
); 
p<
0.
00
1
AU
C
 o
f t
he
 m
ul
tiv
ar
ia
bl
e 
m
od
el
s (
95
%
C
I)
0.
70
2 
(0
.6
06
 –
 0
.7
98
)
0.
76
4 
(0
.6
76
 –
 0
.8
53
)
0.
84
1 
(0
.7
69
 –
 0
.9
13
)
0.
86
1 
(0
.7
96
 –
 0
.9
25
)
a P
SA
 =
 P
ro
sta
te
-s
pe
ci
fic
 a
nt
ig
en
, b
D
R
E 
= 
D
ig
ita
l r
ec
ta
l e
xa
m
in
at
io
n,
 c G
S 
= 
G
le
as
on
 sc
or
e,
 d %
fP
SA
 =
 P
er
ce
nt
 fr
ee
 to
 to
ta
l P
SA
, e
PH
I =
 p
ro
sta
te
 h
ea
lth
 in
de
x
113
PH
I p
re
di
ct
s p
ro
sta
te
ct
om
y 
pa
th
ol
og
y
(Table 4). In univariate analysis, PSA, biopsy GS, %fPSA, %p2PSA and PHI were all predic-
tors for pT3 or pGS≥7. In multivariate analysis for prediction of pT3 or pGS≥7, %fPSA 
(OR 0.92, 95% CI 0.87-0.98), %p2PSA (OR 3.29, 95% CI 1.50-7.20), and PHI (OR 
1.03, 95% CI 1.01-1.06) were all independent predictors. Adding %fPSA, %p2PSA, or 
PHI to the base model (age, PSA, abnormal DRE, biopsy GS) improved the AUC from 
71.7% to 75.7%, 79.6%, and 78.9% respectively.
For prediction of tumor volume >0.5ml (Table 3), %p2PSA and PHI (but not %fPSA) 
were independent predictors, and adding %p2PSA or PHI to the base model improved the 
AUC from 71.7% to 82.0% and 84.5% respectively. For prediction of Epstein signifi cant 
tumor (Table 4), adding %fPSA, %p2PSA or PHI to the base model improved AUC from 
70.2% to 76.4%, 84.1%, and 86.1% respectively.
Th e DCA curves were plotted for tumor volume >0.5ml and pT3 or pGS≥7. Net clinical 
benefi t was observed in using PHI (comparing with %fPSA and PSA) to predict tumor 
volume >0.5ml (Figure 1) across the whole range of threshold probability beyond 20% (the 
probability of tumor volume >0.5ml that the patient would opt for treatment). Net clinical 
benefi t was also observed in using PHI for prediction of pT3 or pGS≥7 (Figure not shown) 
between the threshold probability of 20% and 45%. 
Low and very low risk patients according to NCCN criteria were analyzed in subgroups 
for the eff ect of PHI on upgrading and upstaging. Th ere were 29 low risk and 25 very low 
risk patients. 6 out of 29 low risk patients had upgrade of Gleason score, with upgraded 
patients having a signifi cantly higher PHI values (42.8 Vs 31.9, p=0.032, T-test). Only 
2 out of 25 very low risk patients had an upgrade of Gleason score, and analysis was not 
Figure 1. Decision curve analysis for prediction of tumor volume >0.5 ml, comparing PSA, %fPSA, 
and PHI. Th e x-axis (threshold probability) is probability of tumor volume >0.5 ml that patient would 
opt for treatment; y-axis is net clinical benefi t of diff erent models
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meaningful due to small event number. 22 out of 29 (75.9%) low risk patients had upstage 
to pT2b or above, with upstaged patients having significantly higher phi values (36.8 Vs 
26.0, p=0.023, T-test). 20 out of 25 (80.0%) very low risk patients had upstage to pT2b or 
above, but the difference in PHI values did not reach statistical significance. 
DISCuSSIOn
This study investigated the association of PHI and %p2PSA with RP final pathology in a 
Chinese cohort. Our results supported that PHI or %p2PSA could predict RP pathological 
outcomes including pT3, pGS, upgrade of GS, tumor volume >0.5ml and Epstein signifi-
cant tumor. A commonly used PHI diagnostic cutoff 4 of 35 was also associated with an 
increase in risk of pT3 or pGS≥7 disease from 16.1% to 60.8%, and an increase in risk of 
significant tumor volume (0.5ml) from 25.5% to 72.6%.
In multivariate analyses, adding PHI or %p2PSA to the base model (age, PSA, abnormal 
DRE, and biopsy GS) improved AUC for predicting pT3 or pGS≥7 by 7.2% and 7.9% 
respectively, improved AUC for predicting significant tumor volume (0.5ml) by 12.8% and 
10.3% respectively, and improved AUC for predicting Epstein significant tumor by 15.9% 
and 13.9% respectively. To date, this is the first study to investigate association of PHI or 
%p2PSA with radical prostatectomy final pathology in Chinese men. 
There were 4 previously published papers on relationship of p2PSA or PHI with surgical pa-
thology, and all of them were performed in European men.1, 9-11 The RP pathologic outcomes 
of a study on Dutch and Austrian men showed that PHI value was significantly higher in 
Dutch men with pathologic GS ≥7 (42.4 Vs 36.3) but not in Austrian men, and there was 
no significant difference in %p2PSA values for GS ≥7 in both Dutch and Austrian men.1 A 
study on Italian men reported that PHI and %p2PSA accurately predicted RP pathological 
outcomes including pT3 status (by AUC 2.4-2.5%), pathologic Gleason sum (by AUC 
6.0%), Gleason sum upgrading (by AUC 5.1-5.7%), and tumor volume <0.5ml (by AUC 
3.8-4.2%) in multivariate analyses.9 A study on German men reported that PHI or %p2PSA 
were not independent predictors of RP pathological outcomes in multivariate analysis, but 
using a p2PSA cutoff of 22.5pg/ml could slightly improve the predictive accuracy of pT3 
disease (by 3.6% in AUC) but not pGS.10 A multi-centre European study had shown PHI or 
%p2PSA could improve AUC by 1.2% and 2.3%, respectively, over base model in predicting 
pT3 or pGS ≥7 in multivariate analyses.11 In the current study, the absolute improvements of 
AUC in prediction of various pathologic outcomes in Chinese men were more pronounced 
compared with that in European men. This might be due to differences in prostate cancer 
epidemiology (incidence of prostate cancer and aggressive prostate cancer) and ethnicity in 
performance of PHI or %p2PSA. 
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As the primary objective of the current study was to correlate PHI & %p2PSA with 
prostatectomy pathology, all study bloods were taken 1 day before surgery to allow more 
accurate prediction. In application of the PSA isoforms at the time of screening (systematic 
or opportunistic), a higher %p2PSA or PHI would allow better prediction of the likelihood 
of more advanced prostate cancer at that moment, and patients could be better counselled 
on biopsy and treatment options.
Combining with existing markers including age, PSA, %fPSA, biopsy GS, and abnormal 
DRE, PHI or %p2PSA could improve the accuracy in predicting indolent tumor in terms of 
≤pT2c and pGS≤6, Epstein insignifi cant tumor or tumor volume <0.5ml. As more and more 
non-aggressive prostate cancers are diagnosed in the PSA era, accurate prediction of non-
aggressive tumors could aid in patient counselling on selection of appropriate intervention 
including radical treatment or active surveillance. As the defi nition of insignifi cant tumor in 
RP specimen is controversial18-20, we used 3 diff erent defi nitions for this purpose (≤pT2c and 
pGS≤6, Epstein insignifi cant tumor, or tumor volume <0.5ml).
In decision curve analyses with PHI, net clinical benefi t was seen for pT3 or pGS≥7 in 
the range of threshold probability of 20-45%, and in the whole range of threshold prob-
ability for tumor volume >0.5ml. On the contrary, the decision curve analyses in the studies 
by Guazzoni et al9 and Fossati et al11 showed no signifi cant net clinical benefi t. We postulate 
that the diff erence might be due to much higher proportion (up to 70%) of patients having 
clinically aggressive disease (pT3 or pGS≥7) in the two European cohorts, comparing with 
only 42.2% in the current Chinese cohort. It should be emphasized that, at similar median 
PSA levels (Guazzoni9 5.89 ng/mL, Fossati11 5.25 ng/mL, Current study 9.0 ng/mL) and 
proportion of abnormal DRE (Guazzoni9 13%, Fossati11 30%, Current study 20.8%), the 
proportion of clinically aggressive prostate cancers were much higher in Caucasian than in 
Chinese. Incorporating PHI or %p2PSA to existing markers provided net clinical benefi t in 
predicting pT3 or pGS≥7 in Chinese population with lower incidence of clinically aggressive 
disease. 
Th e strengths of the study included the prospective collection of clinical data and blood 
samples, the adherence of blood processing to recommended protocol15, the analyses of fi nal 
RP pathology instead of biopsy pathology, the reporting of pathologic outcomes by expe-
rienced genitourinary pathologists, and the use of both multivariate analyses and decision 
curve analyses for assessment of statistical and clinical signifi cance. Th e weaknesses of this 
study included relatively small sample size and lack of comparison with other nomograms, 
imagings, or markers. In conclusion, addition of PHI or %p2PSA to existing markers im-
proved predictive accuracy of RP pathological outcomes in Chinese patients, and enabled 
more accurate prediction of non-aggressive cancers for better counselling on intervention. 
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SuPPlEMEnT
Supplementary Figure 1. Boxplot of PHI values for diff erent pathologic outcomes.
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AbSTRACT
Asian have a lower incidence of prostate cancer(PCa). This study aims to compare the 
performance of Prostate health index(PHI) in different ethnic groups. 2488 men (1688 
Asian and 800 European men from 9 sites) with PSA 2-20ng/mL, PHI test results and 
transrectal ultrasound-guided biopsy performed were included. 1652 men had PSA 2-10ng/
mL, normal digital rectal examination(DRE) and underwent initial biopsy. The propor-
tions of PCa(Gleason≥6) and higher grade PCa(HGPCa, Gleason≥7) across different PHI 
ranges were compared. The performance of PSA and PHI were compared using area under 
curve(AUC) and decision curve analyses(DCA). In Asian men, HGPCa was diagnosed 
in 1.0%(PHI<25), 1.9%(PHI 25-35), 13%(PHI 35-55), and 30%(PHI>55) of men. At 
90% sensitivity for HGPCa(PHI>30), 56% biopsies and 33% Gleason 6 cancer diagnoses 
could have been avoided. In European men, HGPCa was diagnosed in 4.1%(PHI<25), 
4.3%(PHI 25-35), 30%(PHI 35-55), and 34%(PHI>55) of men. At 90% sensitivity for 
HGPCa(PHI>40), 40% biopsies and 31% Gleason 6 cancer diagnoses could have been 
avoided. AUC and DCA confirmed benefit of PHI over PSA. The benefit of PHI was also 
seen at repeat biopsy(n=397) or PSA 10-20ng/ml(n=439). PHI is effective in cancer risk 
stratification in both European and Asian men. Population-specific PHI reference ranges 
should however be used. 
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Th e blood test Prostate Health Index(PHI) helps to identify men at higher risk of prostate 
cancer in both Asian and European, and could signifi cantly reduce unnecessary biopsies and 
over-diagnosis of prostate cancer. Diff erent PHI reference ranges should be used for diff erent 
ethnic groups. 
Prostate Health Index(PHI) has been shown to outperform PSA, free PSA(fPSA), or 
PSA density in predicting PCa, and could signifi cantly reduce unnecessary prostate biopsies 
by 30-50%.[1-4] A commonly quoted PHI reference range with corresponding risk of PCa 
(PHI<25: 11%, PHI 25-35: 18%, PHI 35-55: 33%, PHI>55: 52%) in laboratory reports is 
the one reported by Catalona et al. established in mainly Caucasian men with PSA 2-10ng/
ml and normal DRE.[1] Th e PCa rate found in systematic biopsies for PSA <10 ng/ml 
varies across diff erent ethnic groups, ranging from 26-47% in Caucasian to only 15-25% 
in Asian.[5, 6] Th erefore, diff erent PHI reference ranges may be needed for diff erent ethnic 
populations. 
Th is is a European and Asian multicentre study including 9 clinical sites. European 
sites include Paris and Rennes(France), Hamburg and Muenster(Germany). 90-98% men 
are Caucasian in the European cohorts. Asian sites include Asian men from Hong Kong 
and Shanghai(China), Singapore, Tai Chung and Taipei(Taiwan). Men with PSA 2-20ng/
ml(Hybritech calibration) and 10-12 core transrectal ultrasound(TRUS) guided systematic 
prostate biopsies performed were included. A pre-biopsy blood was taken, centrifuged within 
3 hours, immediately stored at −80°C, and subsequently analyzed for PSA, fPSA, and [-2]
proPSA(p2PSA)(Beckman Coulter immunoassay system, Fullerton, CA, USA).[7] Prostate 
Health Index(PHI) was calculated using the formula p2PSA/fPSA x√PSA. Outcomes in-
cluded PCa and higher grade PCa(HGPCa, Gleason 3+4 or above ). 2488 men(1688 Asian 
and 800 European) with PSA 2-20ng/mL and normal DRE were included for analyses.
Th e cohort was divided into 3 diff erent groups for separate analyses: 
Group 1(n=1652): PSA 2-10ng/mL, normal DRE, and initial biopsies,
Group 2(n=397): PSA 2-10ng/mL, normal DRE and repeat biopsies, 
Group 3(n=439): PSA 10-20ng/mL and normal DRE. 
Th e baseline characteristics of the European and Asian cohorts in Group 1 are listed in 
Supplementary Table 1. Th e European cohorts have a higher percentage of repeat biopsies 
and median PHI, a lower PSA level, and similar median prostate size compared with the 
Asian cohorts. Th e PCa detection rates in European and Asian men(Group 1) for diff erent 
PHI ranges are listed in Table 1. PCa and HGPCa risks in European men were 4 times 
higher as compared to Asian men(Chi-square test,p<0.001).
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The AUC of ROC curves when predicting PCa are listed in Supplementary Table 2. In 
predicting PCa and Gleason≥7 PCa, PHI had the highest AUC in both European and Asian 
cohorts, except for Gleason≥3+4 PCa in European men where PHI performed similar to 
PSA density. 
Table 2, based on men in Group 1, depicts sensitivity, specificity, and the number of 
prostate biopsies that could have been saved for different PHI cutoffs in relation to HGPCa. 
The number of HGPCa missed and Gleason 6 cancer diagnoses avoided is listed for each 
cutoff. In European men, at 90% sensitivity for HGPCa(PHI 40), 40% biopsies and 31% 
Gleason 6 cancer diagnoses could have been avoided. In Asian men, at 90% sensitivity for 
HGPCa(PHI 30), 56% biopsies and 33% Gleason 6 cancer diagnoses could have been 
avoided. In the case of Gleason ≥4+3 PCa, PHI cutoff was 40 at 90% sensitivity in Euro-
pean, while saving 40%(201/503) biopsies and 31%(45/147) Gleason 6 cancers. For Asian 
Gleason≥4+3 PCa, PHI cutoff was 30 at 90% sensitivity, while saving 53%(605/1149) 
biopsies and 26%(22/85) Gleason 6 cancers.
Group 2 included 397 men with PSA 2-10, normal DRE, and repeat biopsies. 75% of 
men were European. Median PSA was 5.9(IQR 4.5-7.4)ng/mL. Supplementary Table 3 
shows PCa diagnosis at different PHI ranges. The AUC’s for PCa are: PHI 0.78, PHI density 
0.73, PSA density 0.58, and PSA 0.44. The AUC’s for HGPCa are: PHI 0.78, PHI density 
0.74, PSA density 0.66, and PSA 0.52.
Group 3 included 439 Asian men with PSA 10-20ng/mL and normal DRE. The small 
number(n=33, 7%) of European men were not included in the analysis. Median PSA was 
13(IQR 11-15)ng/mL. Supplementary Table 3 shows PCa diagnosis at different PHI ranges. 
Table 1. Prostate cancers in different Prostate health index (PHI) ranges, for men with PSA 2-10 ng/
mL, normal DRE and initial biopsies (Group 1).
PHI <25 25-35 35-55 >55 Total p-value*
European 
cohort
n=503
Prostate cancer 17/49
(35%)
30/116
(26%)
100/178
(56%)
115/160
(72%)
262/503
(52%)
<0.001
Gleason 3+4 or 
above PCa
2/49
(4.1%)
5/116
(4.3%)
53/178
(30%)
55/160
(34%)
115/503
(23%)
<0.001
Gleason 4+3 or 
above PCa
0/49
(0%)
2/116
(1.7%)
12/178
(6.7%)
16/160
(10%)
30/503
(6.0%)
<0.001
Asian 
cohort 
n=1149
Prostate cancer 20/397
(5.0%)
31/412
(7.5%)
72/276 
(26%)
28/64
(44%)
151/1149
(13%)
<0.001
Gleason 3+4 or 
above PCa
4/397 
(1.0%)
8/412
(1.9%)
35/276 
(13%)
19/64
(30%)
66/1149
(5.7%)
<0.001
Gleason 4+3 or 
above PCa
2/397 
(0.5%)
6/412
(1.5%)
11/276 
(4.0%)
8/64
(13%)
27/1149
(2.3%)
<0.001
*Chi-square tests for Cancer Vs PHI ranges (PHI <25, PHI 25-35, PHI 35-55, and PHI >55)
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The AUC’s for PCa are: PHI 0.76, PHI density 0.77, PSA density 0.67, PSA 0.47. The 
AUC’s for HGPCa are: PHI 0.77, PHI density 0.81, PSA density 0.75, and PSA 0.44.
DCA curves for different biopsy indication scenarios are shown in Supplementary Figure 1. 
In all scenarios, net clinical benefit of PHI was higher as compared to all other markers, 
except in Group 1 European cohorts(Figure 1d) where PHI showed similar performance to 
PSA density in predicting HGPCa.
We created forest plots showing the odd’s ratio of PHI in the different centres for the 
different outcomes in Group 1. These forest plots showed substantial heterogeneity of the 
effect of PHI when predicting the presence of cancer. The grouping factor Asia/Europe was 
able to explain the observed heterogeneity partly. For the outcomes any PCa and Gleason 
≥4+3 there was no statistically significant residual heterogeneity, while there was some 
residual heterogeneity for Gleason≥3+4. After subdividing Europe into the countries there 
was no statistically significant residual heterogeneity. Therefore we presented results grouped 
by continent across all outcomes.
Men in the European cohort had a 4 times higher risk of PCa and HGPCa as compared 
to Asian men. Baseline age and PSA was higher in Asian while prostate size was comparable. 
All 9 cohorts were clinically referred patients and not from any structured PSA screening 
program. The differences in cancer risk are likely related to ethnical differences.
Druskin et al. reported PHI density(AUC 0.82) having better performance than 
PHI(AUC 0.79) in predicting clinically significant PCa.[8] In the current study, PHI den-
sity did not perform better than PHI in most scenarios except Group 3. The larger sample 
size and multi-ethnicity in the current study may be more representative concerning the 
usefulness of PHI density. 
Other well performing tools for PCa diagnosis (e.g. risk calculators) include PSA den-
sity, requiring an estimate of prostate volumes.[9] Multiparametric MRI prostate improves 
diagnosis of clinically significant prostate cancer[10], but in general is related to higher costs 
and requires radiological expertise. MRI and PHI is shown to be complementary to each 
other as each modality missed some significant PCa.[8] As PHI is a simple blood test, it can 
be ordered by general practitioners, and there is no need for interpretation expertise. As the 
cost of a blood test will likely go down with time, the role of PHI as a screening tool is worth 
investigating. 
There are certain strengths in the current study, which include the largest sample size 
to date for PHI research, and the involvement of different ethnic groups from 9 sites. The 
limitations include: 1. Very few prostate MRIs done and potential under-diagnosis, 2. Lack 
of biopsy information like number of positive cores or percentage of cancer in each core, 3. 
No cost effectiveness analysis as the costs in each site are different.
In conclusion, PHI was shown to be more effective than PSA density, %fPSA, or PSA in 
predicting PCa in all subgroups including PSA 2-10ng/mL, PSA 10-20ng/mL, or any his-
tory of prior negative biopsy. By using PHI, more biopsies could have been avoided in Asian 
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men(56% vs 40%) while reducing 30% Gleason 6 diagnoses in both groups. Population-
specifi c PHI reference ranges and cutoff  values should be formulated. 
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Supplementary Figure 1. Decision curve analyses of diff erent scenarios (1a-1h).
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Supplementary Table 1. Baseline characteristics of men with PSA 2-10, normal DRE, and initial 
biopsies.
European
n=503
Asian
n=1149 p-value
Age at TRUS biopsy, median (IQR) 63 (58-68) 65 (61-71) <0.001
TRUS volume (ml), median (IQR)* 41 (31-54) 43 (32-58) 0.449
PSA (ng/ml), median (IQR) 5.0 (4.0-6.4) 6.4 (5.3-7.8) <0.001
% Free PSA, median (IQR) 0.14 (0.10-0.18) 0.19 (0.14-0.24) <0.001
%p2PSA (%), median (IQR) 2.1 (1.5-2.7) 1.1 (0.90-1.5) <0.001
PHI, median (IQR) 45 (33-62) 29 (23-37) <0.001
PCa 262 (52%) 151 (13%) <0.001
HGPCa 115 (23%) 66 (5.7%) <0.001
*TRUS volume measured by Ellipsoid formula. Missing data in TRUS volume: 1 in European, 74 in 
Asian. 
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AbSTRACT
Purpose
To investigate PSA and PHI(prostate health index)-based models for prediction of prostate 
cancer(PCa) and the feasibility of using DRE estimated prostate volume(DRE-PV) in the 
models.
Methods
This study included 569 Chinese men with PSA 4-10ng/mL and non-suspicious DRE with 
transrectal ultrasound(TRUS) 10-core prostate biopsies performed between April 2008 and 
July 2015. DRE-PV was estimated using 3 pre-defined classes: 25ml, 40ml or 60ml. The 
performance of PSA-based and PHI-based predictive models including age, DRE-PV, and 
TRUS prostate volume(TRUS-PV) were analyzed using logistic regression and area under 
the receiver operating curves(AUC), in both the whole cohort and the screening age group 
of 55-75.
Results
PCa and high grade PCa(HGPCa) was diagnosed in 10.9%(62/569) and 2.8%(16/569) 
men, respectively. The performance of DRE-PV based models was similar to TRUS-PV 
based models. In the age group 55-75, the AUCs for PCa of PSA alone, PSA with DRE-PV 
and Age, PHI alone, PHI with DRE-PV and Age, and PHI with TRUS-PV and Age were 
0.54, 0.71, 0.76, 0.78, and 0.78, respectively. The corresponding AUCs for HGPCa were 
higher(0.60, 0.70, 0.85, 0.83, and 0.83). At 10% and 20% risk threshold for PCa, 38.4% 
and 55.4% biopsies could be avoided in the PHI-based model, respectively. 
Conclusions
PHI had better performance over PSA-based models and could reduce unnecessary biopsies. 
A DRE assessed PV can replace TRUS assessed PV in multivariate prediction models to 
facilitate clinical use.
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InTRODuCTIOn
Prostate specifi c antigen(PSA) is widely used as a screening tool for prostate cancer(PCa), 
either in a systematic or opportunistic manner. However, due to its poor predictive ability, 
the sole use of PSA resulted in a lot of unnecessary biopsies and treatments [1-2]. Incorpora-
tion of clinical parameters in a multivariate risk stratifi cation can improve the performance 
of screening [3-5]. Commonly used risk calculators used parameters including age, digital 
rectal examination(DRE) fi nding, prostate volume, ultrasound lesion, and history of prior 
negative biopsy [3-5].
Prostate health index(PHI) was shown to be a signifi cantly better marker than PSA or 
free PSA in predicting PCa and high grade prostate cancers(HGPCa), and using PHI could 
further reduce unnecessary biopsies [6-8]. Similar to the case of PSA-based risk calculators, 
combining PHI with other clinical parameters could further improve the prediction of PCa 
[9-10].
Transrectal ultrasound(TRUS) prostate volume(PV) was shown to improve risk strati-
fi cation in PSA or PHI-based risk calculators [4,11]. In real life practice, prostate volume 
measurement by TRUS is an extra procedure and is not convenient as a part of screening. 
DRE is a routinely performed examination in men at risk of PCa. It has been shown in 
the ERSPC risk calculator that using DRE estimation of prostate size as part of the risk 
stratifi cation resulted in similar cancer prediction compared with TRUS detected prostate 
volume in Caucasian [4].
Th e positive biopsy rate in the ‘diagnostic gray zone’ of PSA 4-10ng/mL varied across 
diff erent ethnic groups and countries [12]. Studies have shown that positive biopsy rates 
were about 30%(range 26-47%) in Caucasians [12], and only 15-25% in Asian [13]. In a 
contemporary Hong Kong Chinese cohort of men with PSA 4-10ng/mL and normal DRE, 
the positive biopsy rate was as low as 13.4% [14]. In these patient groups, up to 85% of 
biopsies were unnecessary, and therefore better risk stratifi cation specifi c to Asian or Chinese 
is needed. 
In this study, we assessed the role of DRE estimated prostate volume in PSA and PHI-
based PCa risk prediction models in a cohort of Chinese men. 
MATERIAlS AnD METHODS
Th is is a prospective cohort recruiting consecutive patients with PSA 4-10ng/mL and non-
suspicious digital rectal examination(DRE), with or without lower urinary tract symptoms, 
who consented before prostate biopsy. Th e blood samples were processed according to the 
criteria described by Semjonow et al [15]. Th e bloods were centrifuged within 3 hours, 
immediately stored at -80°C, and subsequently analyzed for PSA, free PSA and p2PSA 
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using the Beckman Coulter Access 2 Immunoassay System(Beckman Coulter Inc., Brea, 
CA, USA). The exclusion criteria included patients with known history of prostate cancer, 
any suspicious DRE finding, and use of androgen deprivation therapy or 5 alpha-reductase 
inhibitors before the study. Patients with abnormal or suspicious DRE were excluded as PHI 
was approved by the United States Food and Drug Administration(FDA) for patients with 
normal DRE.
Immediately after blood taking, patients were placed in left lateral decubitus position 
with DRE performed by a Urology resident. DRE prostate volume(DRE-PV) was estimated 
by the doctor and recorded by a nurse at that moment. For cases before 2012, the exact 
estimated DRE-PV was subsequently reclassified into one of the 3 classes: <30ml(coded 
as 25ml), 30-50ml(coded as 40ml), or >50ml(coded as 60ml). Since 2012, the DRE-PV 
was directly recorded into one of the 3 classes as stated above. After DRE, TRUS prostate 
volume(TRUS-PV) was measured using the ellipsoid formula. A systematic 10-core TRUS 
guided prostate biopsy was then performed according to the standardized protocol. The 
biopsies were evaluated by genitourinary pathologists blinded to the blood results. PCa were 
graded according to the International Society of Urological Pathology 2005 consensus [16]. 
This study conformed to the provisions of the Declaration of Helsinki, and was approved by 
the ethics committee of our hospital. Informed consent was signed by each patient. 
The primary objective of this study was to compare the performance of various param-
eters in predicting PCa and HGPCa(Gleason score 7 or above). The parameters included 
PSA(Hybritech calibration), Prostate health index(PHI), and other clinical parameters in-
cluding age, previous negative biopsy(PNBx), TRUS-PV, and DRE-PV. %free PSA(%fPSA) 
was calculated by dividing free PSA by total PSA. %p2PSA was calculated using the formula 
p2PSA/freePSA. Prostate health index (PHI) was calculated using the formula (p2PSA/
freePSA)x √PSA. 
Statistically significant differences in patient characteristics between cancer and non-can-
cer patients were assessed using the Mann-Whitney U test for continuous data and the chi-
square test for categorical data. Commonly used PHI cutoffs of 25, 35, and 55 as suggested 
by Catalona [6] were used to stratify the risk of PCa and HGPCa. Multivariate analyses were 
performed for both PSA and PHI, including base parameters of age, DRE-PV, and PNBx. 
The areas under the curves(AUC) of the receiver operating characteristic(ROC) were listed 
for different models, and the regression models were compared using the likelihood ratio 
test. Predictors including PSA, %fPSA, %p2PSA, PHI, TRUS-PV, and DRE-PV were 2-log 
transformed before regression and AUC analyses. Analyses were performed separately for the 
whole cohort and for the screening age of 55-75 years, and results were mainly presented 
in the latter group in which application of screening tests is most appropriate. IBM SPSS 
Statistics for Windows version 22(IBM Corp., Armonk, NY, USA) was used for statistical 
analyses. A 2-sided p-value of <0.05 was considered significant.
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RESulTS
Between April 2008 and July 2015, 2779 TRUS biopsies were performed, with 1314 
patients with PSA 4-10ng/mL and non-suspicious DRE. Among them, 569 patients 
consented for extra blood taking before TRUS biopsy and were included in the current 
study. Complete clinical parameter data and TRUS biopsies were available. Th e baseline 
demographic information of the whole cohort(n=569), the screening age group of 55-75 
years(n=505), and cancer and non-cancer patients are listed in Table 1. PCa was diagnosed 
in 62 out of 569(10.9%) patients in the whole cohort, and in 56 out of 505(11.1%) men 
in the age group of 55-75. Similar data for HGPCa were 16 out of 569 men (2.8%) and 16 
out of 505 men (3.2%) respectively. Th ere was no signifi cant diff erence in clinical and blood 
based parameters between the whole cohort and the group with age 55-75. In PCa patients, 
age, %fPSA, %p2PSA, and PHI were signifi cantly higher, while TRUS-PV and DRE-PV 
were signifi cantly lower (Table 1). Th e PSA values between cancer and non-cancer patients 
were not signifi cantly diff erent. For the comparison of patients who consented for extra 
Table 1. Baseline characteristics
Median
IqRa
Age 55-75
n=505
Overall
n=569
non Cancer
n=507
Cancer patients
n=62 p-value
Age (years) 66
62 - 70
66
61 - 71
66
61 - 71
69
64 - 73
0.005 g
PSA (ng/mL) 6.70
5.63 - 7.97
6.73
5.64 – 8.03
6.74
5.59 – 8.02
6.59
5.96 – 8.35
0.532 g
TRUS-PVb (ml) 46.0
34.5 - 60.7
46.0
33.9 – 60.9
47.6
35.6 – 62.3
34.0
26.0 – 46.3
<0.001 g
DRE-PVc (ml) <0.001 h
<30ml (25ml) 120 (23.8%) 142 (25.0%) 116(22.9%) 26 (41.9%)  
30-50ml (40ml) 198 (39.2%) 218 (38.3%) 192(37.9%) 26 (41.9%)  
>50ml (60ml) 187 (37.0%) 209 (36.7%) 199(39.3%) 10 (16.1%)  
Repeated Biopsy (%) 72 (14.3%) 81 (14.1%) 76 (15.0%) 5 (8.1%) 0.141 h
%fPSAd (%) 0.19
0.15 – 0.25
0.20
0.15 – 0.25
0.20
0.15-0.25
0.16
0.13 – 0.21
0.003 g
%p2PSAe (%) 1.12
0.90 – 1.38
1.12
0.89 – 1.40
1.08
0.86 – 1.34
1.46
1.21 – 1.75
<0.001 g
PHIf 28.7
23.2 – 35.7
28.5
23.0 - 35.8
27.6
22.6 – 33.9
38.2
30.1 – 44.6
<0.001 g
a IQR = Inter-quartile range, b TRUS-PV = Transrectal ultrasound prostate volume, c DRE-PV = 
Digital rectal examination prostate volume, d %fPSA = free PSA / total PSA, e %p2PSA = p2PSA / free 
PSA, f PHI = prostate health index. g Mann-Whitney U-test, between cancer and non-cancer patients. 
h Chi-square test, between cancer and non-cancer patients.
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PHI blood taking before TRUS biopsy with those who did not, the baseline characteristics 
including age, PSA, TRUS-PV, PCa rates and HGPCa rates had no significant difference.
Numbers of PCa and HGPCa diagnosed within the various commonly used PHI ranges 
are shown in Table 2(whole cohort). Using PHI 35 as a cutoff stratified the risk of PCa 
to 5.8%(24/417) in PHI <35 and 25.0%(38/152) in PHI >35. Similarly, PHI 35 cutoff 
stratified the risk of HGPCa to 0.7%(3/417) in PHI <35 and 8.6%(13/152) in PHI >35.
The AUCs of PSA and PHI-based predictive models incorporating TRUS-PV, DRE-PV, 
and age for the group 55-75 years were shown in Table 3. Adding TRUS-PV and age to PSA 
improved the AUC of predicting PCa from 0.54 to 0.72 (likelihood ratio test, p<0.001), 
and improved that of predicting HGPCa from 0.60 to 0.71 (likelihood ratio test, p=0.003). 
Substituting TRUS-PV with DRE-PV in PSA-based models showed similar improvement 
of AUC compared to PSA alone. 
PHI achieved the AUC of 0.76 for PCa and was better than the PSA-based models 
(Table 3). Adding Age and DRE-PV to PHI (model 10) further improved the AUC of 
predicting PCa from 0.76 to 0.78 (likelihood ratio test, p=0.009). Substituting PHI in 
model 10(PHI + DRE-PV + Age) with %fPSA or %p2PSA resulted in AUC of 0.71 and 
0.77 respectively, while adding PSA to model 10 resulted in no additional benefit to the 
AUC of 0.78. 
For HGPCa, adding DRE-PV and age to PSA-based model improved the AUC from 
0.60 to 0.70 (likelihood ratio test, p=0.017)(Table 3). The highest AUC observed was 0.85 
with PHI alone, and there was no additional benefit in AUC in adding age and/or DRE-PV 
to PHI (Table 3). 
The number of biopsies that can be reduced at different risk thresholds for PCa and 
HGPCa in the age group of 55-75 were shown in Table 4. The model with PHI, DRE-PV 
and Age could reduce the most number of biopsies comparing with other models. At 20% 
risk threshold for PCa and HGPCa, 55.4% and 80.2% of the biopsies could be avoided, 
respectively. The results in Table 3-5 for age 55-75 had no significant difference compared 
with that in the whole cohort. 
Table 2. Prostate cancers and High grade prostate cancers in different Prostate health index (PHI) 
ranges (Whole cohort)
PHI <25 25-35 35-55 >55 Total p-value
Prostate cancer 7/192
(3.6%)
17/225
(7.6%)
30/131 
(22.9%)
8/21
(38.1%)
569 <0.001
High grade prostate cancer 1/192 
(0.5%)
2/225
(0.9%)
9/131
(6.9%)
4/21
(19.0%)
569 <0.001
Gleason scores of high grade 
prostate cancer
3+5 (n=1) 3+4 (n=1)
3+5 (n=1)
3+4 (n=5)
3+5 (n=1)
4+5 (n=3)
3+4 (n=3)
4+5 (n=1)
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The box plots of TRUS-PV against DRE-PV classes were shown in Fig 1. Although the 3 
defined DRE-PV classes of 25, 40 and 60ml underestimated the median TRUS-PV of 27.3, 
43.0, and 68.0ml, respectively(p<0.001 in all 3 classes), most performances of DRE-PV in 
the predictive models (Table 3) were similar to that of TRUS-PV. 
Table 4. Number of biopsies that can be reduced compared to all-biopsy strategy in age 55-75 (n=505) 
for PSA and PHI-based calculators
number of biopsies reduced (%)
All cancer
Risk threshold PSA PSA + DRE-PVa + Age PHIb PHI + DRE-PV + Age
5% 55 (10.9%) 78 (15.4%) 110 (21.8%) 140 (27.7%)
10% 81 (16.0%) 124 (24.6%) 153 (30.3%) 194 (38.4%)
20% 105 (20.8%) 189 (37.4%) 240 (47.5%) 280 (55.4%)
30% 111 (22.0%) 285 (56.4%) 284 (56.2%) 317 (62.8%)
40% 127 (25.1%) 328 (65.0%) 309 (61.1%) 358 (70.9%)
High grade cancer
Risk threshold PSA PSA + DRE-PV + Age PHI PHI + DRE-PV + Age
10% 94 (18.6%) 72 (14.3%) 261 (51.7%) 248 (49.1%)
20% 125 (24.8%) 232 (45.9%) 363 (71.9%) 405 (80.2%)
30% 144 (28.5%) 347 (68.7%) 371 (73.5%) 418 (82.8%)
40% 159 (31.5%) 360 (71.3%) 396 (78.4%) 450 (89.1%)
aDRE-PV = DRE estimated prostate volume, bPHI = prostate health index
Figure 1. Box plots of TRUS prostate volume against DRE prostate volume
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DISCuSSIOn
Prostate volume has been shown to be useful in improving performances of a number of PSA 
and PHI-based risk models [4-5, 9-10]. In this study, the value of using DRE prostate size 
estimation in the predictive models was confi rmed in a contemporary Chinese cohort with 
10-core biopsy done. 
Although it has been shown that DRE estimation of TRUS prostate volume was only 
moderately well [17], dividing DRE-PV into 3 classes(25, 40, and 60ml) in the ERSPC risk 
calculators was found to perform as good as TRUS-PV [4]. DRE-PV in the current study 
performed well in both PSA and PHI-based predictive models, and its performance was 
comparable, if not identical, to the performance of models using TRUS-PV. All DRE-PV was 
performed by Urology residents in our hospital with 1-5 years of experience, and therefore 
it is likely that the DRE estimation would be generalizable to other doctors who perform 
DRE of the prostate regularly. TRUS-PV could be replaced by DRE-PV at screening, and 
would be more convenient in both PSA-based and PHI-based scenarios in a clinic setting. 
Th e performance of PSA in predicting PCa in this cohort with PSA 4-10 ng/mL was 
poor(AUC 0.54). If only PSA was available, adding Age and Prostate volume(either TRUS 
or DRE) to a PSA-based model was essential to improve the AUC signifi cantly from 0.54 
to 0.72. 
Th e AUC of PHI alone in predicting PCa was 0.76 and was better than PSA alone(0.54) 
or a PSA-based model(0.71-0.72). In PHI-based models, adding clinical parameters includ-
ing age and DRE volumes slightly improved AUC from 0.76 to 0.78. Th erefore, in the 
presence of PHI, the role of TRUS-PV or DRE-PV, or the ability of DRE-PV substituting 
TRUS-PV, would be less important than that in PSA models. 
When age and DRE volumes were added, the AUC of the PHI-based model(0.78) was 
signifi cantly better than that in the PSA-based model(0.71) (likelihood ratio test, p<0.001). 
Th erefore, when PHI is available, PSA or PSA-based models should not be used for risk 
stratifi cation. Previous negative biopsy(PNBx) did not add further benefi t in terms of AUC 
to any predictive model(Data not shown).
PHI-based model reduced the most number of unnecessary biopsies compared with 
other models. More than half of the biopsies could have been avoided if the risk threshold for 
PCa was 20%. Th e eff ect was more pronounced in the case of HGPCa, in which 49.1% and 
80.2% biopsies would have been avoided at risk thresholds of 10% and 20% respectively. 
Both the whole cohort with age 36-86(n=569) and the group with age 55-75(n=505) 
were analyzed in this study. Th e majority of the analyzed results were presented in the age 
55-75 group as this represented the age group where screening for prostate cancer, be it 
systematic or opportunistic, is most commonly done. Nevertheless, all analyses showed 
similar results for the 2 groups. 
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It has to be noted that a small percentage of high grade prostate cancers were found in 
PHI < 25 (n=1, Gleason 3+5), and PHI 25-35 (n=2, Gleason 3+4 and 3+5) (Table 2). Men 
should be counselled of this small risk of HGPCa even when PHI is <35. Subgroup analysis 
for different Gleason scores of HGPCa was not performed due to the small HGPCa number 
of 16 in this study. 
Out of the 62 patients with PCa diagnosed, 33(53.2%) had radical prostatectomy 
performed. In PHI <35, 2 out of 13(15.4%) radical prostatectomies showed HGPCa in 
final pathology. In PHI >35, 8 out of 20(40.0%) radical prostatectomies showed HGPCa. 
Asian men have very different PCa epidemiology compared with Western men. The PCa 
incidence (per 100,000) in Western men is 5-10 times more than that in most parts of Asia 
and 10 times more than that in Chinese men, but incidence in Asia has been increasing 
rapidly in recent years. [13] With the widespread use of PSA as a means of early detection, 
most PCa in Western were diagnosed at an early stage. This is in contrast to the situation in 
China, where 65% PCa were diagnosed with PSA > 10 ng/mL, and 45% PCa were either 
locally advanced or metastatic. However, in certain parts of China like Hong Kong and 
Macau, only 35% PCa were diagnosed with PSA > 10ng/mL. [13] The positive biopsy rates 
of PCa for PSA 4-10 ng/mL were also lower in Asian men (15-25%) [13] compared with 
Western men (around 30%) [12]. The above differences might be explained by genetic and 
lifestyle differences. The reported incidence of TMPRSS2-ERG gene fusion [18] and PTEN 
inactivation [19] were both lower in Asian or Chinese population, and there were significant 
differences in single nucleotide polymorphisms compared with Caucasians. [13] In terms of 
diet, Asians in general consume more vegetables and less meat than Caucasians. [13]
The strengths of this study included the validation of DRE-PV in replacing TRUS-PV 
in different models, the analysis in a homogeneous group of patients with PSA 4-10ng/mL 
with non-suspicious DRE, the collection of blood samples right before prostate biopsy, a 
standardized blood processing according to Semjonow et al [15], a standardized systematic 
10-core biopsy protocol [20], and the analysis of all biopsy specimen by experienced geni-
tourinary pathologists.
The PCa and HGPCa rates in the current study were much lower than that in Cauca-
sian studies and some Asian studies [12-13]. This was related to exclusion of patients with 
abnormal DRE, and the actual situation of lower positive biopsy rate of PCa and HGPCa 
in Chinese patients. Including patients with or without PHI data in the current institution, 
the rate of HGPCa in men with PSA 4-10 ng/mL and normal DRE was 2.6%(53/2022), 
and was similar to the group with PHI data in this study(2.8%). According to another paper 
on PCa risks in Chinese men, the proportion of men with PSA 4-10ng/mL and normal 
DRE diagnosed with HGPCa and PCa were 3.8% and 13.4%, respectively [14]. They were 
similar to the rates in the current study (HGPCa 2.8% and PCa 10.9%). In patients with 
PSA 4-10ng/mL and abnormal DRE, the rates of HGPCa and PCa were 17.8% and 30.2%, 
respectively [14]. 
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All men in our centre received 10 core systematic biopsy since 2008, as the EAU guide-
lines on prostate cancer has been recommending a systematic prostate biopsy of 10-12 cores 
in recent years until the latest version in 2016. [21] A study by Yoon et al [20] has shown 
that the positive biopsy rates of 10 and 12 cores are similar at 26.4% and 28.4% respectively 
(p=0.378) in a group of men with mean PSA of 10.9 +/- 15.3 ng/mL. In our study, it is 
possible that men with larger prostates might have an underestimated positive biopsy rate, 
but it is very unlikely to have a real impact on outcome considering that our PSA range was 
PSA of 4-10 ng/mL.
Other weaknesses of this study included limited sample size, single institution data, and 
the fact that the results could not be applied to patients with abnormal DRE. A limited 
sample size and single institution data in our study implied that the PSA and PHI-based 
models need to be externally validated in another Chinese or Asian population before 
implementation. 
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In Chapter 1 - General introduction, the two main objectives of this thesis are stated. Th e 
fi rst objective of this thesis is to determine how harms of prostate cancer screening can be 
reduced by using PSA-based risk stratifi cation tools, and how these tools can be applied to 
Asian populations. Th e second objective of this thesis is to investigate the role of the serum 
biomarker Prostate Health Index (PHI) in prostate cancer diagnosis in Asian populations. 
Part 1: By using PSA-based risk stratifi cation tools, can we reduce harms of prostate cancer 
screening? Can these tools be applied to Asian populations?
Can we screen but still reduce overdiagnosis?
Screening for cancer aims to fi nd cancers as early as possible when the chance of cure is 
highest and as such involves healthy people who don’t have any symptoms at that point in 
time. Overdiagnosis is the diagnosis of a latent disease that would not have been diagnosed 
during a person’s lifetime (and would not have aff ected the person at all) without screening. 
Whether the diagnosis of a cancer in a particular patient can be considered as overdiagnosis is 
an interaction of how latent the disease is and how long the patient will live (life expectancy). 
A relatively rapid growing cancer might not necessarily harm the patient or be the cause 
of death if the patient had a short remaining lifetime. On the other hand, a slow growing 
cancer might harm the patient if he or she lives long enough. (Figure 1)
Knowledge on the natural history of prostate cancer is important to understand the 
impact on life expectancy and quality of life of localized prostate cancer if it is left untreated. 
In a long term observational study by Johanssen et al, 223 Swedish men with localized 
prostate cancer diagnosed in 1977-1984 (pre-PSA era) without initial active treatment were 
observed. [1] Most men did not suff er from prostate cancer in the fi rst 15 years, but progres-
Figure 1. Prostate cancer screening in association with life expectancy and disease course
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sion and prostate cancer death increased rapidly at 15-20 years in those who were still alive. 
After 30 years of follow-up and death of 99% of men in the cohort, it was observed that 17% 
of men died from prostate cancer, usually between 15-25 years after diagnosis. [2]
The control arms of randomized trials on surgery versus observation also gave us insights 
to the natural history of localized prostate cancer. The Scandinavian Prostate Cancer Group 
4 (SPCG4) in the pre-PSA era randomized 699 men between 1989 and 1999 to radical 
surgery versus watchful waiting. [3] Prostate cancer mortality was 20% at 15 years of follow-
up in the watchful waiting group. The Prostate Cancer Intervention Versus Observation 
Trial (PIVOT) in the early PSA era randomized 731 men between 1994 and 2002. [4] Most 
men in PIVOT had low to intermediate risk disease. In the observation arm, prostate cancer 
mortality was about 20% at 15 years, and in the low risk subgroup, cancer mortality was less 
than 5% at 15 years. In short, localized prostate cancer has excellent 15-year cancer specific 
survival without initial curative intent treatment, and the benefit of treatment was mostly 
observed in younger (<65) and non-low risk prostate cancer patients. [3]
Screening of prostate cancer with a PSA cutoff of 3 ng/mL in the European Randomized 
study of Screening for Prostate Cancer (ERSPC) showed a 20% reduction of prostate cancer 
mortality and a 30% reduction of metastatic disease at 9 years follow-up. [5, 6] However, 
overdiagnosis of low risk prostate cancer was significant. Applying mathematical simulation 
models in the Rotterdam section of the ERSPC data, using an algorithm of screening men 
at 55-70 years every 4 years would lead to 40% overdiagnosis. [7] 
In a cost-effectiveness study using the Microstimulation Screening Analysis (MISCAN) 
model, screening for prostate cancer every 2 years for 3 times between the age of 55 and 59 
would result in the best incremental cost-effectiveness ratio. The upper age limit of screening 
to maintain a similar cost-effectiveness ratio could be increased to 72 if better quality of 
life could be achieved by applying active surveillance for low risk prostate cancer. [8] From 
a decision process model, Zhang et al. suggested the optimal stopping age of PSA testing 
was 76 from the patients’ perspective (Quality adjusted life years, QALYs) and 71 from the 
societal perspective (cost-effectiveness). [9]
In view of the rising life expectancy, the uncertainty of remaining lifetime of an indi-
vidual, the improvement of treatment outcomes and complication profile, and availability 
of numerous life-prolonging therapy even in case of metastatic disease, it is difficult to set a 
specific age limit to stop screening for prostate cancer. Instead, an individual assessment with 
proper counseling and shared decision-making would be more appropriate in the current 
era. 
Prostate cancer is particularly amenable to overdiagnosis as there is a considerable reser-
voir of so-called latent disease which can be detected by a relatively simple procedure, the 
systematic prostate biopsy. Although obvious as it may seem, prostate cancer screening is 
frequently mixed up with PSA based screening. While systematic large scale screening for 
161
G
en
er
al
 D
isc
us
sio
n
prostate cancer by a PSA-only approach may not be appropriate, it does not mean that there 
should be no prostate cancer screening at all. Th e issue is not that black and white. 
To improve the effi  cacy of prostate cancer screening, men at a higher risk of prostate 
cancer can be selected, and they include men with positive family history, genetic disposition 
to prostate cancer, and ethnically Black men. 
Men with a positive family history of prostate cancer are at a relative risk of 2.5-4.4 
in those with 1-2 aff ected fi rst-degree relatives, and is also associated with an earlier onset 
of disease (before 65 years old). [10, 11] Genetic mutations identifi ed in Genome-wide 
association studies (GWAS) could explain 25-33% familial risks of prostate cancer, but it 
is not cost-eff ective to screen all susceptible loci and the harm-to-benefi t ratio is unknown. 
[12, 13] Th e risk of prostate cancer in ethnically black men can be more than double of that 
in Caucasian in the same region, while risk of prostate cancer death can be similar or higher 
depending on regions being studied. [14, 15] 
Better tools for detection of (potentially aggressive) prostate cancer have emerged since 
the PSA era, which include multivariate approaches, i.e. combining relevant information 
from multiple sources like e.g. clinical data, blood, urine markers, genetic tools, and novel 
imaging techniques. Such an approach may help to reduce unnecessary testing (e.g. biopsy) 
and over-diagnosis of non-lethal cancers, while, and this is crucial, not missing the diagnosis 
of a potentially lethal prostate cancer. [16-21] (Figure 2)
Life expectancy and prostate cancer screening
According to data from World Health Organization (WHO), the worldwide life expectancy 
at birth has been on the rise in the past decades from 67.7 in 2000 to 72.2 years in 2017. 
In Caucasian men who reached 70 years of age, the life expectancy in North America and 
Western Europe ranges from 14-16 years. Figure 3 shows an example of life expectancy data 
Figure 2. Eff ect of using biomarkers, risk calculators and/or MRI imaging in biopsy and outcomes
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in the Netherlands. Dutch men at 70 years old have 15 years of life expectancy, and those 
with higher education level had 4 extra years of life expectancy. [22] (Figure 3)
In Asian men who reached 70 years of age, the life expectancies in India, China, South 
Korea, Singapore and Japan are 11.2, 11.5, 14.6, 15.3 and 15.7 years. [23] However, life 
expectancy of urban and rural areas in Asian countries can have great variations. In China, 
in more developed cities like Hong Kong, the life expectancies of men at 70, 75 and 78 
years old are 16.0, 12.5, and 10.6 years. [24] A 70 year-old men in the urban regions like 
Beijing, Shanghai, Hong Kong, Macau, Tianjin, or Zhejiang would have about 15 years 
of life expectancy. In less developed regions of China, the life expectancy is in general 5-8 
years less. [25] There is also evidence that higher education level is associated with longer life 
expectancy. [22] Therefore, eligibility for prostate cancer screening (or age to stop screening) 
needs to be individualized in the context of life expectancy. While men at 70 years old in 
urban Asia have about 15 years of life expectancy and therefore should still be eligible for 
prostate cancer screening, those in rural Asia may have less than 10 years of life expectancy 
at 70 years old. Furthermore, screening should be done not only on the basis of a PSA test 
but additional risk stratification using risk calculators, biomarkers and/or MRI to avoid 
unnecessary prostate biopsy and diagnosis of indolent prostate cancer. (Figure 4, Figure 5)
Figure 3. Remaining life expectancy in the Dutch men
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Figure 4. Prostate cancer screening in Urban Asian setting in association with life expectancy at 70 
years old and disease course in the context of PSA, biomarkers and MRI. 
Figure 5. Prostate cancer screening in Rural Asian setting in association with life expectancy at 65 years 
old and disease course in the context of PSA, biomarkers and MRI. 
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To reduce harms of prostate cancer screening by using PSA-based risk stratification tools in 
Asian men?
Part of the harms of prostate cancer screening included unnecessary prostate biopsies in men 
with no cancer and the associated biopsy complications. PSA-based risk stratification tools 
(e.g. PSA density, Prostate cancer risk calculators) can reduce such harms. 
PSA density
PSA density, calculated with PSA divided by prostate volume, was first reported by Benson 
et al in 1992 to have better ability to predict prostate cancer than PSA. [26] A further study 
in 3140 men showed that in the PSA range of 4-20 ng/mL, PSA density could improve 
cancer risk stratification compared with PSA alone. [27] Bazinet et al suggested PSA density 
of 0.15 for PSA 4-10 ng/mL [28], but Catalona et al showed in a cohort of almost 5000 men 
with sextant biopsy, that adding prostate volume significantly improved positive predictive 
value, but almost half of cancers might be missed by using PSA density cutoff of 0.15. [29] 
In chapter 3 of this thesis, the role of PSA density was being explored in 854 Asian men 
with elevated PSA > 4ng/mL in 2009-2012. [30] The cohort was divided into obese and 
non-obese men, with obese man having similar PSA levels (8.2 Vs 7.9 ng/mL, p=0.416) 
but larger prostate sizes (63ml Vs 52ml, p<0.001). The performance of PSA density was 
significantly better than PSA in obese men (AUC 0.73 Vs 0.51) but only slightly better than 
PSA in non-obese men (AUC 0.65 Vs 0.62). The risk of prostate cancer in obese men with 
PSA density > 0.15 was 4 times the risk in men with PSA density < 0.15, while it was only 2 
times the risk in non-obese men. The study demonstrated value of PSA value in Asian men 
and in obese Asian men in particular. [30]
Teoh et al reported the performance of PSA density in another cohort of 2600 Chinese 
men in Hong Kong in 2000-2013, confirming the superiority of PSA density over PSA. [31] 
At PSA density 0.15, 90% sensitivity and 42% specificity for any grade prostate cancer was 
achieved. 
Although prostate volume can be easily measured by ultrasound in the clinic, transrectal 
ultrasound (TRUS) still involves an extra procedure and cost. Using Digital rectal examina-
tion (DRE) to estimate prostate size accurately is difficult, but when DRE-estimated prostate 
volume was categorized to 25, 40 and 60ml in a study by Roobol et al, the corresponding 
TRUS-measured volumes were found to be very similar at 27, 46, and 69ml, respectively. 
[16] Another study done in Asian (Chinese) men (Chapter 10 of this thesis) [32] prospec-
tively validated the DRE-estimated prostate volume in 569 men by Urology residents, and 
the corresponding TRUS-measured volumes were 27, 43, and 68ml, which were almost 
identical to the result obtained from the Caucasian study [16]. The AUCs of the models with 
PSA+DRE prostate volume Vs PSA + TRUS prostate volume in predicting prostate cancer 
(and high-grade prostate cancer) were completely identical. [32]
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In the current era of MRI imaging for prostate cancer diagnosis, PSA density could also 
help to stratify men who need a prostate biopsy (or a repeat biopsy in active surveillance). 
Washino et al showed that in patients with MRI prostates of PI-RADS ≤ 3 AND PSA 
density < 0.15, no clinically signifi cant prostate cancer was being diagnosed. [33] Th erefore, 
PSA density still has a defi nite value in improving performance of PSA in the contemporary 
era. 
Prostate cancer risk calculator
By adding clinical factors to PSA, a multivariate approach to risk stratifi cation can be used to 
better predict prostate risk and reduce unnecessary biopsies. Among the many risk calcula-
tors for prostate cancer prediction, the ERSPC risk calculator was shown to have excellent 
performance. [34] Th e ERSPC risk calculators added clinical risk factors including prostate 
volume, DRE fi nding and TRUS fi nding to PSA to improve the performance of PSA-based 
screening [35], and it has been externally validated. [36, 37] A risk-based strategy was pro-
posed to select appropriate men for biopsy. By using a positive biopsy probability cutoff  of 
12.5%, 33% biopsies and 13% indolent cancer diagnosis would have been avoided. [38]
Th e ERSPC risk calculator (RC3 for initial biopsy) was being externally validated in 
a 3000-men cohort in Hong Kong. [39] (Chapter 4) Th e AUCs were 0.75 and 0.84 for 
prostate cancer and high grade prostate cancer, respectively, but there were overestimation of 
10–40% for PCa and 10–30% for HGPCa across the whole range of predicted probabilities 
at calibration. Adaptations of the formulas (by setting-specifi c adjustments to the intercept 
constant) were performed and the recalibrated models were applied to the validation cohort 
of Chinese men in another hospital (n = 2214). Th e adapted ERSPC risk calculator showed 
excellent calibration and net clinical benefi t over the original ERSPC RC3 in Chinese men. 
Th erefore, the adapted form of ERSPC risk calculator could be applied in the Asian setting 
using easily available factors: PSA, DRE fi nding, and prostate volume. Th e adaptation to 
Asian setting is very important as estimating the cancer risk in Asian men using Caucasian-
validated risk calculator would result in gross over-estimation of cancer risk and even more 
unnecessary biopsies. 
Prostate biopsy complications can be reduced by applying PSA-based risk stratifi cation tools
Th e other reason that renders prostate cancer screening harmful is the complications associ-
ated with prostate biopsy as a result of an elevated PSA. Th e complications include pain, 
haematuria, per rectal bleeding, haematospermia, acute retention of urine, and post TRUS 
biopsy sepsis. Post TRUS biopsy sepsis was infamous for its associated severe morbidities, 
potential intensive care requirements, and very rarely mortality. [40]
Unnecessary biopsies could be reduced by using a risk prediction models like the ERSPC 
or PCPT risk calculators. [18, 34] Th e proportion of biopsy complications that could be 
reduced have not been described previously. Chapter 5 of this thesis reviewed the biopsy 
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complications of 10747 screened men in Rotterdam section of ERSPC in 1993-2015. [41] 
67.4% of biopsies had at least one complication, 3.9% had fever and 0.9% required hospital 
admission. The fever rate was found to be static over the years, but the hospital admission 
rate tripled from 0.6% (1993–1996) to 2.1% (2009–2015) in recent years, implying more 
severe infection in more recent biopsies. This might be related to a doubled prevalence of the 
sepsis risk factor diabetes mellitus in the later rounds of screening. [42, 43]
Among 7704 biopsies which fit the criteria for ERSPC risk calculators (RC3 for first round 
of screening, RC4 for subsequent rounds of screening), 35.8% of biopsies (2757/7704), 
37.4% of complications (1972/5268), 39.4% of fever events (128/325) and 42.3% of ad-
missions (30/71) could have been avoided by using the recommended risk-based thresholds 
of < 12.5% risk for any prostate cancer and < 3% risk for high grade cancer. [38, 41]
Although obvious as it may seem, i.e. complications reduced by not performing the 
procedure, the harms of unnecessary biopsies need to be emphasized again and again. None 
of the risk calculators or novel tools in prostate cancer diagnosis is perfect, but they all 
performed much better than PSA alone. Therefore, for the sake of our patients, biopsy 
decisions based on PSA alone should be abandoned. 
Conclusion of the first part of thesis
In using PSA-based tools like PSA density or risk calculators, we can better select men at a 
higher risk of potentially life threatening prostate cancer and as such candidates for further 
assessment ( e.g. MRI and or prostate biopsy). When we apply risk assessment tools devel-
oped on predominantly Caucasian patient cohorts in Asian men with lower risk of prostate 
cancer, adaptations of the risk calculators are needed to avoid over-estimating cancer risks, 
which in turn might result in the opposite of what we want to achieve, i.e. more unnecessary 
biopsies. 
Part 2: The use of Prostate Health Index (PHI) in prostate cancer diagnosis in Asian 
populations
What are the performance characteristics of PHI in the Asian setting and do we need a 
different PHI reference range for Asian and Caucasian? 
The Prostate Health Index (PHI), a mathematical formula combining total PSA, free PSA 
and [-2] proPSA (or p2PSA), has been shown to have a better sensitivity, specificity and 
AUC compared with PSA and %freePSA in Caucasian men with PSA 2-10 ng/mL since. 
[44-46] The PHI blood test was approved by FDA in 2012 for use in men > 50 years 
old with PSA 4-10 ng/mL and normal DRE. [47] Numerous subsequent studies in other 
Caucasian population have confirmed the benefits of using PHI in men with elevated PSA 
< 10 ng/mL. [48] 
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While the reason that proPSA is elevated in prostate cancer tissues is not entirely un-
derstood, it is postulated that decreased processing of PSA in cancer cells might contribute 
to an increased level of proPSA and [-2]proPSA in particular. In prostate cancer cells, a 
loss of cellular architecture or cellular disruption may explain the increased leakage of the 
enzymatically inactive proPSA forms of the free PSA into the blood stream, and therefore 
elevated levels of these proPSA detected in blood. [49, 50] 
As mentioned in the Introduction (Chapter 1), Asian population have a signifi cantly 
lower incidence of prostate cancer and lower prostate cancer detection rate in the PSA gray 
zone of 4-10 ng/mL Th erefore it is clinically important to validate the value of PHI in Asian 
men. 
PHI in Asian men
Chapter 6 described the fi rst PHI study done in Asian men. [51] In 230 Hong Kong Chi-
nese men with PSA 4-10 ng/mL and normal DRE, bloods were taken immediately before 
an initial ≥10-core systematic prostate biopsy and analyzed for PSA, free PSA and p2PSA. 
Th e specifi city of PHI was about 3 times that of PSA (50% Vs 17%). Th e AUC of PHI, PSA 
density, %freePSA and PSA was 0.78, 0.63, 0.57, and 0.55, respectively. At 90% sensitivity 
of PHI (cutoff  26.5) for Gleason ≥7 cancers, 45% unnecessary biopsies could be avoided. 
In this study with mean PSA of 6.3 ng/mL and prostate volume of 46ml, only 21 (9.3%) 
men were diagnosed to have prostate cancer. [51] Th is was similar to the usual 11% cancer 
detection rate in the same institution in Hong Kong Chinese men with PSA 4-10 ng/mL 
and normal DRE. 
In a subsequent study in Shanghai Chinese men, superiority of PHI over PSA was also 
shown (AUC 0.73 Vs 0.53) in the subset of PSA 2-10 ng/mL with 30% abnormal DRE and 
17.6% cancer detection rate. [52] Ito et al reported in a cohort of Japanese men with PSA 
2-10 ng/mL and 22% cancer detection rate, 28% biopsies could be avoided by using PHI 
at a sensitivity of 95%. [53]
PHI in Asian men with PSA > 10 ng/mL
Chapter 7 described the use of blood test PHI in a cohort of 312 Chinese men with PSA 
10-20 (mean 13.3) ng/mL and normal DRE. [54]. Th e AUC for any cancer detection for 
PSA, %fPSA, %p2PSA and PHI was 0.58, 0.69, 0.76 and 0.73. Using PHI or %p2PSA 
was shown to provide net clinical benefi t over PSA and %freePSA over the whole range of 
probability threshold. Adding age, PSA and repeated biopsy to a multivariate model with 
%p2PSA or PHI increased the AUC (prostate cancer) to 0.78-0.79, and AUC (high grade 
prostate cancer) to 0.83-0.84. [54] Th e cancer detection rates in diff erent PHI ranges were 
shown in Table 1.
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As observed in this study with median PSA of 13.4 ng/mL and PSA density of 0.21, the 
cancer and high-grade cancer detection rates were only 17.0% and 7.7%, respectively. They 
were still lower than the reported cancer detection rate in Caucasian studies with PSA 2-10 
ng/mL. Another study in Chinese men with a subset of men with PSA 10-20 ng/mL and 
30% abnormal DRE showed that the AUC of PHI was 0.79 for PHI and 0.57 for PSA. [55] 
Therefore, the use of PHI can be extended to Asian men with PSA 10-20 ng/mL.
PHI predicts aggressive prostate cancer
A high PHI value not only predicts prostate cancer but also high grade prostate cancer. A 
study by Catalona et al showed that there were 42% Gleason 7 cancers on prostate biopsy 
in a high PHI group (PHI > 55) but only 26% in a low PHI group (PHI < 25). [44] In the 
era of systematic biopsy, discrepancy of Gleason score on biopsy and radical prostatectomy is 
common. PHI and p2PSA was also associated with more aggressive prostate cancer in radical 
prostatectomy specimens in a number of studies in Caucasian men. A study in Italian men 
%p2PSA and PHI improved the prediction of pT3 (by 2.5%), pathologic Gleason sum (by 
6.0%), Gleason sum upgrading (by 5.7%) and indolent cancer with tumor volume < 0.5ml 
(by 4.2%) in multivariate analyses. [56] However, a study in a German cohort showed that 
PHI or p2PSA were not independent predictors of worse pathology outcomes in radical 
prostatectomy upon multivariate analyses, but using a p2PSA cutoff of 22.5 pg/mL could 
modestly improve pT3 prediction by 3.6% in AUC. [57] A multicentre European study 
showed PHI or %p2PSA improved AUC for pT3 or Gleason score ≥7 by 1.2-2.3% in 
multivariate analyses. [58] 
Chapter 8 described the first report on the association of PHI and aggressive prosta-
tectomy pathology in an Asian cohort. [59] PHI or %p2PSA was significantly higher in 
patients with pT3 disease, pathologic Gleason score ≥7, Gleason score upgrade, tumor 
volume >0.5 ml, and Epstein criteria for significant tumor (all p=0.001). The risk of pT3 
or pathologic Gleason score ≥7 was 16.1% for PHI < 35 and 60.8% for PHI > 35 (specific-
ity 84%). In multivariate analyses, adding PHI or %p2PSA to the base model (including 
Table 1. Cancer detection rates in different Prostate Health Index (PHI) ranges in men with PSA 10-
20 ng/mL and normal DRE Cancer, adapted from Chapter 7.
Prostate Health Index <35 35-55 >55 Total
Any prostate cancer 12/178 
(6.7%)
23/101 
(22.8%)
18/33 
(54.5%)
312
Initial biopsies 11/146 
(7.5%)
30/85
 (23.5%)
15/29 
(51.7%)
260
Repeated biopsies 1/32 
(3.1%)
3/16 
(18.8%)
3/4 
(75.0%)
52
High grade prostate cancer 4/178
(2.2%)
8/101
(7.9%)
12/33
(36.4%)
312
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Age, PSA, abnormal DRE, and biopsy Gleason score) improved the prediction of pT3 or 
pathologic Gleason score ≥7 by 7.2-7.9% on AUC. Decision curve analyses showed a net 
clinical benefi t in using PHI in prediction of tumor volume > 0.5ml, or pT3 or pathologic 
Gleason score ≥7. [59] Th erefore, PHI or %p2PSA could be used to predict men with more 
aggressive fi nal pathology in Asian men.
As PHI predicts fi nal pathology, there could be a role for PHI to be included as marker 
for patients on active surveillance to receive active treatment if aggressive pathology is likely 
in case of high PHI values. Caucasian and Japanese studies have reported that [-2]proPSA 
could predict biopsy reclassifi cation in men on active surveillance. [60, 61] In a study in 140 
Chinese men who fi t Prostate Cancer Research International: Active Surveillance (PRIAS) 
criteria, a low PHI was found to predict organ-confi ned disease. [62] Th erefore, a baseline 
PHI could provide useful information before consideration of active surveillance. 
Diff erent PHI reference ranges for Caucasian and Asian. 
As mentioned in Introduction (Chapter 1), the meaning of a mildly elevated PSA of 4-10 
ng/mL is diff erent in Caucasian and Asian. It was shown in Chapter 6 that in a cohort of 
Hong Kong Chinese men, only about 10% men with PSA 4-10 ng/mL and normal DRE 
was diagnosed with prostate cancer on 10-core systematic biopsy. [51] When PHI was avail-
able in the public health care system in Hong Kong since 2016, the reference range used in 
the PHI laboratory reports was the one published by Catalona et al. [44] (Figure 6)
Figure 6. Prostate Health Index lab report in Hong Kong in May, 2016
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From the Caucasian reference range, about 11% had prostate cancer in the lowest PHI 
range (lowest cancer risk) of PHI < 25, which is similar to the overall risk of cancer in Hong 
Kong Chinese men (10-15%) with PSA 4-10 ng/mL. Such reference range results in an 
overestimation of cancer risk and may lead to even more unnecessary biopsies. Therefore, it 
is inappropriate for use in Asian or Chinese men. 
Chapter 9 is a multi-centre evaluation of the role of PHI in regions with different 
prevalences of prostate cancers. [19] The performance of PHI in 4 European cities in France 
and Germany and 5 Asian cities in China, Taiwan and Singapore with a total of 2488 men 
with biopsies done were compared. In men with PSA 2-10 ng/mL and normal DRE, there 
was a 4-fold difference in positive biopsy rates in Caucasian Vs Asian men (52% Vs 13%). 
In men at a lower PHI range of < 35, cancer risks were 28.5% in Caucasian and 6.3% in 
Asian, and Gleason ≥7 cancer risks were 4.2% Vs 1.5%. This study suggests a different PHI 
reference range should be used for different ethnic groups, especially in situation where 
cancer epidemiology was very different. 
Among European men, at 90% sensitivity for Gleason ≥7 cancers (PHI 40), 40% of 
biopsies and 31% of Gleason 6 PC diagnoses could have been avoided. Among Asian men, 
at 90% sensitivity for Gleason ≥7 cancer (PHI 30), 56% of biopsies and 33% of Gleason 6 
PC diagnoses could have been avoided. (Table 2, Chapter 6) [19] Therefore, the use of the 
PHI blood test could reduce more than half of unnecessary initial biopsies in Asian men 
with elevated PSA 2-10 ng/mL and normal DRE. 
Back in Hong Kong, we have generated a PHI reference range from 569 Hong Kong 
Chinese men with PSA 4-10 ng/mL, normal DRE and prostate biopsy done. (Chapter 10) 
[32] Since 2017, a new PHI reference range for Hong Kong Chinese has been added in the 
PHI lab report. (Figure 7) Hopefully this could provide accurate risk estimation for men 
with PSA and PHI taken. 
In the letter to the editor for the paper in Chapter 10 [19], Heidegger and Pichler 
queried the lack of detailed cancer information in Gleason 6 cancers including number of 
positive cores and percentage involvement in each core. The co-authors and I fully agreed to 
Table 2. Comparison of prostate cancer prevalence, life expectancy and benefit harm ratio of cancer 
screening in Asian, Black and Caucasian.
Prevalence
Metastatic disease 
at presentation life expectancy
PSA screening- 
benefit harm 
ratio
Optimized 
screening#- 
benefit harm 
ratio
Asian * ** **/*** * ***
Black *** *** ** ** ***
Caucasian ** * *** ** ***
# Optimized screening = PSA screening followed by risk stratification tool optimized for particular 
population
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the comment and having such information could potentially change some Gleason 6 cancers 
to signifi cant. Th ey also mentioned about the impact of MRI prostate in cancer diagnosis 
and a pre-biopsy MRI is currently being recommended in EAU guideline since March 2019. 
Th e authors and I are fully aware of the role of MRI, but the patients in the study were 
recruited years before the recent EAU recommendation and most of them did not have a 
pre-biopsy MRI. All of the above have been mentioned in the discussion part of the original 
manuscript and therefore we did not provide a reply to the letter. [63]
In the editorial for the paper (Chapter 10) by Zlotta and Kuk, comments were made 
concerning the potential underestimation of cancer incidence in Asia. Th e authors including 
myself agreed that cancer incidence has been climbing up in Asia in recent years, which 
might be related to more PSA testing and more awareness to prostate cancer. However, the 
current absolute number of prostate cancer being diagnosed and also the positive biopsy 
rates in PSA 4-10 ng/mL were still much lower than that in Caucasian. Th e suggestion 
of whether prostate cancers are developed at a later age in Asian is an aspect which we 
should explore further. A prostate cancer study in including PSA, PHI and MRI prostate is 
currently in progress in Hong Kong Chinese men, and hopefully the results would give us 
more insights into the epidemiology and the optimal screening strategy for prostate cancer. 
(Clinicaltrials NCT03891732)
Figure 7. Prostate Health Index lab report in Hong Kong in August, 2018.
172
C
ha
pt
er
 1
2
Adding PHI to PSA based predictive models
In chapters 6-9, the value of PHI in Asian men and the need of a separate reference range 
have been described. PHI could be added in a predictive model to further improve its per-
formance. Lughezzani et al developed a nomogram by adding PHI to clinical parameters 
including age, prostate volume, DRE, and history of prior negative biopsy. [64] Adding 
PHI to the baseline model with the 4 clinical factors improved AUC from 0.73 to 0.80, 
and it was externally validated in another clinical cohort, showing AUC of 0.75 and clinical 
benefit on decision curve analyses. [65] Roobol et al added PHI to the original ERSPC risk 
calculators RC3 and RC4 for initial and repeated screening settings (with DRE finding 
and DRE estimated prostate volume), and showed that the performance of the recalibrated 
ERSPC-based risk calculator including PHI (AUC 0.75 for any cancer, and 0.69 for high 
grade cancer) was similar to the one developed by Lughezzani et al. [66]
In chapter 10, PHI was compared with PSA-based and PHI-based predictive models 
in a Chinese cohort of men with PSA 4-10 ng/mL and normal DRE. [32] Adding age 
and prostate volume to PSA improved the AUC of cancer detection from 0.54 to 0.71 
(DRE-estimated prostate volume) or 0.72 (TRUS measured prostate volume), and about 
25% biopsies could be avoided at 90% sensitivity for any cancer. This confirmed again the 
importance of a multivariable predictive model. The AUC for PHI alone in the same cohort 
was 0.76 and already better than the PSA-based predictive model (0.72), and if age and 
DRE-estimated prostate volume was added to PHI, the AUC further improved from 0.76 
to 0.78 (p<0.001). [32] For high grade prostate cancer, however, PHI alone had a high AUC 
of 0.85 and adding age and prostate volume did not further improve the AUC. 
Zhu et al used the same factors of PHI, Age and TRUS estimated prostate volume and 
generated a PHI-based risk calculator for prostate cancer in Shanghai Chinese men with PSA 
< 10 with normal DRE. [67] It was externally validated in a Hong Kong Chinese cohort 
with PSA 4-10 ng/mL, normal DRE and a cancer detection rate of 9.1%. An AUC of 0.79 
and good calibration was achieved. [67]
Therefore, similar to PSA and PSA-based predictive models, simple and easily available 
clinical factors like age, DRE finding and prostate size could be added into a PHI-based 
predictive model to improve performance. However, the magnitude of added benefit of 
including these clinical factors to PHI was less than that of adding them to PSA. 
PHI use in a real-life Asian setting
There have been numerous validation studies of PHI showing the proportion of biopsies 
that can potentially be avoided by using a particular cutoff. [19, 48] However, the impact 
of a test in actual clinical practice is important to prove the effectiveness in its application. 
There was only 1 publication so far reviewing the use of PHI in real-world scenarios. 
It included 345 Caucasian men in academic centres with a median PSA of 5.8ng/mL and 
>90% normal DRE. Compared with a historical cohort without PHI, men who decided not 
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for biopsy increased from 52% to 61%, negative biopsy reduced from 25.5% to 17.5%, and 
Gleason Grade group ≥2 cancers remained unchanged at 13.5%. [68] However, this showed 
the eff ectiveness of applying PHI at one time point only.
Chapter 11 (Manuscript under submission) showed the impact of routine PHI on consecu-
tive Chinese men in actual clinical practice in academic and non-academic centres in Hong 
Kong. Out of 2839 men with a median PSA of 6.1 (IQR 4.6-8.1)ng/mL, 11.5% with PHI <35 
and 46.4% with PHI >35 decided for an immediate biopsy. PHI was shown to be the strongest 
predictor (OR 7.1, p<0.001) for an immediate biopsy decision, followed by younger age, prior 
negative biopsy, and a higher PSA level. Th e positive biopsy rates increased from 10.9% (histori-
cal cohort) to 28.3%, and Gleason grade group ≥2 cancers increased from 2.8% to 14.7%. 
Th e second part of Chapter 11 illustrates 2 year follow-up data in the fi rst 1392 non-
cancerous men with a median of 2.2 (range 2.0-2.6) years of follow-up. 9.8% (110/1127) 
in PHI<35 and 26.4% (70/265) in PHI>35 subsequently had a biopsy along follow-up 
(p<0.001), resulting in 11.0% (12/109) and 28.6% (20/70) Gleason Grade group ≥2 diag-
nosis, respectively (p=0.003). In men with PHI >55 with subsequent biopsies done within 2 
years, 78% of biopsies revealed Gleason Grade group ≥2 cancers. Th is is the fi rst PHI study 
to have longer term follow-up data available, and men with higher PHI ranges of >35, and 
>55 in particular, should be strongly encouraged to receive early biopsy. 
Conclusion of the second part of thesis
PHI could predict prostate cancer and aggressive prostate cancer in Asian men with elevated 
PSA, but an Asian-specifi  c PHI reference range needs to be used to avoid overestimation of 
cancer risks and further unnecessary biopsies. A multivariate approach including PHI could 
further improve prostate cancer prediction. PHI is also shown to be eff  ective in real-life 
application. (Figure 8)
Figure 8. Biopsy decision in Asian men according to PHI result
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Future perspectives
To screen, or not to screen, that is the question. It is always a balance of benefits and harms.
The US Preventive Services Task Force (USPSTF) recommended against PSA-based prostate 
cancer screening in 2012 [69] as a result of conflicting results on prostate cancer mortality 
and harms of overdiagnosis from the randomized controlled trials. [5, 70, 71] This had led 
to widespread change of PSA screening practice in general practitioners, and cancer statistics 
from the United States have shown for the first time since 1990 an increase in prostate 
cancer mortality in 2016. [72] The updated analyses of ERSPC trial with longer follow-up 
time showed that, in addition to maintained prostate cancer mortality reduction of 20%, 
the number needed to screen (NNS) to prevent one cancer mortality reduced from 742 
(at 13 year follow-up) to 570 (at 16 year follow-up). The number needed to treat (NNT) 
also reduced further from 26 to 18. [73, 74] The 19-year follow-up data in a section of the 
ERSPC in Rotterdam comprising one of the earliest study cohorts showed the trend of 
54% reduction in metastatic disease and 52% reduction in of prostate cancer death with a 
longer follow-up. [75] The 18-year follow-up data in the Goteborg trial reported NNS of 
139 and NNT of 13 for organized screening every 2 years. It also showed that opportunistic 
PSA testing was much less effective than organized screening in terms of reducing prostate 
cancer mortality reduction and overdiagnosis problem. [76] The USPSTF updated their 
recommendation in 2018 for men aged 55-69 years to an individual patient-based decision 
after a doctor’s counselling. [77] 
The benefits of organized prostate cancer screening could be seen, but the harms of 
over-investigation (biopsy), over-diagnosis and over-treatment of indolent cancers need to 
be reduced before screening could be applied on a population level. While the optimal 
screening strategy remains to be defined, it was shown that more intensive screening was 
associated with more overdiagnosis. [78] However, we have more than PSA and DRE in the 
modern era of prostate cancer detection. While a man with PSA > 3 ng/mL would be offered 
a sextant prostate biopsy in the ERSPC trial, it should no longer be the case in the current 
era. We have numerous tools to help us to stratify the risk of a man with elevated PSA, 
especially in the PSA gray zone of 4-10 ng/mL where most men with elevated PSA would 
fall into. The use of well-performing risk calculators like the ERSPC risk calculator could 
reduce unnecessary biopsies, but validation and calibration is needed to improve perfor-
mance in specific ethnic groups. [36, 38, 39] Novel urine tests like PCA3 (with or without 
TMPRSS2:ERG) and Urine molecular biomarker-based risk score (SelectMDx) [79-81], 
and blood tests like PHI and a 4-Kallikrein panel(4K) [44, 82] could help to predict signifi-
cant prostate cancers, reduce a significant proportion of unnecessary biopsies and diagnosis 
of indolent Gleason 6 prostate cancers. The cost of such tests would go down eventually, 
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and as discussed in an earlier part of this chapter, the cost of a PHI test was reduced by 80% 
in a matter of few years. Th e use of multiparametric MRI prostate (including T1W, T2W, 
DWI and DCE sequences) accompanied with high quality imaging in men with elevated 
PSA could reduce unnecessary biopsies and diagnosis of insignifi cant cancers, allow targeted 
biopsy (and reduce systematic biopsies) and improve detection of signifi cant prostate cancer. 
[20, 21, 83] Radiological expertise and standardized MRI reporting is however required to 
maximize the benefi ts of MRI. Th e availability and cost of a multiparametric MRI prostate is 
also a concern for most places in the world. A shorter biparametric MRI protocol including 
only T2W and DWI sequences was shown in a meta-analysis to have similar performance 
compared with multiparametric protocol, and could avoid gadolinium contrast and reduce 
scanning time and cost. [84] 
In Asia, the incidence of prostate cancer and the cancer detection rate for elevated PSA 
is lower than in Caucasian, but the proportion of metastatic prostate cancer at diagnosis is 
higher. Th e proportion of metastatic disease is inversely proportional to the degree of cancer 
screening, and therefore there is a need for screening in regions with higher proportion of 
metastatic disease like Asia. While the number needed to screen to detect a signifi cant cancer 
might be higher in Asian men, there is a greater need for the use of risk-stratifi cation tools 
to better select men for biopsy in order to reduce the number needed to biopsy to detect 
a signifi cant cancer. As shown in chapter 9 of this thesis, the proportion of unnecessary 
biopsies that can be reduced by using biomarkers like PHI can be higher in Asian than 
Caucasian. Th erefore, the best screening protocol (Age range and Screening method) for 
a particular ethnic group or population need to be tailor-made or adapted from existing 
protocols for another population. (Table 2)
I believe the combination of PSA, clinical risk factors and a low-cost biomarker would 
form the basis of future prostate cancer screening to help select men at risk of signifi cant 
prostate cancer to receive MRI prostate and biopsy. A combination of MRI and risk calcula-
tors or a combination of MRI and biomarkers could potentially further reduce unnecessary 
biopsies. [85, 86] Currently, a smart phone app like the Rotterdam prostate cancer risk 
calculator can help doctors to calculate the risk easily. [87, 88] In the future, the patient 
should have all tests done in a one-stop clinic and the Urologist should have the risk of 
cancer automatically generated on the computer screen to facilitate counselling. 
Another harm of screening is about biopsy complications. Th e most fearsome complica-
tion of a transrectal ultrasound guided biopsy of the prostate is sepsis, and unfortunately 
the sepsis associated with resistant bacteria is on the rise. [40] Transperineal prostate biopsy 
could reduce the risk of sepsis to 0.1-0.3% and eliminate per rectal bleeding, but was tradi-
tionally associated with the need of spinal or general anaesthesia, and a higher risk of urinary 
retention after biopsy. [89] However, the feasibility of doing transperineal prostate biopsy 
under local anaesthesia with low rate of infection and urinary retention has recently been 
reported. [90, 91] A ‘Trexit’ initiative from London to change all prostate biopsies in United 
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Kingdom from transrectal to transperineal is underway, and severe sepsis after a prostate 
biopsy could potentially be reduced to near zero in the future. [92]
The problem of overdiagnosis of insignificant prostate cancer could partly be alleviated 
by the use of the novel diagnostic tools and biopsy being limited to man at high risk of 
significant cancer. However, when insignificant cancer was diagnosed on biopsy, the patient 
should be put on active surveillance to reduce over-treatment. [93] It is however important 
to note that a significant proportion of men on active surveillance without clinical progres-
sion would change to active treatment in 2-3 years, so instead of putting a lot of men to 
active surveillance, it remains important to reduce overdiagnosis in the first place. [93] In 
well selected men with intermediate prostate cancer, focal therapy could be used to treat 
the cancer and avoid the complications of a radical prostatectomy or radiotherapy. In a 
large series of men who received high-intensity focused ultrasound (HIFU) using focal or 
hemi-ablation technique, a high freedom from radical treatment rate of 91% and 81% at 5 
and 8 years was observed. [94] 
With a smarter approach to prostate cancer screening and avoidance of treatment in low 
risk cancers, the amount of harm observed in the screening trials could be greatly reduced. 
This would improve the benefit to harm ratio in prostate cancer screening. The European 
Association of Urology (EAU) has released an updated policy paper on PSA screening 
for prostate cancer in January 2019, with the aim to reopen discussion on the need of 
population-based prostate cancer screening program in European Union. [95] 
Hopefully, the day will come when all eligible men can be screened for prostate cancer 
with a population-specific protocol, only men at high risk of significant prostate cancer 
(on multivariate risk assessment tools incorporating biomarkers and imaging) should be 
biopsied, only significant prostate cancers should be treated (by focal therapy if possible), 
and no more metastatic prostate cancer. 
In fact, ‘To screen, or not to screen’, is NOT the question. 
The question should be, how should we screen? 
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Chapter 1 (General Introduction) gives an overview of all available information regarding 
PSA-based screening for prostate cancer. Th e development of PSA-based risk stratifi cation 
tools including PSA density, the Rotterdam Prostate Cancer Risk Calculator, and Prostate 
Health Index (PHI) is discussed and viewed in the setting of the epidemiological diff er-
ences of prostate cancer in western and Asian populations. On the basis of this information 
research questions were formulated, addressed (Chapter 2-11 and discussed Chapter 12 
(General discussion)).
Part 1: by using PSA-based risk stratifi cation tools, can we reduce harms of prostate 
cancer screening? Can these tools be applied to Asian populations?
Chapter 2 consists of a review on PSA-based prostate cancer screening discussing the co-
inciding problems of overdiagnosis and potential ways to reduce these problems. Available 
data show that there are men that could benefi t from screening and that long-term follow-up 
data of the largest RCT (ERSPC) show that the number needed to screen and number 
needed to treat to avoid a prostate cancer death continues to drop and comes into the 
range of e.g. breast cancer screening programs. Appropriate use of risk-stratifi cation tools 
including risk calculators, blood and urine biomarkers, and MRI imaging could selectively 
identify men that could benefi t from screening and as such have the ability to improve the 
benefi t-to-harm ratio of screening. 
Th e role of PSA density in Asian men is being explored in Chapter 3. PSA density has a 
better performance than PSA alone in prostate cancer detection in Asian men, and the eff ect 
was found to be more prominent in obese men. Obese men with an elevated PSA density > 
0.15 were found to have four times the risk of prostate cancer in similar PSA levels. 
With respect to the use of risk-stratifi cation tools, the Rotterdam Prostate Cancer Risk 
Calculator has shown to predict prostate cancer and high-grade prostate cancer better than 
PSA alone. Th e Rotterdam Prostate Cancer Risk Calculator has been validated in multiple 
Caucasian cohorts. Chapter 4 showed that the Rotterdam Prostate Cancer Risk Calculator 
performed well in Asian men, but overestimation of cancer risk was observed. After simple 
adaptation of the formula, the recalibrated Rotterdam Prostate Cancer Risk Calculator 
formula showed excellent calibration in another Asian validation cohort with accurate 
prediction of cancer risks. As shown in Chapter 5, by applying the Rotterdam Prostate 
Cancer Risk Calculator, 36% of unnecessary biopsies, 39% of post-biopsy fever, and 42% of 
hospital admissions could be avoided. Th is is especially important in the face of the increas-
ing post-biopsy sepsis rates. 
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Part 2: The use of Prostate Health Index (PHI) in prostate cancer diagnosis in Asian 
populations
The blood test Prostate Health Index (PHI) was shown to improve prostate cancer detection 
in Caucasian men. In Chapter 1 (General introduction), the lower prevalence of prostate 
cancer in Asian men was discussed, and in Chapter 4, it was shown that the Rotterdam Pros-
tate Cancer Risk Calculator needs to be adjusted before application in Asian men. Whether 
the PHI blood test can be applied to Asian men was unknown. 
In Chapter 6, the first application of the PHI test in Asian men was performed in 
men with PSA 4-10 ng/mL with normal DRE, with PHI having three times the specificity 
compared to PSA, and avoiding 45% of biopsies at 90% sensitivity for high-grade prostate 
cancer. The use of PHI was further extended to Asian men with PSA 10-20 ng/mL and 
normal DRE in Chapter 7. It was shown that in Asian men with lower prevalence of cancer, 
PHI performed much better than PSA or percentage free PSA even in the case of PSA 10-20 
ng/mL. Chapters 6 and 7 showed that PHI correlates with risk of prostate cancer in Asian 
men, while Chapter 8 shows that PHI predicts aggressive pathology. In men with PHI levels 
of >35, the risk of pT3 or Gleason score ≥7 disease was 60.8%, compared with just 16.1% 
in men with PHI < 35. Therefore, in addition to biopsy decision, a PHI test could also guide 
treatment decisions (active surveillance vs. radical treatment). 
The PHI reference range showed the risk of prostate cancer in different PHI ranges as 
supported by Caucasian data. Chapter 9 is a multi-center evaluation of the role of PHI in 
regions with different prevalences of prostate cancer, including men from four European 
cities and four Asian cities. In men with PSA < 10 ng/mL, a four-fold difference in prostate 
cancer risk was observed between European and Asian men, and gross differences were 
observed in the cancer rates at different PHI ranges also. An ethnic specific PHI reference 
range should be used for Asian men to avoid over-estimation of cancer risk and even more 
unnecessary biopsies. In using 90% sensitivity for high-grade prostate cancer, 56% of un-
necessary biopsies and 33% of Gleason 6 cancers could be reduced in Asian men, compared 
to 40% and 31% in European, respectively. 
As for the Rotterdam Prostate Cancer Risk Calculator, adding multivariable clinical fac-
tors to PSA improved cancer prediction. In Chapter 10 it was shown that this was similar 
in Asian men. Taking into account multiple factors next to PHI, e.g. DRE, prostate size and 
age, improved the capability of selectively identifying men with an elevated risk of having 
prostate cancer. For higher-grade cancers such an effect was not seen. Also in Asian men with 
relatively high PSA levels (10-20 ng/mL) further risk stratification was possible by (Chapter 
7) including age, PSA and history of negative biopsy in the decision to biopsy. 
While most papers on novel prostate cancer biomarkers report on the theoretical percent-
age of biopsies that could be reduced at a certain cutoff, the impact of a test in actual clinical 
practice is not commonly reported. In Chapter 11, the clinical impact of introducing PHI 
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in routine clinical care in Hong Kong-Chinese men with elevated PSA is reported. In men 
with PSA 2-10 ng/mL, 82.0% of men decided not to undergo immediate biopsy after know-
ing their PHI results. By selecting higher risk men for biopsy with PHI, the percentage of 
prostate cancer diagnoses with Gleason 3+3 or 3+4 increased from 2.8% (data from a purely 
PSA-based strategy) to 14.7%. For men with more than two years of follow-up after an 
initial PHI test, 9.8% with PHI <35 and 26.4% with PHI >35 subsequently had a biopsy, 
resulting in 11.0% and 28.6% Gleason ≥3+4 diagnosis, respectively. By incorporating PHI 
into the routine clinical pathway, more than 80% of biopsies were avoided and high grade 
prostate cancer detection rate improved as compared to a PSA driven strategy. A higher 
baseline PHI was correlated to subsequent biopsy outcome and as such can serve as a tool to 
individualize the frequency of follow-up visits.
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In hoofdstuk 1 wordt een overzicht gegeven van de beschikbare informatie omtrent vroege 
opsporing van prostaatkanker. Verder wordt de ontwikkeling van risicostratifi catiemiddelen, 
zoals de PSA-density, de Prostaatwijzer en de Prostate Health Index (PHI, bloedtest) be-
schreven. Daarbij wordt de vraag gesteld welke epidemiologische verschillen met betrekking 
tot prostaatkanker er bestaan tussen Westerse (Kaukasische) en Aziatische populaties. Op 
basis hiervan worden de onderzoeksvragen geformuleerd die ten grondslag liggen aan dit 
proefschrift en zullen worden beantwoord in de hoofdstukken 2-11 en bediscussieerd in 
hoofdstuk 12 (Discussie). 
Deel 1: Kunnen we door het gebruik van risicostratifi catiemiddelen de nadelen van vroege op-
sporing van prostaatkanker verminderen? Kunnen deze risicostratifi catiemiddelen ook één-op-één 
worden toegepast binnen een Aziatische populatie? 
In hoofdstuk 2 wordt in een review vroege opsporing van prostaatkanker met behulp van 
de PSA-test besproken, evenals de problemen rondom overdiagnose en welke mogelijkheden 
er bestaan om de overdiagnose te verminderen. Data beschikbaar in de wetenschappelijke 
literatuur tonen dat bepaalde mannen voordeel kunnen hebben van vroege opsporing van 
prostaatkanker. Langetermijn data van de grootste gerandomiseerde studie naar vroege 
opsporing van prostaatkanker (ERSPC) laat zien dat het aantal mannen wat moet worden 
gescreend om één prostaatkankerdode te voorkomen nog altijd daalt. Dat geldt ook voor 
het aantal mannen wat moet worden behandeld om één prostaatkankerdode te voorkomen. 
Deze getallen komen nu in de buurt van de getallen die bij vroege opsporing van borstkanker 
als acceptabel werden beschouwd voor de invoering van een landelijk screeningprogramma. 
Het toepassen van risicostratifi catiemiddelen zoals een risicowijzer, merkstoff en uit het bloed 
of de urine, en het toepassen van de MRI kan het mogelijk maken om nog selectiever te 
screenen op prostaatkanker, zodat alleen de mannen die er echt voordeel van zullen onder-
vinden gediagnosticeerd en (mogelijk) behandeld zullen worden. 
De toepassing van één zo’n risicostratifi catiemiddel, de PSA-density, wordt beschreven 
in hoofdstuk 3. Door naast PSA ook naar het volume van de prostaat (PSA-density = PSA/
volume van de prostaat) te kijken, kan binnen de Aziatische populatie prostaatkanker beter 
worden gediagnosticeerd. Dit eff ect bleek nog groter in obese Aziatische mannen. Obese 
Aziatische mannen met een PSA-density >0.15 hadden een vier keer zo hoge kans op pros-
taatkanker bij vergelijkbare PSA-waarden. 
Een ander risicostratifi catiehulpmiddel, de Prostaatwijzer, heeft laten zien dat door 
variabelen te combineren tot een formule, deze beter in staat is het risico op prostaatkanker 
en het risico op hooggradig prostaatkanker te voorspellen dan wanneer alleen PSA zou 
worden gebruikt. De Prostaatwijzer werd meermaals gevalideerd in andere cohorten van 
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Westerse mannen. In hoofdstuk 4 wordt juist gekeken of de Prostaatwijzer ook kan worden 
toegepast in een Aziatische setting. In eerste instantie presteerde de Prostaatwijzer voldoende 
bij toepassing in een Aziatische setting, maar bestond er wel het risico dat de kans op pros-
taatkanker te hoog werd ingeschat. Daarop werd de formule achter de Prostaatwijzer voor 
Aziatische mannen aangepast, waarna de Prostaatwijzer veel beter presteerde. Als proef op 
de som werd dit gecontroleerd in een ander cohort Aziatische mannen. Daaruit bleek dat na 
de aanpassing de kans op prostaatkanker voor Aziatische mannen accuraat werd voorspeld. 
In hoofdstuk 5 blijkt vervolgens dat door de toepassing van de Prostaatwijzer, 36% van 
de onnodige biopten had kunnen worden voorkomen, net als 39% van de gevallen waarbij 
koorts optreedt na het nemen van een biopt, of 42% van het aantal ziekenhuisopnames na 
een biopt. Dit is met name van belang met betrekking tot het stijgende percentage sepsis dat 
optreedt na het nemen van prostaatbiopten. 
Deel 2: Het gebruik van de Prostate Health Index bij het diagnosticeren van prostaatkanker in 
Aziatische mannen. 
Bij Kaukasische mannen is gebleken dat de PHI bloedtest toegevoegde waarde heeft 
voor het diagnosticeren van prostaatkanker. In de introductie werd de lagere prevalentie van 
prostaatkanker onder Aziatische mannen reeds beschreven en in hoofdstuk 4 lieten we zien 
dat de formule achter de Prostaatwijzer moest worden aangepast voordat de Prostaatwijzer 
kon worden toegepast in een Aziatische populatie. Het was nog niet bekend of de PHI 
één-op-één kon worden toegepast bij Aziatische mannen. 
Hoofdstuk 6 beschrijft een studie waarin de PHI voor het eerst wordt toegepast bij 
Aziatische mannen met een PSA 4-10 ng/mL en een normaal DRE. PHI bleek een drie keer 
hogere specificiteit te hebben dan PSA, waardoor 45% van de biopten – waarvan met 90% 
zekerheid kan worden gezegd dat het geen hooggradig prostaatkanker betrof – kon worden 
voorkomen. In hoofdstuk 7 werd de PHI bloedtest ook toegepast bij Aziatische mannen 
met een PSA 10-20 ng/mL en een normaal DRE. Ook hier liet de toepassing van PHI 
veel betere resultaten zien, dan wanneer alleen voor de toepassing van de PSA was gekozen. 
Hoofdstuk 6 en 7 laten dus zien dat er een verband bestaat tussen de PHI en het risico op 
prostaatkanker bij Aziatische mannen. In hoofdstuk 8 laten we vervolgens zien dat PHI ook 
kan voorspellen welke kankers een agressievere pathologie vertonen. In mannen met een 
PHI score >35, had 60.8% een risico op pT3 of Gleason ≥ 7 prostaatkanker. Voor mannen 
met een PHI score <35 was dit risico 16.1%. Naast dat de uitkomst van de PHI bloedtest de 
beslissing om wel of geen biopt te nemen zou kunnen beïnvloeden, zou de score ook kunnen 
worden meegenomen bij het maken van een behandelbeslissing als prostaatkanker eenmaal 
is gediagnosticeerd. 
De PHI referentiewaarde laat het risico op prostaatkanker zien binnen verschillende PHI 
ranges. Deze zijn gebaseerd op data van Kaukasische mannen. In hoofdstuk 9 wordt de 
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rol van PHI onderzocht in verschillende regio’s waar de prevalentie van prostaatkanker van 
elkaar verschilt. Zo worden er mannen geïncludeerd uit vier Europese steden en mannen uit 
vier Aziatische steden. In mannen met een PSA <10 ng/mL werd er een vier keer zo groot 
verschil gezien in het risico op prostaatkanker tussen Europese en Aziatische mannen. Ook 
werden er verschillen gezien in het aantal kankers bij verschillende PHI ranges tussen Euro-
pese en Aziatische mannen. Het is daarom aan te raden om een aangepaste referentiewaarde 
te gebruiken wanneer het Aziatische mannen betreft om zo te voorkomen dat het risico op 
prostaatkanker wordt overschat en er nog meer onnodige biopten worden genomen. Bij 
een sensitiviteit van 90% van hooggradige prostaatkanker kan bij Aziatische mannen 56% 
onnodige biopten worden voorkomen en 33% Gleason 6 tumoren, in vergelijking met 40% 
en 31%, respectievelijk, bij Europese mannen. 
Bij de Prostaatwijzer zagen we al dat het toevoegen van variabelen aan de achterliggende 
formule de inschatting van het risico verbeterd. Dit geldt ook het toevoegen van variabelen 
aan de formule wanneer deze in een Aziatische populatie wordt toegepast. Zo blijkt in 
hoofdstuk 10 dat het opnemen van DRE, de grootte van de prostaat en leeftijd, naast de 
uitslag van de PHI bloedtest, het mogelijk maakt om met nog meer zekerheid te voorspellen 
wie een verhoogt risico heeft op het krijgen van prostaatkanker. Voor hooggradig prostaat-
kanker zagen we zo’n eff ect niet. Maar in hoofdstuk 7 zagen we dat voor Aziatische mannen 
met een relatief hogere PSA-waarde tussen de 10-20 ng/mL verdere risicostratifi catie op basis 
van leeftijd, PSA, en eerdere negatieve biopten wel mogelijk was. 
In de meeste wetenschappelijke artikelen wordt er geschreven over hoe de toepassing van 
nieuwe bloedtesten (zoals PHI) in theorie biopten zou kunnen besparen. In hoofdstuk 11 
wordt een studie beschreven waarin de daadwerkelijke impact van PHI in de dagelijkse klini-
sche praktijk wordt gerapporteerd. Van de Hong Kong-Chinese mannen met een PSA-waarde 
tussen 2-10 ng/mL besloot 82% van de mannen nadat ze hun PHI-score hadden gehoord 
om niet direct een biopt te ondergaan. Door met behulp van PHI alleen die mannen met 
een hoger-risico ook daadwerkelijk te biopteren steeg het aantal Gleason 3+3=6 en Gleason 
3+4=7 (Gleason Grade groep ≥2) kankers van 2.8% (wanneer alleen een PSA-strategie zou 
worden toegepast) naar 14.7%. Van de mannen met meer dan twee jaar follow-up die een 
PHI bloedtest ondergingen, werden 9.8% met een PHI-score <35 en 26.4% met een PHI-
score >35 alsnog gebiopteerd, wat resulteerde in 11% en 28.6% Gleason ≥3+4=7 diagnoses. 
Door PHI in de klinische praktijk toe te passen, konden meer dan 80% van de biopten 
worden voorkomen. Ook het aantal hooggradige prostaatkankers dat werd gediagnosticeerd 
verbeterde ten opzichte van het aantal diagnosis wanneer een strategie met alleen PSA zou 
worden toegepast. Een hogere PHI waarde bij het eerste meetmoment was gecorreleerd aan 
de gevonden bioptuitkomsten naderhand en kan daarom worden ingezet om het aantal 
vervolgbezoeken per patiënt te optimaliseren. 
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204
C
ha
pt
er
 1
2
Annual EAU meeting, Munich, Germany 2016  1 
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